File COPY


```
=> file registry
FILE 'REGISTRY' ENTERED AT 11:32:03 ON 17 FEB 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2006 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES:   15 FEB 2006  HIGHEST RN 874326-73-5
DICTIONARY FILE UPDATES:  15 FEB 2006  HIGHEST RN 874326-73-5

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH JULY 14, 2005

  Please note that search-term pricing does apply when
  conducting SmartSELECT searches.

*********************************************************************
*                                                                   *
* The CA roles and document type information have been removed from *
* the IDE default display format and the ED field has been added,   *
* effective March 20, 2005.  A new display format, IDERL, is now    *
* available and contains the CA role and document type information. *
*                                                                   *
*********************************************************************

Structure search iteration limits have been increased.  See HELP SLIMITS
for details.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document.  For information
on property searching in REGISTRY, refer to:

http://www.cas.org/ONLINE/UG/regprops.html

=> d stat que L19

L1              STR
```

C 77 N 78







Page 1-A





Page 1-B





Page 2-A







Page 2-B





Page 3-A



Page 3-B
VAR G1=5/11/17/23
VAR G2=77/78
VAR G3=33/39/45/51/61
NODE ATTRIBUTES:

NSPEC	IS R	AT	1
NSPEC	IS R	AT	2
NSPEC	IS R	AT	3
NSPEC	IS R	AT	4
NSPEC	IS R	AT	5
NSPEC	IS R	AT	6
NSPEC	IS R	AT	7
NSPEC	IS R	AT	8
NSPEC	IS R	AT	9
NSPEC	IS R	AT	10
NSPEC	IS R	AT	11
NSPEC	IS R	AT	12
NSPEC	IS R	AT	13
NSPEC	IS R	AT	14
NSPEC	IS R	AT	15
NSPEC	IS R	AT	16
NSPEC	IS R	AT	17
NSPEC	IS R	AT	18
NSPEC	IS R	AT	19
NSPEC	IS R	AT	20
NSPEC	IS R	AT	21
NSPEC	IS R	AT	22
NSPEC	IS R	AT	23
NSPEC	IS R	AT	24
NSPEC	IS C	AT	25
NSPEC	IS R	AT	26
NSPEC	IS R	AT	27
NSPEC	IS R	AT	28
NSPEC	IS R	AT	29
NSPEC	IS R	AT	30
NSPEC	IS R	AT	31
NSPEC	IS R	AT	32
NSPEC	IS R	AT	33
NSPEC	IS R	AT	34

```
NSPEC   IS R      AT  35
NSPEC   IS R      AT  36
NSPEC   IS R      AT  37
NSPEC   IS R      AT  38
NSPEC   IS R      AT  39
NSPEC   IS R      AT  40
NSPEC   IS R      AT  41
NSPEC   IS R      AT  42
NSPEC   IS R      AT  43
NSPEC   IS R      AT  44
NSPEC   IS R      AT  45
NSPEC   IS R      AT  46
NSPEC   IS R      AT  47
NSPEC   IS R      AT  48
NSPEC   IS R      AT  49
NSPEC   IS R      AT  50
NSPEC   IS R      AT  51
NSPEC   IS R      AT  52
NSPEC   IS R      AT  53
NSPEC   IS R      AT  54
NSPEC   IS C      AT  55
NSPEC   IS C      AT  56
NSPEC   IS C      AT  57
NSPEC   IS C      AT  58
NSPEC   IS R      AT  59
NSPEC   IS R      AT  60
NSPEC   IS R      AT  61
NSPEC   IS R      AT  62
NSPEC   IS R      AT  63
NSPEC   IS R      AT  64
NSPEC   IS C      AT  65
NSPEC   IS C      AT  66
NSPEC   IS C      AT  67
NSPEC   IS C      AT  68
NSPEC   IS C      AT  69
NSPEC   IS C      AT  70
NSPEC   IS C      AT  71
NSPEC   IS C      AT  72
NSPEC   IS C      AT  73
NSPEC   IS C      AT  74
NSPEC   IS C      AT  75
NSPEC   IS C      AT  76
CONNECT IS E3  RC AT  66
CONNECT IS E3  RC AT  67
CONNECT IS E3  RC AT  68
CONNECT IS E3  RC AT  69
CONNECT IS E3  RC AT  70
CONNECT IS E1  RC AT  71
CONNECT IS E1  RC AT  72
CONNECT IS E1  RC AT  73
CONNECT IS E1  RC AT  74
CONNECT IS E1  RC AT  75
DEFAULT MLEVEL IS ATOM
MLEVEL  IS CLASS  AT  55 56 57 58 65 66 67 68 69 70 71 72 73 74 75
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS  78
```

STEREO ATTRIBUTES: NONE
L2 (4356201)SEA FILE=REGISTRY ABB=ON PLU=ON NC5/ESS
L3 281 SEA FILE=REGISTRY SUB=L2 SSS FUL L1
L10 STR

C 107N 108





G4 106



Page 1-A





Page 1-B



Page 2-A



Page 2-B







Page 3-A



Page 3-B
VAR G1=5/11/17/23
VAR G2=107/108
VAR G3=32/38/44/50/60
VAR G4=27/78/90
NODE ATTRIBUTES:

NSPEC	IS R	AT	1
NSPEC	IS R	AT	2
NSPEC	IS R	AT	3
NSPEC	IS R	AT	4
NSPEC	IS R	AT	5
NSPEC	IS R	AT	6
NSPEC	IS R	AT	7
NSPEC	IS R	AT	8
NSPEC	IS R	AT	9
NSPEC	IS R	AT	10
NSPEC	IS R	AT	11
NSPEC	IS R	AT	12
NSPEC	IS R	AT	13
NSPEC	IS R	AT	14
NSPEC	IS R	AT	15
NSPEC	IS R	AT	16
NSPEC	IS R	AT	17
NSPEC	IS R	AT	18
NSPEC	IS R	AT	19
NSPEC	IS R	AT	20
NSPEC	IS R	AT	21
NSPEC	IS R	AT	22
NSPEC	IS R	AT	23
NSPEC	IS R	AT	24
NSPEC	IS R	AT	25
NSPEC	IS R	AT	26
NSPEC	IS R	AT	27
NSPEC	IS R	AT	28
NSPEC	IS R	AT	29
NSPEC	IS R	AT	30

```
NSPEC   IS R      AT  31
NSPEC   IS R      AT  32
NSPEC   IS R      AT  33
NSPEC   IS R      AT  34
NSPEC   IS R      AT  35
NSPEC   IS R      AT  36
NSPEC   IS R      AT  37
NSPEC   IS R      AT  38
NSPEC   IS R      AT  39
NSPEC   IS R      AT  40
NSPEC   IS R      AT  41
NSPEC   IS R      AT  42
NSPEC   IS R      AT  43
NSPEC   IS R      AT  44
NSPEC   IS R      AT  45
NSPEC   IS R      AT  46
NSPEC   IS R      AT  47
NSPEC   IS R      AT  48
NSPEC   IS R      AT  49
NSPEC   IS R      AT  50
NSPEC   IS R      AT  51
NSPEC   IS R      AT  52
NSPEC   IS R      AT  53
NSPEC   IS C      AT  54
NSPEC   IS C      AT  55
NSPEC   IS C      AT  56
NSPEC   IS C      AT  57
NSPEC   IS R      AT  58
NSPEC   IS R      AT  59
NSPEC   IS R      AT  60
NSPEC   IS R      AT  61
NSPEC   IS R      AT  62
NSPEC   IS R      AT  63
NSPEC   IS C      AT  64
NSPEC   IS C      AT  65
NSPEC   IS C      AT  66
NSPEC   IS C      AT  67
NSPEC   IS C      AT  68
NSPEC   IS C      AT  69
NSPEC   IS C      AT  70
NSPEC   IS C      AT  71
NSPEC   IS C      AT  72
NSPEC   IS C      AT  73
NSPEC   IS C      AT  74
NSPEC   IS C      AT  75
NSPEC   IS R      AT  76
NSPEC   IS R      AT  77
NSPEC   IS R      AT  78
NSPEC   IS R      AT  79
NSPEC   IS R      AT  80
NSPEC   IS R      AT  81
NSPEC   IS R      AT  82
NSPEC   IS R      AT  83
NSPEC   IS R      AT  84
NSPEC   IS R      AT  85
NSPEC   IS C      AT  86
NSPEC   IS C      AT  87
NSPEC   IS R      AT  88
NSPEC   IS R      AT  89
NSPEC   IS R      AT  90
```

```
NSPEC   IS R       AT  91
NSPEC   IS R       AT  92
NSPEC   IS R       AT  93
NSPEC   IS R       AT  94
NSPEC   IS R       AT  95
NSPEC   IS R       AT  96
NSPEC   IS R       AT  97
NSPEC   IS R       AT  98
NSPEC   IS R       AT  99
NSPEC   IS R       AT 100
NSPEC   IS R       AT 101
NSPEC   IS R       AT 102
NSPEC   IS R       AT 103
NSPEC   IS R       AT 104
NSPEC   IS R       AT 105
NSPEC   IS C       AT 106
CONNECT IS E3   RC AT  65
CONNECT IS E3   RC AT  66
CONNECT IS E3   RC AT  67
CONNECT IS E3   RC AT  68
CONNECT IS E3   RC AT  69
CONNECT IS E1   RC AT  70
CONNECT IS E1   RC AT  71
CONNECT IS E1   RC AT  72
CONNECT IS E1   RC AT  73
CONNECT IS E1   RC AT  74
CONNECT IS E2   RC AT 100
CONNECT IS E2   RC AT 102
DEFAULT MLEVEL IS ATOM
MLEVEL  IS CLASS  AT  54 55 56 57 64 65 66 67 68 69 70 71 72 73 74
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS 108

STEREO ATTRIBUTES: NONE
L12          180 SEA FILE=REGISTRY SUB=L3 SSS FUL L10
L13            1 SEA FILE=REGISTRY ABB=ON  PLU=ON  "CARBAMIC ACID, (3-(5-(3,4-BI
                 S(PHENYLMETHOXY)PHENYL)-1-(2-PYRIDINYL)-1H-PYRAZOL-3-YL)PHENYL)
                 -, PHENYLMETHYL ESTER"/CN
L14            1 SEA FILE=REGISTRY ABB=ON  PLU=ON  "BENZAMIDE, N-(4-(2-(2-CHLORO
                 PHENYL)-4-(3-METHYLPHENYL)-5-THIAZOLYL)-2-PYRIDINYL)-"/CN
L15            1 SEA FILE=REGISTRY ABB=ON  PLU=ON  "BENZENEACETAMIDE, N-(4-(2-(2
                 -CHLOROPHENYL)-4-(3-METHYLPHENYL)-5-THIAZOLYL)-2-PYRIDINYL)-"/C
                 N
L16            1 SEA FILE=REGISTRY ABB=ON  PLU=ON  "BENZENEPROPANAMIDE,
                 N-(4-(2-(2-CHLOROPHENYL)-4-(3-METHYLPHENYL)-5-THIAZOLYL)-2-PYRI
                 DINYL)-"/CN
L17            4 SEA FILE=REGISTRY ABB=ON  PLU=ON  (L13 OR L14 OR L15 OR L16)
L18          101 SEA FILE=REGISTRY ABB=ON  PLU=ON  L3 [redacted] L12
L19          105 SEA FILE=REGISTRY ABB=ON  PLU=ON  L18 OR L17
```

these 4 (out of the 180 "not" structures) are still good

STRUCTURE QUERY L#

```
=> file caplus

FILE 'CAPLUS' ENTERED AT 11:32:05 ON 17 FEB 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)
```

AUTHOR SEARCH

FILE COVERS 1907 - 17 Feb 2006 VOL 144 ISS 9
FILE LAST UPDATED: 16 Feb 2006 (20060216/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

http://www.cas.org/infopolicy.html
'OBI' IS DEFAULT SEARCH FIELD FOR 'CAPLUS' FILE

=> d que nos L27

```
L24        10289 SEA FILE=CAPLUS ABB=ON  PLU=ON  SINGH R?/AU
L25          208 SEA FILE=CAPLUS ABB=ON  PLU=ON  GOFF D?/AU
L26          396 SEA FILE=CAPLUS ABB=ON  PLU=ON  PARTRIDGE J?/AU
L27            5 SEA FILE=CAPLUS ABB=ON  PLU=ON  L24 AND L25 AND L26
```

=> d que nos L28

```
L24        10289 SEA FILE=CAPLUS ABB=ON  PLU=ON  SINGH R?/AU
L25          208 SEA FILE=CAPLUS ABB=ON  PLU=ON  GOFF D?/AU
L26          396 SEA FILE=CAPLUS ABB=ON  PLU=ON  PARTRIDGE J?/AU
L28            9 SEA FILE=CAPLUS ABB=ON  PLU=ON  L24 AND (L25 OR L26)
```

=> d que nos L29

```
L25          208 SEA FILE=CAPLUS ABB=ON  PLU=ON  GOFF D?/AU
L26          396 SEA FILE=CAPLUS ABB=ON  PLU=ON  PARTRIDGE J?/AU
L29            5 SEA FILE=CAPLUS ABB=ON  PLU=ON  L25 AND L26
```

=> d que nos L46

```
L1               STR
L2  (    4356201)SEA FILE=REGISTRY ABB=ON  PLU=ON  NC5/ESS
L3           281 SEA FILE=REGISTRY SUB=L2 SSS FUL L1
L10              STR
L12          180 SEA FILE=REGISTRY SUB=L3 SSS FUL L10
L13            1 SEA FILE=REGISTRY ABB=ON  PLU=ON  "CARBAMIC ACID, (3-(5-(3,4-BI
                 S(PHENYLMETHOXY)PHENYL)-1-(2-PYRIDINYL)-1H-PYRAZOL-3-YL)PHENYL)
                 -, PHENYLMETHYL ESTER"/CN
L14            1 SEA FILE=REGISTRY ABB=ON  PLU=ON  "BENZAMIDE, N-(4-(2-(2-CHLORO
                 PHENYL)-4-(3-METHYLPHENYL)-5-THIAZOLYL)-2-PYRIDINYL)-"/CN
L15            1 SEA FILE=REGISTRY ABB=ON  PLU=ON  "BENZENEACETAMIDE, N-(4-(2-(2
                 -CHLOROPHENYL)-4-(3-METHYLPHENYL)-5-THIAZOLYL)-2-PYRIDINYL)-"/C
                 N
L16            1 SEA FILE=REGISTRY ABB=ON  PLU=ON  "BENZENEPROPANAMIDE,
```

```
                N-(4-(2-(2-CHLOROPHENYL)-4-(3-METHYLPHENYL)-5-THIAZOLYL)-2-PYRI
                DINYL)-"/CN
L17             4 SEA FILE=REGISTRY ABB=ON  PLU=ON  (L13 OR L14 OR L15 OR L16)
L18           101 SEA FILE=REGISTRY ABB=ON  PLU=ON  L3 NOT L12
L19           105 SEA FILE=REGISTRY ABB=ON  PLU=ON  L18 OR L17
L20            14 SEA FILE=CAPLUS ABB=ON  PLU=ON  L19
L24         10289 SEA FILE=CAPLUS ABB=ON  PLU=ON  SINGH R?/AU
L25           208 SEA FILE=CAPLUS ABB=ON  PLU=ON  GOFF D?/AU
L26           396 SEA FILE=CAPLUS ABB=ON  PLU=ON  PARTRIDGE J?/AU
L46             2 SEA FILE=CAPLUS ABB=ON  PLU=ON  (L24 OR L25 OR L26) AND L20
                  (author search results that were also structure search results)

=> s L27-L29 or L46

L47             9 (L27 OR L28 OR L29) OR L46

=> file uspatfull

FILE 'USPATFULL' ENTERED AT 11:32:09 ON 17 FEB 2006
CA INDEXING COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

FILE COVERS 1971 TO PATENT PUBLICATION DATE: 16 Feb 2006 (20060216/PD)
FILE LAST UPDATED: 16 Feb 2006 (20060216/ED)
HIGHEST GRANTED PATENT NUMBER: US7000250
HIGHEST APPLICATION PUBLICATION NUMBER: US2006037120
CA INDEXING IS CURRENT THROUGH 14 Feb 2006 (20060214/UPCA)
ISSUE CLASS FIELDS (/INCL) CURRENT THROUGH: 16 Feb 2006 (20060216/PD)
REVISED CLASS FIELDS (/NCL) LAST RELOADED: Dec 2005
USPTO MANUAL OF CLASSIFICATIONS THESAURUS ISSUE DATE: Dec 2005


=> d que nos L33

L30           565 SEA FILE=USPATFULL ABB=ON  PLU=ON  SINGH R?/AU
L31            73 SEA FILE=USPATFULL ABB=ON  PLU=ON  GOFF D?/AU
L32            83 SEA FILE=USPATFULL ABB=ON  PLU=ON  PARTRIDGE J?/AU
L33             5 SEA FILE=USPATFULL ABB=ON  PLU=ON  L30 AND L31 AND L32


=> d que nos L34

L30           565 SEA FILE=USPATFULL ABB=ON  PLU=ON  SINGH R?/AU
L31            73 SEA FILE=USPATFULL ABB=ON  PLU=ON  GOFF D?/AU
L32            83 SEA FILE=USPATFULL ABB=ON  PLU=ON  PARTRIDGE J?/AU
L34             7 SEA FILE=USPATFULL ABB=ON  PLU=ON  L30 AND (L31 OR L32)


=> d que nos L35

L31            73 SEA FILE=USPATFULL ABB=ON  PLU=ON  GOFF D?/AU
L32            83 SEA FILE=USPATFULL ABB=ON  PLU=ON  PARTRIDGE J?/AU
L35             5 SEA FILE=USPATFULL ABB=ON  PLU=ON  L31 AND L32


=> d que nos L43

L1                STR
L2  (   4356201)SEA FILE=REGISTRY ABB=ON  PLU=ON  NC5/ESS
L3            281 SEA FILE=REGISTRY SUB=L2 SSS FUL L1
L10               STR
```

```
L12          180 SEA FILE=REGISTRY SUB=L3 SSS FUL L10
L13            1 SEA FILE=REGISTRY ABB=ON  PLU=ON  "CARBAMIC ACID, (3-(5-(3,4-BI
                 S(PHENYLMETHOXY)PHENYL)-1-(2-PYRIDINYL)-1H-PYRAZOL-3-YL)PHENYL)
                 -, PHENYLMETHYL ESTER"/CN
L14            1 SEA FILE=REGISTRY ABB=ON  PLU=ON  "BENZAMIDE, N-(4-(2-(2-CHLORO
                 PHENYL)-4-(3-METHYLPHENYL)-5-THIAZOLYL)-2-PYRIDINYL)-"/CN
L15            1 SEA FILE=REGISTRY ABB=ON  PLU=ON  "BENZENEACETAMIDE, N-(4-(2-(2
                 -CHLOROPHENYL)-4-(3-METHYLPHENYL)-5-THIAZOLYL)-2-PYRIDINYL)-"/C
                 N
L16            1 SEA FILE=REGISTRY ABB=ON  PLU=ON  "BENZENEPROPANAMIDE,
                 N-(4-(2-(2-CHLOROPHENYL)-4-(3-METHYLPHENYL)-5-THIAZOLYL)-2-PYRI
                 DINYL)-"/CN
L17            4 SEA FILE=REGISTRY ABB=ON  PLU=ON  (L13 OR L14 OR L15 OR L16)
L18          101 SEA FILE=REGISTRY ABB=ON  PLU=ON  L3 NOT L12
L19          105 SEA FILE=REGISTRY ABB=ON  PLU=ON  L18 OR L17
L22           13 SEA FILE=USPATFULL ABB=ON  PLU=ON  L19
L30          565 SEA FILE=USPATFULL ABB=ON  PLU=ON  SINGH R?/AU
L31           73 SEA FILE=USPATFULL ABB=ON  PLU=ON  GOFF D?/AU
L32           83 SEA FILE=USPATFULL ABB=ON  PLU=ON  PARTRIDGE J?/AU
L33            5 SEA FILE=USPATFULL ABB=ON  PLU=ON  L30 AND L31 AND L32
L34            7 SEA FILE=USPATFULL ABB=ON  PLU=ON  L30 AND (L31 OR L32)
L35            5 SEA FILE=USPATFULL ABB=ON  PLU=ON  L31 AND L32
L43            2 SEA FILE=USPATFULL ABB=ON  PLU=ON  (L33 OR L34 OR L35) AND L22
```

```
=> d que nos L44

L1              STR
L2   (   4356201)SEA FILE=REGISTRY ABB=ON  PLU=ON  NC5/ESS
L3           281 SEA FILE=REGISTRY SUB=L2 SSS FUL L1
L10              STR
L12          180 SEA FILE=REGISTRY SUB=L3 SSS FUL L10
L13            1 SEA FILE=REGISTRY ABB=ON  PLU=ON  "CARBAMIC ACID, (3-(5-(3,4-BI
                 S(PHENYLMETHOXY)PHENYL)-1-(2-PYRIDINYL)-1H-PYRAZOL-3-YL)PHENYL)
                 -, PHENYLMETHYL ESTER"/CN
L14            1 SEA FILE=REGISTRY ABB=ON  PLU=ON  "BENZAMIDE, N-(4-(2-(2-CHLORO
                 PHENYL)-4-(3-METHYLPHENYL)-5-THIAZOLYL)-2-PYRIDINYL)-"/CN
L15            1 SEA FILE=REGISTRY ABB=ON  PLU=ON  "BENZENEACETAMIDE, N-(4-(2-(2
                 -CHLOROPHENYL)-4-(3-METHYLPHENYL)-5-THIAZOLYL)-2-PYRIDINYL)-"/C
                 N
L16            1 SEA FILE=REGISTRY ABB=ON  PLU=ON  "BENZENEPROPANAMIDE,
                 N-(4-(2-(2-CHLOROPHENYL)-4-(3-METHYLPHENYL)-5-THIAZOLYL)-2-PYRI
                 DINYL)-"/CN
L17            4 SEA FILE=REGISTRY ABB=ON  PLU=ON  (L13 OR L14 OR L15 OR L16)
L18          101 SEA FILE=REGISTRY ABB=ON  PLU=ON  L3 NOT L12
L19          105 SEA FILE=REGISTRY ABB=ON  PLU=ON  L18 OR L17
L22           13 SEA FILE=USPATFULL ABB=ON  PLU=ON  L19
L30          565 SEA FILE=USPATFULL ABB=ON  PLU=ON  SINGH R?/AU
L31           73 SEA FILE=USPATFULL ABB=ON  PLU=ON  GOFF D?/AU
L32           83 SEA FILE=USPATFULL ABB=ON  PLU=ON  PARTRIDGE J?/AU
L44            2 SEA FILE=USPATFULL ABB=ON  PLU=ON  (L30 OR L31 OR L32) AND L22
```

(author search results that were also structure search results)

```
=> s L33-L35 or L43-L44

L48            7 (L33 OR L34 OR L35) OR (L43 OR L44)

=> file toxcenter
```

```
FILE 'TOXCENTER' ENTERED AT 11:32:13 ON 17 FEB 2006
COPYRIGHT (C) 2006 ACS


FILE COVERS 1907 TO 14 Feb 2006 (20060214/ED)

This file contains CAS Registry Numbers for easy and accurate substance
identification.

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TOXCENTER has been enhanced with new files segments and search fields.
See HELP CONTENT for more information.

TOXCENTER thesauri in the /CN, /CT, and /MN fields incorporate the
MeSH 2006 vocabulary.
See http://www.nlm.nih.gov/mesh/
    http://www.nlm.nih.gov/pubs/techbull/nd05/nd05_med_data_changes.html
    http://www.nlm.nih.gov/pubs/techbull/nd05/nd05_2006_MeSH.html
for a description of changes.

=> d que nos L39

L36         2326 SEA FILE=TOXCENTER ABB=ON  PLU=ON  SINGH R?/AU
L37          171 SEA FILE=TOXCENTER ABB=ON  PLU=ON  GOFF D?/AU
L38          101 SEA FILE=TOXCENTER ABB=ON  PLU=ON  PARTRIDGE J?/AU
L39            1 SEA FILE=TOXCENTER ABB=ON  PLU=ON  L36 AND L37 AND L38


=> d que nos L40

L36         2326 SEA FILE=TOXCENTER ABB=ON  PLU=ON  SINGH R?/AU
L37          171 SEA FILE=TOXCENTER ABB=ON  PLU=ON  GOFF D?/AU
L38          101 SEA FILE=TOXCENTER ABB=ON  PLU=ON  PARTRIDGE J?/AU
L40            2 SEA FILE=TOXCENTER ABB=ON  PLU=ON  L36 AND (L37 OR L38)


=> d que nos L41

L37          171 SEA FILE=TOXCENTER ABB=ON  PLU=ON  GOFF D?/AU
L38          101 SEA FILE=TOXCENTER ABB=ON  PLU=ON  PARTRIDGE J?/AU
L41            1 SEA FILE=TOXCENTER ABB=ON  PLU=ON  L37 AND L38


=> d que nos L42

L1               STR
L2  (   4356201) SEA FILE=REGISTRY ABB=ON  PLU=ON  NC5/ESS
L3           281 SEA FILE=REGISTRY SUB=L2 SSS FUL L1
L10              STR
L12          180 SEA FILE=REGISTRY SUB=L3 SSS FUL L10
L13            1 SEA FILE=REGISTRY ABB=ON  PLU=ON  "CARBAMIC ACID, (3-(5-(3,4-BI
                 S(PHENYLMETHOXY)PHENYL)-1-(2-PYRIDINYL)-1H-PYRAZOL-3-YL)PHENYL)
                 -, PHENYLMETHYL ESTER"/CN
L14            1 SEA FILE=REGISTRY ABB=ON  PLU=ON  "BENZAMIDE, N-(4-(2-(2-CHLORO
                 PHENYL)-4-(3-METHYLPHENYL)-5-THIAZOLYL)-2-PYRIDINYL)-"/CN
L15            1 SEA FILE=REGISTRY ABB=ON  PLU=ON  "BENZENEACETAMIDE, N-(4-(2-(2
                 -CHLOROPHENYL)-4-(3-METHYLPHENYL)-5-THIAZOLYL)-2-PYRIDINYL)-"/C
                 N
```

```
L16             1 SEA FILE=REGISTRY ABB=ON  PLU=ON  "BENZENEPROPANAMIDE,
                  N-(4-(2-(2-CHLOROPHENYL)-4-(3-METHYLPHENYL)-5-THIAZOLYL)-2-PYRI
                  DINYL)-"/CN
L17             4 SEA FILE=REGISTRY ABB=ON  PLU=ON  (L13 OR L14 OR L15 OR L16)
L18           101 SEA FILE=REGISTRY ABB=ON  PLU=ON  L3 NOT L12
L19           105 SEA FILE=REGISTRY ABB=ON  PLU=ON  L18 OR L17
L23             4 SEA FILE=TOXCENTER ABB=ON  PLU=ON  L19
L36          2326 SEA FILE=TOXCENTER ABB=ON  PLU=ON  SINGH R?/AU
L37           171 SEA FILE=TOXCENTER ABB=ON  PLU=ON  GOFF D?/AU
L38           101 SEA FILE=TOXCENTER ABB=ON  PLU=ON  PARTRIDGE J?/AU
L39             1 SEA FILE=TOXCENTER ABB=ON  PLU=ON  L36 AND L37 AND L38
L40             2 SEA FILE=TOXCENTER ABB=ON  PLU=ON  L36 AND (L37 OR L38)
L41             1 SEA FILE=TOXCENTER ABB=ON  PLU=ON  L37 AND L38
L42             1 SEA FILE=TOXCENTER ABB=ON  PLU=ON  (L39 OR L40 OR L41) AND L23
```

```
=> d que nos L45

L1              STR
L2  (   4356201)SEA FILE=REGISTRY ABB=ON  PLU=ON  NC5/ESS
L3            281 SEA FILE=REGISTRY SUB=L2 SSS FUL L1
L10             STR
L12           180 SEA FILE=REGISTRY SUB=L3 SSS FUL L10
L13             1 SEA FILE=REGISTRY ABB=ON  PLU=ON  "CARBAMIC ACID, (3-(5-(3,4-BI
                  S(PHENYLMETHOXY)PHENYL)-1-(2-PYRIDINYL)-1H-PYRAZOL-3-YL)PHENYL)
                  -, PHENYLMETHYL ESTER"/CN
L14             1 SEA FILE=REGISTRY ABB=ON  PLU=ON  "BENZAMIDE, N-(4-(2-(2-CHLORO
                  PHENYL)-4-(3-METHYLPHENYL)-5-THIAZOLYL)-2-PYRIDINYL)-"/CN
L15             1 SEA FILE=REGISTRY ABB=ON  PLU=ON  "BENZENEACETAMIDE, N-(4-(2-(2
                  -CHLOROPHENYL)-4-(3-METHYLPHENYL)-5-THIAZOLYL)-2-PYRIDINYL)-"/C
                  N
L16             1 SEA FILE=REGISTRY ABB=ON  PLU=ON  "BENZENEPROPANAMIDE,
                  N-(4-(2-(2-CHLOROPHENYL)-4-(3-METHYLPHENYL)-5-THIAZOLYL)-2-PYRI
                  DINYL)-"/CN
L17             4 SEA FILE=REGISTRY ABB=ON  PLU=ON  (L13 OR L14 OR L15 OR L16)
L18           101 SEA FILE=REGISTRY ABB=ON  PLU=ON  L3 NOT L12
L19           105 SEA FILE=REGISTRY ABB=ON  PLU=ON  L18 OR L17
L23             4 SEA FILE=TOXCENTER ABB=ON  PLU=ON  L19
L36          2326 SEA FILE=TOXCENTER ABB=ON  PLU=ON  SINGH R?/AU
L37           171 SEA FILE=TOXCENTER ABB=ON  PLU=ON  GOFF D?/AU
L38           101 SEA FILE=TOXCENTER ABB=ON  PLU=ON  PARTRIDGE J?/AU
L45             1 SEA FILE=TOXCENTER ABB=ON  PLU=ON  (L36 OR L37 OR L38) AND L23
```

(author search results that were also structure search results)

```
=> s L39-L42 or L45

L49             2 (L39 OR L40 OR L41 OR L42) OR L45

=> => dup rem L47 L48 L49
FILE 'CAPLUS' ENTERED AT 11:33:37 ON 17 FEB 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'USPATFULL' ENTERED AT 11:33:37 ON 17 FEB 2006
CA INDEXING COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'TOXCENTER' ENTERED AT 11:33:37 ON 17 FEB 2006
```

COPYRIGHT (C) 2006 ACS
PROCESSING COMPLETED FOR L47
PROCESSING COMPLETED FOR L48
PROCESSING COMPLETED FOR L49
L50 15 DUP REM L47 L48 L49 (3 DUPLICATES REMOVED)
ANSWERS '1-9' FROM FILE CAPLUS
ANSWERS '10-15' FROM FILE USPATFULL

=> d ibib abs hitind hitstr L50 1-9; d ibib abs hitstr L50 10-15

L50 ANSWER 1 OF 15 CAPLUS COPYRIGHT 2006 ACS on STN DUPLICATE 1
ACCESSION NUMBER: 2004:430800 CAPLUS
DOCUMENT NUMBER: 140:423667
TITLE: A preparation of rhodanine derivatives, useful as inhibitors of ubiquitination
INVENTOR(S): **Singh, Rajinder**; Ramesh, Usha V.; **Goff, Dane**; Laidig, Guy; Issakani, Sarkiz D.; Huang, Jianing; Payan, Donald G.
PATENT ASSIGNEE(S): Rigel Pharmaceuticals, Inc., USA
SOURCE: PCT Int. Appl., 71 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004043955	A1	20040527	WO 2003-US36747	20031113
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
EP 1597255	A1	20051123	EP 2003-783609	20031113
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				

PRIORITY APPLN. INFO.:
US 2002-426280P P 20021113
US 2003-514951P P 20031028
WO 2003-US36747 W 20031113

OTHER SOURCE(S): MARPAT 140:423667
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB This invention describes rhodanine derivs. of formula I [wherein: A is (hetero)aryl; B is C1-6alkyl or C2-6alkenyl; X is S, O, etc.; Y is S, O, S(O), or SO2, etc.; R1 = H, NH2, C1-6alkyl, or C1-2alkenyl, etc.; R2 = H, halogen, C1-6alkyl, C0-6alkyl-(hetero)aryl, or NO2, etc.; R3 = H, C1-6alkyl, or C2-6alkenyl; or R3 and B together with the carbon atom to which they are attached form an alkenyl or a spirocyclic ring], useful as inhibitors of ubiquitination. The compds. and compns. of the invention

are useful as inhibitors of the biochem. pathways of organisms in which ubiquitination is involved. The invention compds. were screened in MDM2 assay (measuring the attachment of ubiquitin to p53) and APC-11/APC-2 ligase assay (auto-ubiquitination). In particular, the compds. and compns. are useful for treating cell proliferative diseases such as cancers. For instance, rhodanine derivative II was prepared via addition of Et thioglycolate to benzyl isothiocyanate, intramol. heterocyclization of the obtained carboxylate III, and condensation of furan derivative IV with the obtained thiazolone V (example 1).

IC ICM C07D417-06
ICS C07D417-14; A61K031-427; A61P035-00
CC 28-7 (Heterocyclic Compounds (More Than One Hetero Atom))
Section cross-reference(s): 1, 63
REFERENCE COUNT: 22 THERE ARE 22 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L50 ANSWER 2 OF 15 CAPLUS COPYRIGHT 2006 ACS on STN DUPLICATE 2
ACCESSION NUMBER: 2004:182875 CAPLUS
DOCUMENT NUMBER: 140:235699
TITLE: Preparation of pyridyl substituted heterocycles useful for treating or preventing HCV infection
INVENTOR(S): **Singh, Rajinder; Goff, Dane; Partridge, John**
PATENT ASSIGNEE(S): Rigel Pharmaceuticals, Inc., USA
SOURCE: PCT Int. Appl., 158 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
WO 2004018463	A2	20040304	WO 2003-US26478		20030822
WO 2004018463	A3	20040506			
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW					
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG					
CA 2494164	AA	20040304	CA 2003-2494164		20030822
US 2004127497	A1	20040701	US 2003-646348		20030822
EP 1530569	A2	20050518	EP 2003-793349		20030822
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK					
BR 2003013755	A	20050621	BR 2003-13755		20030822
JP 2006501312	T2	20060112	JP 2005-501778		20030822
NO 2005001404	A	20050510	NO 2005-1404		20050317
PRIORITY APPLN. INFO.:			US 2002-405467P	P	20020823
			US 2002-417837P	P	20021011
			US 2003-471373P	P	20030515
			US 2003-646348	A	20030822
			WO 2003-US26478	W	20030822

OTHER SOURCE(S): MARPAT 140:235699
GI



I



II



III

AB The present invention relates to the preparation of pyridyl substituted heterocycles I and II [B ring is aromatic or nonarom. ring that includes 1-4 heteroatoms, wherein X, Y, and Z independently = C, CH, N, substituted N, S, or O, provided that X and Y are not both O; U and T independently = C, CH, or N; Z = N or CH; A = N or CR2; B = N or CR3; D = N or CR4; E = N or CR5; G = N or CR6; J = N or CR14; K = N or CR8; L = N or CR9; M = N or CR10; R2 and R6 = H, halo, (un)substituted-alkyl, -alkoxy, -carbamoyl, etc.; R3 and R5 = H, halo, (un)substituted-alkyl, -alkylthio, -carbamoyl, etc.; R4 = H, halo, (un)substituted-alkyl, -alkylthio, -alkoxy, -dialkylamino, etc.; R8, R9, R10, R14 = H or halo; R7 = NR11COR12; R11 = H or alkyl; R12 = substituted alkyl or (un)substituted cycloheteroalkyl; with provisions that (i) at least one of A, B, D, E, G, J, K, L or M = n, (ii) no more than one of A, B, D, E or G = N, and (iii) no more than one of J, K, L or M = N] and hydro isomers thereof and pharmaceutical compns. thereof that inhibit replication and/or proliferation of HCV virus. Thus, e.g., III, was prepared by cyclocondensation of 2-ethynyl-4-(dichloromethylcarboxamido)pyridine (preparation given) with the chlorooxime of 2-fluoro-6-trifluoromethylbenzaldehyde. The inhibitory activity of I was confirmed using an HCV replicon assay with numerous compds. possessing IC50 values of less than 10 μM. The present invention also relates to the use of the pyridyl heterocycles and hydro isomers thereof and/or pharmaceutical compns. comprising the compds. to treat or prevent HCV infections.

IC ICM C07D413-14
ICS C07D401-14; C07D417-14; C07D413-04; C07D417-04; C07D401-04; A61K031-4439; A61P031-12

CC 28-6 (Heterocyclic Compounds (More Than One Hetero Atom))
Section cross-reference(s): 1, 63

IT **667931-22-8P 667931-24-0P 667931-28-4P**
667931-30-8P 667931-32-0P 667931-34-2P
667931-36-4P 667931-38-6P 667931-40-0P
667931-42-2P 667931-44-4P 667931-46-6P

667931-48-8P 667931-50-2P 667931-52-4P
667931-60-4P 667931-62-6P 667931-64-8P
667931-68-2P 667931-80-8P
RL: ADV (Adverse effect, including toxicity); PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(drug candidate; prepare and cytotoxicity of pyridylisoxazoles for treatment of hepatitis C virus infections)

IT **667931-26-2P 667931-56-8P 667931-58-0P**
667931-66-0P 667931-70-6P 667931-72-8P
667931-74-0P 667931-76-2P **667931-78-4P**
667931-82-0P 667931-84-2P 667931-87-5P
667931-89-7P 667931-91-1P 667931-92-2P
667931-94-4P 667931-96-6P 667931-98-8P
667932-00-5P 667932-02-7P 667932-04-9P
667932-06-1P 667932-08-3P 667932-10-7P
667932-12-9P 667932-14-1P 667932-16-3P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(drug candidate; prepare and cytotoxicity of pyridylisoxazoles for treatment of hepatitis C virus infections)

IT **667931-22-8P 667931-24-0P 667931-28-4P**
667931-30-8P 667931-32-0P 667931-34-2P
667931-36-4P 667931-38-6P 667931-40-0P
667931-42-2P 667931-44-4P 667931-46-6P
667931-48-8P 667931-50-2P 667931-52-4P
667931-60-4P 667931-62-6P 667931-64-8P
667931-68-2P 667931-80-8P
RL: ADV (Adverse effect, including toxicity); PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(drug candidate; prepare and cytotoxicity of pyridylisoxazoles for treatment of hepatitis C virus infections)

RN 667931-22-8 CAPLUS
CN Acetamide, 2,2-dichloro-N-[2-[3-(2-chloro-6-fluorophenyl)-5-isoxazolyl]-4-pyridinyl]- (9CI) (CA INDEX NAME)



RN 667931-24-0 CAPLUS
CN Acetamide, 2,2-dichloro-N-[2-[3-[2-fluoro-6-(trifluoromethyl)phenyl]-5-isoxazolyl]-4-pyridinyl]- (9CI) (CA INDEX NAME)



RN 667931-28-4 CAPLUS
CN Acetamide, 2,2-dichloro-N-[5-[3-(2,6-dichlorophenyl)-5-isoxazolyl]-3-pyridinyl]- (9CI) (CA INDEX NAME)



RN 667931-30-8 CAPLUS
CN Acetamide, 2,2-dichloro-N-[2-[3-(2,6-dichlorophenyl)-5-isoxazolyl]-4-pyridinyl]- (9CI) (CA INDEX NAME)



RN 667931-32-0 CAPLUS
CN Acetamide, 2,2-dichloro-N-[3-[3-(3,5-dichloro-4-pyridinyl)-5-isoxazolyl]phenyl]- (9CI) (CA INDEX NAME)



RN 667931-34-2 CAPLUS
CN Acetamide, 2,2-dichloro-N-[5-[3-(2-chloro-6-fluorophenyl)-5-isoxazolyl]-3-pyridinyl]- (9CI) (CA INDEX NAME)



RN 667931-36-4 CAPLUS
CN Acetamide, 2,2-dichloro-N-[5-[3-(2-fluoro-6-methoxyphenyl)-5-isoxazolyl]-3-pyridinyl]- (9CI) (CA INDEX NAME)



RN 667931-38-6 CAPLUS
CN Acetamide, 2,2-dichloro-N-[2-[3-(2,6-dimethylphenyl)-5-isoxazolyl]-4-pyridinyl]- (9CI) (CA INDEX NAME)



RN 667931-40-0 CAPLUS
CN Acetamide, 2,2-dichloro-N-[5-[3-(2,6-dimethylphenyl)-5-isoxazolyl]-3-pyridinyl]- (9CI) (CA INDEX NAME)



RN 667931-42-2 CAPLUS
CN Acetamide, 2,2-dichloro-N-[5-[3-(2,6-difluorophenyl)-5-isoxazolyl]-3-pyridinyl]- (9CI) (CA INDEX NAME)



RN 667931-44-4 CAPLUS
CN Acetamide, 2,2-dichloro-N-[5-[3-(2,3-dichlorophenyl)-5-isoxazolyl]-3-pyridinyl]- (9CI) (CA INDEX NAME)



RN 667931-46-6 CAPLUS
CN Acetamide, 2,2-dichloro-N-[2-[3-[2-(4-morpholinyl)-6-(trifluoromethyl)phenyl]-5-isoxazolyl]-4-pyridinyl]- (9CI) (CA INDEX NAME)



RN 667931-48-8 CAPLUS
CN Acetamide, 2,2-dichloro-N-[3-[3-(3-methyl-2-pyridinyl)-5-isoxazolyl]phenyl]- (9CI) (CA INDEX NAME)



RN 667931-50-2 CAPLUS
CN Acetamide, 2,2-dichloro-N-[6-[3-(2,6-dichlorophenyl)-5-isoxazolyl]-2-pyridinyl]- (9CI) (CA INDEX NAME)



RN 667931-52-4 CAPLUS
CN Acetamide, 2,2-dichloro-N-[5-[3-[2-fluoro-6-(trifluoromethyl)phenyl]-5-isoxazolyl]-3-pyridinyl]- (9CI) (CA INDEX NAME)



RN 667931-60-4 CAPLUS
CN Acetamide, 2,2-dichloro-N-[2-[3-[2-fluoro-6-(4-morpholinylsulfonyl)phenyl]-5-isoxazolyl]-4-pyridinyl]- (9CI) (CA INDEX NAME)



RN 667931-62-6 CAPLUS
CN Acetamide, 2,2-dichloro-N-[2-[3-[2-methoxy-6-(trifluoromethyl)phenyl]-5-isoxazolyl]-4-pyridinyl]- (9CI) (CA INDEX NAME)



RN 667931-64-8 CAPLUS
CN Acetamide, 2,2-dichloro-N-[2-[3-(2,6-dichlorophenyl)-5-isoxazolyl]-4-pyridinyl]-N-methyl- (9CI) (CA INDEX NAME)



RN 667931-68-2 CAPLUS
CN Acetamide, 2,2-dichloro-N-[5-[3-[2-methoxy-6-(trifluoromethyl)phenyl]-5-isoxazolyl]-3-pyridinyl]- (9CI) (CA INDEX NAME)



RN 667931-80-8 CAPLUS
CN Acetamide, 2,2-dichloro-N-[5-[3-[2-chloro-6-[4-(2-pyridinyl)-1-piperazinyl]phenyl]-5-isoxazolyl]-3-pyridinyl]- (9CI) (CA INDEX NAME)



IT **667931-26-2P 667931-56-8P 667931-58-0P**
667931-66-0P 667931-70-6P 667931-72-8P
667931-74-0P 667931-78-4P 667931-82-0P
667931-84-2P 667931-87-5P 667931-89-7P
667931-91-1P 667931-92-2P 667931-94-4P
667931-96-6P 667931-98-8P 667932-00-5P
667932-02-7P 667932-04-9P 667932-06-1P
667932-08-3P 667932-10-7P 667932-12-9P
667932-14-1P 667932-16-3P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(drug candidate; prepare and cytotoxicity of pyridylisoxazoles for treatment of hepatitis C virus infections)

RN 667931-26-2 CAPLUS
CN Acetamide, 2,2-dichloro-N-[2-[3-(2-fluoro-6-methoxyphenyl)-5-isoxazolyl]-4-pyridinyl]- (9CI) (CA INDEX NAME)



RN 667931-56-8 CAPLUS
CN Acetamide, 2,2-dichloro-N-[2-[3-(2,6-dichlorophenyl)-5-isoxazolyl]-1-oxido-4-pyridinyl]- (9CI) (CA INDEX NAME)



RN 667931-58-0 CAPLUS
CN 3-Pyridinecarboxylic acid, 2-[5-[3-[(dichloroacetyl)amino]phenyl]-3-isoxazolyl]-, ethyl ester (9CI) (CA INDEX NAME)



RN 667931-66-0 CAPLUS
CN Acetamide, 2,2-dichloro-N-[2-[3-[2-chloro-6-[4-(2-pyridinyl)-1-piperazinyl]phenyl]-5-isoxazolyl]-4-pyridinyl]- (9CI) (CA INDEX NAME)



RN 667931-70-6 CAPLUS
CN Acetamide, 2,2-dichloro-N-[5-[3-[2-[4-(2-pyridinyl)-1-piperazinyl]-6-

(trifluoromethyl)phenyl]-5-isoxazolyl]-3-pyridinyl]- (9CI) (CA INDEX NAME)



RN 667931-72-8 CAPLUS
CN Acetamide, N-[5-[3-[2-(4-acetyl-1-piperazinyl)-6-chlorophenyl]-5-isoxazolyl]-3-pyridinyl]-2,2-dichloro- (9CI) (CA INDEX NAME)



RN 667931-74-0 CAPLUS
CN Acetamide, 2,2-dichloro-N-[5-[3-[2-chloro-6-(4-ethyl-1-piperazinyl)phenyl]-5-isoxazolyl]-3-pyridinyl]- (9CI) (CA INDEX NAME)



RN 667931-78-4 CAPLUS
CN Acetamide, 2,2-dichloro-N-[5-[3-[2-(trifluoromethyl)phenyl]-5-isoxazolyl]-3-pyridinyl]- (9CI) (CA INDEX NAME)



RN 667931-82-0 CAPLUS
CN 1-Piperazinecarboxylic acid, 4-[3-chloro-2-[5-[5-[(dichloroacetyl)amino]-3-pyridinyl]-3-isoxazolyl]phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 667931-84-2 CAPLUS
CN Acetamide, 2,2-dichloro-N-[5-[3-[2-chloro-6-(1-piperazinyl)phenyl]-5-isoxazolyl]-3-pyridinyl]- (9CI) (CA INDEX NAME)



RN 667931-87-5 CAPLUS
CN Acetamide, 2,2-dichloro-N-[5-[3-[2-chloro-6-[[(1,1-dimethylethyl)dimethylsilyl]oxy]phenyl]-5-isoxazolyl]-3-pyridinyl]- (9CI) (CA INDEX NAME)



RN 667931-89-7 CAPLUS
CN Acetamide, 2,2-dichloro-N-[5-[3-(2-chloro-6-hydroxyphenyl)-5-isoxazolyl]-3-pyridinyl]- (9CI) (CA INDEX NAME)



RN 667931-91-1 CAPLUS
CN Carbamic acid, ethyl-, 3-chloro-2-[5-[5-[(dichloroacetyl)amino]-3-pyridinyl]-3-isoxazolyl]phenyl ester (9CI) (CA INDEX NAME)



RN 667931-92-2 CAPLUS

CN 1-Piperazinecarboxamide, 4-[3-chloro-2-[5-[5-[(dichloroacetyl)amino]-3-pyridinyl]-3-isoxazolyl]phenyl]-N-ethyl- (9CI) (CA INDEX NAME)



RN 667931-94-4 CAPLUS
CN Acetamide, 2,2-dichloro-N-[2-[3-[2-chloro-6-[[(1,1-dimethylethyl)dimethylsilyl]oxy]phenyl]-5-isoxazolyl]-4-pyridinyl]- (9CI) (CA INDEX NAME)



RN 667931-96-6 CAPLUS
CN Carbamic acid, propyl-, 3-chloro-2-[5-[4-[(dichloroacetyl)amino]-2-pyridinyl]-3-isoxazolyl]phenyl ester (9CI) (CA INDEX NAME)



RN 667931-98-8 CAPLUS
CN Acetamide, 2,2-dichloro-N-[2-[3-[2-chloro-6-(methoxymethoxy)phenyl]-5-isoxazolyl]-4-pyridinyl]- (9CI) (CA INDEX NAME)



RN 667932-00-5 CAPLUS
CN Acetamide, 2,2-dichloro-N-[2-[3-(2-chloro-6-hydroxyphenyl)-5-isoxazolyl]-4-pyridinyl]- (9CI) (CA INDEX NAME)



RN 667932-02-7 CAPLUS
CN Acetamide, 2,2-dichloro-N-[3-[3-[4-chloro-2-(dimethylamino)-3-pyridinyl]-5-isoxazolyl]phenyl]- (9CI) (CA INDEX NAME)



RN 667932-04-9 CAPLUS
CN Acetamide, 2,2-dichloro-N-[3-[3-(2,4-dichloro-3-pyridinyl)-5-isoxazolyl]phenyl]- (9CI) (CA INDEX NAME)



RN 667932-06-1 CAPLUS
CN Acetamide, 2,2-dichloro-N-[3-[3-[2-chloro-4-(4-morpholinyl)-3-pyridinyl]-5-isoxazolyl]phenyl]- (9CI) (CA INDEX NAME)



RN 667932-08-3 CAPLUS
CN Acetamide, N-[3-[3-(6-bromo-2-pyridinyl)-5-isoxazolyl]phenyl]-2,2-dichloro- (9CI) (CA INDEX NAME)



RN 667932-10-7 CAPLUS
CN Acetamide, 2,2-dichloro-N-[2-[3-(2,6-dichlorophenyl)-5-isoxazolyl]-4-pyridinyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 667932-12-9 CAPLUS
CN Acetamide, 2,2-dichloro-N-[2-[3-(2,6-dichlorophenyl)-5-isoxazolyl]-4-pyridinyl]-, mono(4-methylbenzenesulfonate) (9CI) (CA INDEX NAME)

CM 1

CRN 667931-30-8
CMF C16 H9 Cl4 N3 O2



CM 2

CRN 104-15-4
CMF C7 H8 O3 S



RN 667932-14-1 CAPLUS
CN Ethanesulfonic acid, compd. with 2,2-dichloro-N-[2-[3-(2,6-dichlorophenyl)-5-isoxazolyl]-4-pyridinyl]acetamide (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 667931-30-8
CMF C16 H9 Cl4 N3 O2



CM 2

CRN 594-45-6
CMF C2 H6 O3 S



RN 667932-16-3 CAPLUS
CN Acetamide, 2,2-dichloro-N-[2-[3-(2,6-dichlorophenyl)-5-isoxazolyl]-4-pyridinyl]-, mononitrate (9CI) (CA INDEX NAME)

CM 1

CRN 667931-30-8
CMF C16 H9 Cl4 N3 O2



CM 2

CRN 7697-37-2
CMF H N O3



L50 ANSWER 3 OF 15 CAPLUS COPYRIGHT 2006 ACS on STN DUPLICATE 3
ACCESSION NUMBER: 2004:589255 CAPLUS
DOCUMENT NUMBER: 141:140418
TITLE: Preparation of diphenylazoles for treatment of hepatitis C infection
INVENTOR(S): **Singh, Rajinder; Goff, Dane; Partridge, John**
PATENT ASSIGNEE(S): USA
SOURCE: U.S. Pat. Appl. Publ., 92 pp.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE

US 2004142985	A1	20040722	US 2003-440349 20030515
WO 2004103366	A1	20041202	WO 2004-US14520 20040510

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW

RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: US 2003-440349 A 20030515
OTHER SOURCE(S): MARPAT 141:140418
GI



I

AB Title compds. [I; X, Y, Z = C, CH, N, NR16, NR18, S, O; U, T = C, CH, N; R2-R6, R8-R10, R13 = H, OH, SH, cyano, NO2, N3, F, Cl, Br, iodo, (substituted) alkyl, heteroalkyl, cycloalkyl, haloalkyl, alkoxy, aryl, aryloxy, PhO, aralkyl, etc.; R11 = H, alkyl; R12 = mono- or dihalomethyl; R16, R18 = H, (substituted) alkyl, heteroalkyl, cycloheteroalkyl, aralkoxy,aryl, aryloxy, PhO, carbamoyl, etc.; with provisos], were prepared Thus, 3-(3-aminophenyl)-5-(2,6-dichlorophenyl)isoxazole (preparation given) in THF was treated with Et3N and then with dichloroacetyl chloride under ice cooling to give 2,2-dichloro-N-[3-[5-(2,6-dichlorophenyl)-3-isoxazolyl]phenyl]acetamide. Some I inhibited HCV replication with IC50 values in the nanomolar range.

IC ICM A61K031-4245
ICS A61K031-4196; C07D271-12; C07D249-14
INCL 514364000; 514383000; 548131000; 548264800
CC 28-6 (Heterocyclic Compounds (More Than One Hetero Atom))
Section cross-reference(s): 1

L50 ANSWER 4 OF 15 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2005:1126672 CAPLUS
DOCUMENT NUMBER: 143:405897
TITLE: Heterocyclic anti-viral compounds comprising metabolizable moieties and their uses as inhibitors of hepatitis C virus replication and/or proliferation for treatment of hepatitis C infection
INVENTOR(S): **Singh, Rajinder**; **Goff, Dane**; Kolluri, Rao S. S.; Darwish, Ihab S.; **Partridge, John**; Cooper, Robin; Lu, Henry H.; Park, Gary
PATENT ASSIGNEE(S): Rigel Pharmaceuticals, Inc., USA

SOURCE: PCT Int. Appl., 149 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005097760	A1	20051020	WO 2005-US9909	20050325
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 2005239751	A1	20051027	US 2005-90823	20050325
PRIORITY APPLN. INFO.:			US 2004-556625P P	20040326
			US 2004-582903P P	20040624

OTHER SOURCE(S): MARPAT 143:405897

AB The invention is related to substituted diphenyl-, diheteroaryl- and mixed Ph heteroaryl substituted 5-membered heterocycle compds. of formula A-B-D-(CO)n-N(R11)-CO-CX2-R12 (I) [A = substituted Ph, 6-membered heteroaryl, provided that at least one of the substituents is located in the ortho position; B = (un)saturated, aromatic heteroat. ring having from 1 to 3 annular heteroatoms, with proviso; D = Ph, heteroaryl with provisos; n = 0-1; R11 = H, lower alkyl, aryloxy, 5-substituted 2-oxo-1,3-dioxol-4-yl, etc.; R12 = H, OCO-alkyl, aryloxycarbonyl, alkylcarbonyl, PO3H2 and derivs., etc.; X = H, halo, provided both X are not H; including pharmaceutically acceptable salts, hydrates, solvates, and N-oxides], prodrugs and compns. thereof useful for treating or preventing Hepatitis C virus (HCV) infections. The invention is particularly related to di-Ph and Ph pyridinyl isoxazoles of formula I. For example, a 3-step synthesis, starting from 3-ethynylaniline and 2,2-dichloro-2-(diethoxyphosphonyl)acetyl chloride (preparation given), was given for 2,2-Dichloro-2-(dihydroxyphosphonyl)-N-[3-[3-(2,6-dichlorophenyl)-5-isoxazolyl]phenyl]acetamide. The invention is also related to the use of compds. and compns. to inhibit HCV replication and/or proliferation and to treat or prevent HCV infections in humans and animals. Selected I inhibited HCV translation or replication with IC50's < 10 μM in a replicon and/or Western blot assay.

IC ICM C07D261-08
ICS C07D413-04; A61K031-4439; A61P031-12

CC 28-6 (Heterocyclic Compounds (More Than One Hetero Atom))
Section cross-reference(s): 1, 63

IT **867215-83-6P**, 2,2-Dichloro-N-[2-[3-(2,6-dichlorophenyl)-5-isoxazolyl]-4-pyridyl]-N-[(5-tert-butyl-2-oxo-1,3-dioxol-4-yl)methyl]acetamide
RL: PAC (Pharmacological activity); PKT (Pharmacokinetics); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(drug candidate; preparation of substituted heterocyclic prodrugs for treating HCV infection)

IT 867215-36-9P **867215-95-0P**, tert-Butyl 4-[3-[2,2-Dichloro-N-[2-[3-

(2,6-dichlorophenyl)isoxazol-5-yl]pyridin-4-yl]acetamido]propanoyl]benzoat
e 867216-30-6P, tert-Butyl 2-[3-[[2-[3-(2,6-Dichlorophenyl)isoxazol-5-
yl]pyridin-4-yl]amino]propanoyl]pyrrolidine-1-carboxylate 867216-39-5P,
tert-Butyl 4-[3-Chloro-2-[5-[3-[2,2-dichloro-N-[(5-isopropyl-2-oxo-1,3-
dioxol-4-yl)methyl]acetamido]phenyl]isoxazol-3-yl]phenoxy]piperidine-1-
carboxylate **867216-46-4P**, Di-tert-butyl [[4-[3-[2,2-Dichloro-N-
[2-[3-(2,6-dichlorophenyl)isoxazol-5-yl]pyridin-4-
yl]acetamido]propyl]phenyl]methyl]phosphonate
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic
preparation); THU (Therapeutic use); BIOL (Biological study); PREP
(Preparation); RACT (Reactant or reagent); USES (Uses)
(drug candidate; preparation of substituted heterocyclic prodrugs for
treating HCV infection)

IT **667931-30-8P** 867215-38-1P, 2,2-Dichloro-2-(dihydroxyphosphonyl)-
N-[3-[3-(2,6-dichlorophenyl)-5-isoxazolyl]phenyl]acetamide 867215-39-2P,
2-Chloro-2-(diethoxyphosphonyl)-N-[3-[3-(2,6-dichlorophenyl)-5-
isoxazolyl]phenyl]acetamide 867215-40-5P, 2-Chloro-2-
(diethoxyphosphonyl)-2-fluoro-N-[3-[3-(2,6-dichlorophenyl)-5-
isoxazolyl]phenyl]acetamide 867215-41-6P, 2-(Diethoxyphosphonyl)-2,2-
difluoro-N-[3-[3-(2,6-dichlorophenyl)-5-isoxazolyl]phenyl]acetamide
867215-42-7P, 2,2-Dichloro-2-(diisopropoxyphosphonyl)-N-[3-[3-(2,6-
dichlorophenyl)-5-isoxazolyl]phenyl]acetamide 867215-43-8P,
2,2-Dichloro-2-(diethoxyphosphonyl)-N-[3-[3-(2-trifluoromethylphenyl)-5-
isoxazolyl]phenyl]acetamide 867215-44-9P, 2,2-Dichloro-2-
(diethoxyphosphonyl)-N-[3-[3-(2-fluoro-6-trifluoromethylphenyl)-5-
isoxazolyl]phenyl]acetamide 867215-45-0P, 2,2-Dichloro-2-(tert-
butoxycarbonyl)-N-[3-[3-(2,6-dichlorophenyl)-5-isoxazolyl]phenyl]acetamide
867215-48-3P, 2,2-Dichloro-2-(isopropoxycarbonyl)-N-[3-[3-(2,6-
dichlorophenyl)-5-isoxazolyl]phenyl]acetamide 867215-51-8P,
2,2-Dichloro-2-[[[(1S)-ethoxycarbonyl-1-(methyl)methyl]oxy]carbonyl]-N-[3-
[3-(2,6-dichlorophenyl)-5-isoxazolyl]phenyl]acetamide 867215-52-9P
867215-53-0P, 2,2-Dichloro-2-[[(1-adamantyl)oxy]carbonyl]-N-[3-[3-(2,6-
dichlorophenyl)-5-isoxazolyl]phenyl]acetamide 867215-54-1P,
2,2-Dichloro-2-((1R,2S,5R)-menthyloxycarbonyl)-N-[3-[3-(2,6-
dichlorophenyl)-5-isoxazolyl]phenyl]acetamide 867215-55-2P,
2,2-Dichloro-2-(sec-butoxycarbonyl)-N-[3-[3-(2,6-dichlorophenyl)-5-
isoxazolyl]phenyl]acetamide 867215-56-3P, 2,2-Dichloro-2-
(cyclohexyloxycarbonyl)-N-[3-[3-(2,6-dichlorophenyl)-5-
isoxazolyl]phenyl]acetamide 867215-57-4P, 2,2-Dichloro-2-
(neopentyloxycarbonyl)-N-[3-[3-(2,6-dichlorophenyl)-5-
isoxazolyl]phenyl]acetamide 867215-58-5P, 2,2-Dichloro-2-
(benzyloxycarbonyl)-N-[3-[3-(2,6-dichlorophenyl)-5-
isoxazolyl]phenyl]acetamide 867215-59-6P, 2,2-Dichloro-2-
(methoxycarbonyl)-N-[2-[3-(2,6-dichlorophenyl)-5-
isoxazolyl]phenyl]acetamide **867215-60-9P**, 2,2-Dichloro-2-(tert-
butoxycarbonyl)-N-[2-[3-(2,6-dichlorophenyl)-5-isoxazolyl]-4-
pyridyl]acetamide 867215-61-0P, 2,2-Dichloro-2-(tert-butoxycarbonyl)-N-
[3-[3-(2-chloro-6-methoxyphenyl)-5-isoxazolyl]phenyl]acetamide
867215-62-1P, 2,2-Dichloro-2-(methoxycarbonyl)-N-[3-[3-(2-cyclopropyl-6-
trifluoromethylphenyl)-5-isoxazolyl]phenyl]acetamide 867215-63-2P,
2,2-Dichloro-2-(methoxycarbonyl)-N-[3-[3-(2-chloro-6-methoxyphenyl)-5-
isoxazolyl]phenyl]acetamide **867215-64-3P**, 2,2-Dichloro-2-
(methoxycarbonyl)-N-[3-[3-(4-chloro-2-dimethylaminopyridin-3-yl)-5-
isoxazolyl]phenyl]acetamide 867215-65-4P, 2,2-Dichloro-2-
(methoxycarbonyl)-N-[3-[3-(2-trifluoromethylphenyl)-5-
isoxazolyl]phenyl]acetamide 867215-66-5P, 2,2-Dichloro-2-
(methoxycarbonyl)-N-[3-[3-(2-fluoro-6-trifluoromethylphenyl)-5-
isoxazolyl]phenyl]acetamide 867215-67-6P, 2,2-Dichloro-N-[3-[3-(2,6-
dichlorophenyl)-5-isoxazolyl]phenyl]-N-[(5-methyl-2-oxo-1,3-dioxol-4-
yl)methyl]acetamide 867215-69-8P, 2,2-Dichloro-N-[3-[3-(2,6-

dichlorophenyl)isoxazol-5-yl]phenyl]-N-[(5-tert-butyl-2-oxo-1,3-dioxol-4-yl)methyl]acetamide 867215-71-2P, 2,2-Dichloro-N-[3-[3-(2-chloro-6-methoxyphenyl)-5-isoxazolyl]phenyl]-N-[(5-methyl-2-oxo-1,3-dioxol-4-yl)methyl]acetamide **867215-72-3P**, 2,2-Dichloro-N-[3-[3-(2,4-dichloropyridin-3-yl)-5-isoxazolyl]phenyl]-N-[(5-methyl-2-oxo-1,3-dioxol-4-yl)methyl]acetamide **867215-73-4P**, 2,2-Dichloro-N-[3-[3-(4-chloro-2-dimethylaminopyridin-3-yl)-5-isoxazolyl]phenyl]-N-[(5-methyl-2-oxo-1,3-dioxol-4-yl)methyl]acetamide 867215-74-5P, 2,2-Dichloro-N-[3-[3-(2,6-dichlorophenyl)-5-isoxazolyl]phenyl]-N-[(5-isopropyl-2-oxo-1,3-dioxol-4-yl)methyl]acetamide **867215-75-6P**, 2,2-Dichloro-N-[3-[3-(4-chloro-2-dimethylaminopyridin-3-yl)-5-isoxazolyl]phenyl]-N-[(5-isopropyl-2-oxo-1,3-dioxol-4-yl)methyl]acetamide 867215-76-7P, 2,2-Dichloro-N-[3-[3-(2-chloro-6-tert-butoxycarbonylphenyl)-5-isoxazolyl]phenyl]-N-[(5-isopropyl-2-oxo-1,3-dioxol-4-yl)methyl]acetamide 867215-77-8P, 2,2-Dichloro-N-[3-[3-(2-chloro-6-methoxyphenyl)-5-isoxazolyl]phenyl]-N-[(5-isopropyl-2-oxo-1,3-dioxol-4-yl)methyl]acetamide 867215-78-9P, 2,2-Dichloro-N-[3-[3-(2,6-dichlorophenyl)-5-isoxazolyl]phenyl]-N-[(5-propyl-2-oxo-1,3-dioxol-4-yl)methyl]acetamide 867215-79-0P, 2,2-Dichloro-N-[3-[3-(2,6-dichlorophenyl)-5-isoxazolyl]phenyl]-N-[(5-cyclohexyl-2-oxo-1,3-dioxol-4-yl)methyl]acetamide 867215-80-3P, 2,2-Dichloro-N-[3-[3-(2,6-dichlorophenyl)-5-isoxazolyl]phenyl]-N-[(5-ethyl-2-oxo-1,3-dioxol-4-yl)methyl]acetamide **867215-81-4P**, 2,2-Dichloro-N-[2-[3-(2,6-dichlorophenyl)-5-isoxazolyl]-4-pyridyl]-N-[(5-methyl-2-oxo-1,3-dioxol-4-yl)methyl]acetamide **867215-82-5P**, 2,2-Dichloro-N-[2-[3-(2,6-dichlorophenyl)-5-isoxazolyl]-4-pyridyl]-N-[(5-isopropyl-2-oxo-1,3-dioxol-4-yl)methyl]acetamide **867215-84-7P**, 2,2-Dichloro-N-[2-[3-(2,6-dichlorophenyl)-5-isoxazolyl]-4-pyridyl]-N-[(5-pentyl-2-oxo-1,3-dioxol-4-yl)methyl]acetamide 867215-85-8P, 2,2-Dichloro-N-[3-[3-(2,6-dichlorophenyl)-5-isoxazolyl]phenyl]-N-[(5-ethoxycarbonyl-2-oxo-1,3-dioxol-4-yl)methyl]acetamide 867215-86-9P, 2,2-Dichloro-N-[3-[3-(2,6-dichlorophenyl)isoxazol-5-yl]phenyl]-N-[2-(phenylsulfonyl)ethyl]acetamide **867215-89-2P**, 2,2-Dichloro-N-[2-[3-(2,6-dichlorophenyl)isoxazol-5-yl]pyridin-4-yl]-N-[3-oxo-3-(pyridin-3-yl)propyl]acetamide **867215-92-7P**, 4-[3-[2,2-Dichloro-N-[2-[3-(2,6-dichlorophenyl)isoxazol-5-yl]pyridin-4-yl]acetamido]propanoyl]benzoic Acid **867215-96-1P**, 2,2-Dichloro-N-[2-[3-(2,6-dichlorophenyl)isoxazol-5-yl]pyridin-4-yl]-N-[3-(morpholino)-3-oxopropyl]acetamide 867216-00-0P, Ethyl 2-[4-[3-[2,2-Dichloro-N-[3-[3-(2,6-dichlorophenyl)isoxazol-5-yl]phenyl]acetamido]propanoyl]phenyl]acetate **867216-01-1P**, N-(4-Amino-3-oxo-5-phenylpentyl)-2,2-dichloro-N-[2-[3-(2,6-dichlorophenyl)isoxazol-5-yl]pyridin-4-yl]acetamide **867216-02-2P**, 2,2-Dichloro-N-[2-[3-(2,6-dichlorophenyl)isoxazol-5-yl]pyridin-4-yl]-N-[3-oxo-3-(piperidin-4-yl)propyl]acetamide **867216-03-3P**, 2,2-Dichloro-N-[2-[3-(2,6-dichlorophenyl)isoxazol-5-yl]pyridin-4-yl]-N-[3-oxo-3-(pyrrolidin-2-yl)propyl]acetamide **867216-04-4P**, tert-Butyl 3-[3-[2,2-Dichloro-N-[2-[3-(2,6-dichlorophenyl)isoxazol-5-yl]pyridin-4-yl]acetamido]propanoyl]piperidine-1-carboxylate **867216-06-6P**, 2,2-Dichloro-N-[2-[3-(2,6-dichlorophenyl)isoxazol-5-yl]pyridin-4-yl]-N-[3-oxo-3-(piperidin-3-yl)propyl]acetamide **867216-07-7P**, tert-Butyl 4-[4-[3-[2,2-Dichloro-N-[2-[3-(2,6-dichlorophenyl)isoxazol-5-yl]pyridin-4-yl]acetamido]propanoyl]phenyl]piperazine-1-carboxylate **867216-08-8P**, 4-[[2,2-Dichloro-N-[2-[3-(2,6-dichlorophenyl)isoxazol-5-yl]pyridin-4-yl]acetamido]methyl]-2,6-dimethylphenyl propylcarbamate 867216-11-3P, 2,2-Dichloro-N-[3-[3-(2,6-dichlorophenyl)isoxazol-5-yl]phenyl]-N'-methylmalonamide 867216-15-7P, 2,2-Dichloro-N-[3-[3-(2,6-dichlorophenyl)isoxazol-5-yl]phenyl]-N-[[2-oxo-5-(pyrrolidin-2-yl)-1,3-dioxol-4-yl]methyl]acetamide 867216-16-8P, 2,2-Dichloro-N-[3-[3-(2,6-dichlorophenyl)isoxazol-5-yl]phenyl]-N-[[2-oxo-5-(pyrrolidin-2-yl)-1,3-dioxol-4-yl]methyl]acetamide monotrifluoroacetate **867216-32-8P**, 2,2-Dichloro-N-[2-[3-(2,6-dichlorophenyl)isoxazol-5-

yl]pyridin-4-yl]-N-[[2-(pyridin-2-yl)ethoxy]methyl]acetamide 867216-34-0P, 2,2-Dichloro-N-[3-[3-[2-chloro-6-(piperidin-4-yloxy)phenyl]isoxazol-5-yl]phenyl]-N-[(5-isopropyl-2-oxo-1,3-dioxol-4-yl)methyl]acetamide 867216-36-2P, 2,2-Dichloro-N-(3-ethynylphenyl)-N-[(5-isopropyl-2-oxo-1,3-dioxol-4-yl)methyl]acetamide **867216-40-8P**, 2,2-Dichloro-N-[2-[3-(2,6-Dichlorophenyl)isoxazol-5-yl]pyridin-4-yl]-N-[(1-methyl-1H-imidazol-2-yl)methyl]acetamide **867216-42-0P**, [4-[3-[2,2-Dichloro-N-[2-[3-(2,6-dichlorophenyl)isoxazol-5-yl]pyridin-4-yl]acetamido]propyl]benzyl]phosphonic Acid 867216-47-5P 867216-52-2P, 2,2-Dichloro-N-[3-[3-(2,6-dichlorophenyl)isoxazol-5-yl]phenyl]-N'-(3-morpholinopropyl)malonamide 867216-53-3P, 2,2-Dichloro-N-[3-[3-(2,6-dichlorophenyl)isoxazol-5-yl]phenyl]-N'-[(pyridin-2-yl)methyl]malonamide 867216-54-4P, 2,2-Dichloro-N-[3-[3-(2,6-dichlorophenyl)isoxazol-5-yl]phenyl]-N'-(2-hydroxyethyl)malonamide 867216-55-5P, Propyl [4-[[2,2-Dichloro-N-[3-[3-(2,6-dichlorophenyl)isoxazol-5-yl]phenyl]acetamido]methyl]phenyl]carbamate 867216-56-6P, 2,2-Dichloro-N-[3-[3-(2,6-dichlorophenyl)isoxazol-5-yl]phenyl]-N-[[2-oxo-5-(piperidin-3-yl)-1,3-dioxol-4-yl]methyl]acetamide 867216-57-7P, 2,2-Dichloro-N-[3-[3-(2,6-dichlorophenyl)isoxazol-5-yl]phenyl]-N-[(5-neopentyl-2-oxo-1,3-dioxol-4-yl)methyl]acetamide 867216-58-8P, 2,2-Dichloro-N-[(5-cyclobutyl-2-oxo-1,3-dioxol-4-yl)methyl]-N-[3-[3-(2,6-dichlorophenyl)isoxazol-5-yl]phenyl]acetamide 867216-59-9P, Isopropyl 2,2-Dichloro-3-[[3-[3-(2-chloro-6-methoxyphenyl)isoxazol-5-yl]phenyl]amino]-3-oxopropanoate **867216-60-2P**, tert-Butyl 4-[[2,2-Dichloro-N-[2-[3-(2,6-dichlorophenyl)isoxazol-5-yl]pyridin-4-yl]acetamido]methyl]benzoate **867216-61-3P**, 2,2-Dichloro-N-[2-[3-(2,6-dichlorophenyl)isoxazol-5-yl]pyridin-4-yl]-N-[4-(2-morpholinoethoxy)benzyl]acetamide **867216-62-4P**, 2,2-Dichloro-N-[2-[3-(2,6-dichlorophenyl)isoxazol-5-yl]pyridin-4-yl]-N-[4-(4-ethylpiperazin-1-yl)benzyl]acetamide 867216-63-5P, N-[(5-Benzyl-2-oxo-1,3-dioxol-4-yl)methyl]-2,2-dichloro-N-[3-[3-(2,6-dichlorophenyl)isoxazol-5-yl]phenyl]acetamide **867216-64-6P**, 2,2-Dichloro-N-[2-[3-(2,6-dichlorophenyl)isoxazol-5-yl]pyridin-4-yl]-N-(2-morpholinoethyl)acetamide 867216-65-7P, 3-Chloro-2-[5-[3-[2,2-dichloro-N-[(5-isopropyl-2-oxo-1,3-dioxol-4-yl)methyl]acetamido]phenyl]isoxazol-3-yl]benzoic Acid 867216-66-8P, 2,2-Dichloro-N-[3-[3-[2-cyclopropyl-6-(trifluoromethyl)phenyl]isoxazol-5-yl]phenyl]-N-[(5-isopropyl-2-oxo-1,3-dioxol-4-yl)methyl]acetamide 867216-67-9P, 2,2-Dichloro-N-[(5-isopropyl-2-oxo-1,3-dioxol-4-yl)methyl]-N-[3-[3-[2-methoxy-6-(trifluoromethyl)phenyl]isoxazol-5-yl]phenyl]acetamide 867216-68-0P, Methyl 3-Chloro-2-[5-[3-[2,2-dichloro-N-[(5-isopropyl-2-oxo-1,3-dioxol-4-yl)methyl]acetamido]phenyl]isoxazol-3-yl]benzoate 867216-69-1P, N-[3-[3-[2-(1-Acetylpiperidin-4-yloxy)-6-chlorophenyl]isoxazol-5-yl]phenyl]-2,2-dichloro-N-[(5-isopropyl-2-oxo-1,3-dioxol-4-yl)methyl]acetamide **867216-70-4P**, 2,2-Dichloro-N-[2-[3-(2,6-dichlorophenyl)isoxazol-5-yl]pyridin-4-yl]-N-[(5-neopentyl-2-oxo-1,3-dioxol-4-yl)methyl]acetamide **867216-71-5P**, 4-[3-[2,2-Dichloro-N-[2-[3-(2,6-dichlorophenyl)isoxazol-5-yl]pyridin-4-yl]acetamido]propyl]phenyl diethyl phosphate **867216-72-6P**, tert-Butyl 4-[4-[3-[2,2-Dichloro-N-[2-[3-(2,6-dichlorophenyl)isoxazol-5-yl]pyridin-4-yl]acetamido]propyl]phenyl]piperazine-1-carboxylate **867216-73-7P**, tert-Butyl 4-[3-[2,2-Dichloro-N-[2-[3-(2,6-dichlorophenyl)isoxazol-5-yl]pyridin-4-yl]acetamido]propyl]benzoate **867216-74-8P**, 2,2-Dichloro-N-[2-[3-(2,6-dichlorophenyl)isoxazol-5-yl]pyridin-4-yl]-N-[3-[4-(piperazin-1-yl)phenyl]propyl]acetamide 867216-77-1P, 2,2-Dichloro-N-[3-[3-(2,6-dichlorophenyl)-5-isoxazolyl]phenyl]-N-[2-(4-fluorobenzoyl)ethyl]Acetamide 867216-80-6P, 2,2-Dichloro-N-[3-[3-(2,6-dichlorophenyl)-5-isoxazolyl]phenyl]-N-[2-(benzoyl)propyl]Acetamide **867216-82-8P** 867216-83-9P, 2,2-Dichloro-N-[3-[3-(2,6-dichlorophenyl)-5-isoxazolyl]phenyl]-N-[2-

(benzoyl)ethyl]Acetamide 867216-84-0P, 2,2-Dichloro-N-[3-[3-(2,6-dichlorophenyl)-5-isoxazolyl]phenyl]-N-[2-(4-methoxybenzoyl)ethyl]Acetamide 867216-85-1P, 2,2-Dichloro-N-[3-[3-(2,6-dichlorophenyl)-5-isoxazolyl]phenyl]-N-[2-(4-chlorobenzoyl)ethyl]Acetamide 867216-86-2P, 2,2-Dichloro-N-[3-[3-(2,6-dichlorophenyl)-5-isoxazolyl]pyridin-4-yl]-N-[2-(4-fluorobenzoyl)ethyl]Acetamide 867216-87-3P, 2,2-Dichloro-N-[3-[3-[2-chloro-6-(N-acetyl-4-piperidinyloxy)phenyl]-5-isoxazolyl]phenyl]-N-[2-(4-fluorobenzoyl)ethyl]Acetamide 867216-88-4P, 2,2-Dichloro-N-[3-[3-(2-cyclopropyl-6-trifluoromethylphenyl)-5-isoxazolyl]phenyl]-N-[2-(4-fluorobenzoyl)ethyl]Acetamide 867216-89-5P, 2,2-Dichloro-N-[3-[3-(2-chloro-6-methoxyphenyl)-5-isoxazolyl]phenyl]-N-[2-(4-fluorobenzoyl)ethyl]Acetamide 867216-90-8P, 2,2-Dichloro-N-[3-[3-(2-chloro-6-tert-butoxycarbonylphenyl)-5-isoxazolyl]phenyl]-N-[2-(4-fluorobenzoyl)ethyl]Acetamide 867216-91-9P, 2,2-Dichloro-N-[3-[3-(2-chloro-6-hydroxycarbonylphenyl)-5-isoxazolyl]phenyl]-N-[2-(4-fluorobenzoyl)ethyl]Acetamide 867216-92-0P, 2,2-Dichloro-N-[3-[3-[2-chloro-6-(methoxycarbonyl)phenyl]-5-isoxazolyl]phenyl]-N-[2-(4-fluorobenzoyl)ethyl]Acetamide 867216-93-1P 867216-94-2P 867216-95-3P 867216-96-4P 867216-97-5P 867216-98-6P **867217-01-4P** **867217-04-7P** 867217-07-0P **867217-10-5P** 867217-13-8P **867217-15-0P** 867217-17-2P **867217-19-4P** 867217-21-8P **867217-23-0P** 867217-25-2P 867217-28-5P 867217-31-0P **867217-34-3P** 867217-39-8P 867217-40-1P **867217-41-2P** **867217-42-3P** **867217-43-4P** **867217-44-5P** 867217-45-6P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(drug candidate; preparation of substituted heterocyclic prodrugs for treating HCV infection)

IT **867215-83-6P**, 2,2-Dichloro-N-[2-[3-(2,6-dichlorophenyl)-5-isoxazolyl]-4-pyridyl]-N-[(5-tert-butyl-2-oxo-1,3-dioxol-4-yl)methyl]acetamide

RL: PAC (Pharmacological activity); PKT (Pharmacokinetics); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(drug candidate; preparation of substituted heterocyclic prodrugs for treating HCV infection)

RN 867215-83-6 CAPLUS

CN Acetamide, 2,2-dichloro-N-[2-[3-(2,6-dichlorophenyl)-5-isoxazolyl]-4-pyridinyl]-N-[[5-(1,1-dimethylethyl)-2-oxo-1,3-dioxol-4-yl]methyl]- (9CI) (CA INDEX NAME)



IT **867215-95-0P**, tert-Butyl 4-[3-[2,2-Dichloro-N-[2-[3-(2,6-

dichlorophenyl)isoxazol-5-yl]pyridin-4-yl]acetamido]propanoyl]benzoate **867216-46-4P**, Di-tert-butyl [[4-[3-[2,2-Dichloro-N-[2-[3-(2,6-dichlorophenyl)isoxazol-5-yl]pyridin-4-yl]acetamido]propyl]phenyl]methyl]phosphonate
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(drug candidate; preparation of substituted heterocyclic prodrugs for treating HCV infection)

RN 867215-95-0 CAPLUS
CN Benzoic acid, 4-[3-[(dichloroacetyl)[2-[3-(2,6-dichlorophenyl)-5-isoxazolyl]-4-pyridinyl]amino]-1-oxopropyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 867216-46-4 CAPLUS
CN Phosphonic acid, [[4-[3-[(dichloroacetyl)[2-[3-(2,6-dichlorophenyl)-5-isoxazolyl]-4-pyridinyl]amino]propyl]phenyl]methyl]-, bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)



IT **667931-30-8P 867215-60-9P**, 2,2-Dichloro-2-(tert-butoxycarbonyl)-N-[2-[3-(2,6-dichlorophenyl)-5-isoxazolyl]-4-pyridyl]acetamide **867215-64-3P**, 2,2-Dichloro-2-(methoxycarbonyl)-N-[3-[3-(4-chloro-2-dimethylaminopyridin-3-yl)-5-isoxazolyl]phenyl]acetamide **867215-72-3P**, 2,2-Dichloro-N-[3-[3-(2,4-dichloropyridin-3-yl)-5-isoxazolyl]phenyl]-N-[(5-methyl-2-oxo-1,3-dioxol-4-yl)methyl]acetamide **867215-73-4P**, 2,2-Dichloro-N-[3-[3-(4-chloro-2-dimethylaminopyridin-3-yl)-5-isoxazolyl]phenyl]-N-[(5-methyl-2-

oxo-1,3-dioxol-4-yl)methyl]acetamide **867215-75-6P**, 2,2-Dichloro-N-[3-[3-(4-chloro-2-dimethylaminopyridin-3-yl)-5-isoxazolyl]phenyl]-N-[(5-isopropyl-2-oxo-1,3-dioxol-4-yl)methyl]acetamide **867215-81-4P**, 2,2-Dichloro-N-[2-[3-(2,6-dichlorophenyl)-5-isoxazolyl]-4-pyridyl]-N-[(5-methyl-2-oxo-1,3-dioxol-4-yl)methyl]acetamide **867215-82-5P**, 2,2-Dichloro-N-[2-[3-(2,6-dichlorophenyl)-5-isoxazolyl]-4-pyridyl]-N-[(5-isopropyl-2-oxo-1,3-dioxol-4-yl)methyl]acetamide **867215-84-7P**, 2,2-Dichloro-N-[2-[3-(2,6-dichlorophenyl)-5-isoxazolyl]-4-pyridyl]-N-[(5-pentyl-2-oxo-1,3-dioxol-4-yl)methyl]acetamide **867215-89-2P**, 2,2-Dichloro-N-[2-[3-(2,6-dichlorophenyl)isoxazol-5-yl]pyridin-4-yl]-N-[3-oxo-3-(pyridin-3-yl)propyl]acetamide **867215-92-7P**, 4-[3-[2,2-Dichloro-N-[2-[3-(2,6-dichlorophenyl)isoxazol-5-yl]pyridin-4-yl]acetamido]propanoyl]benzoic Acid **867215-96-1P**, 2,2-Dichloro-N-[2-[3-(2,6-dichlorophenyl)isoxazol-5-yl]pyridin-4-yl]-N-[3-(morpholino)-3-oxopropyl]acetamide **867216-01-1P**, N-(4-Amino-3-oxo-5-phenylpentyl)-2,2-dichloro-N-[2-[3-(2,6-dichlorophenyl)isoxazol-5-yl]pyridin-4-yl]acetamide **867216-02-2P**, 2,2-Dichloro-N-[2-[3-(2,6-dichlorophenyl)isoxazol-5-yl]pyridin-4-yl]-N-[3-oxo-3-(piperidin-4-yl)propyl]acetamide **867216-03-3P**, 2,2-Dichloro-N-[2-[3-(2,6-dichlorophenyl)isoxazol-5-yl]pyridin-4-yl]-N-[3-oxo-3-(pyrrolidin-2-yl)propyl]acetamide **867216-04-4P**, tert-Butyl 3-[3-[2,2-Dichloro-N-[2-[3-(2,6-dichlorophenyl)isoxazol-5-yl]pyridin-4-yl]acetamido]propanoyl]piperidine-1-carboxylate **867216-06-6P**, 2,2-Dichloro-N-[2-[3-(2,6-dichlorophenyl)isoxazol-5-yl]pyridin-4-yl]-N-[3-oxo-3-(piperidin-3-yl)propyl]acetamide **867216-07-7P**, tert-Butyl 4-[4-[3-[2,2-Dichloro-N-[2-[3-(2,6-dichlorophenyl)isoxazol-5-yl]pyridin-4-yl]acetamido]propanoyl]phenyl]piperazine-1-carboxylate **867216-08-8P**, 4-[[2,2-Dichloro-N-[2-[3-(2,6-dichlorophenyl)isoxazol-5-yl]pyridin-4-yl]acetamido]methyl]-2,6-dimethylphenyl propylcarbamate **867216-32-8P**, 2,2-Dichloro-N-[2-[3-(2,6-dichlorophenyl)isoxazol-5-yl]pyridin-4-yl]-N-[[2-(pyridin-2-yl)ethoxy]methyl]acetamide **867216-40-8P**, 2,2-Dichloro-N-[2-[3-(2,6-Dichlorophenyl)isoxazol-5-yl]pyridin-4-yl]-N-[(1-methyl-1H-imidazol-2-yl)methyl]acetamide **867216-42-0P**, [4-[3-[2,2-Dichloro-N-[2-[3-(2,6-dichlorophenyl)isoxazol-5-yl]pyridin-4-yl]acetamido]propyl]benzyl]phosphonic Acid **867216-60-2P**, tert-Butyl 4-[[2,2-Dichloro-N-[2-[3-(2,6-dichlorophenyl)isoxazol-5-yl]pyridin-4-yl]acetamido]methyl]benzoate **867216-61-3P**, 2,2-Dichloro-N-[2-[3-(2,6-dichlorophenyl)isoxazol-5-yl]pyridin-4-yl]-N-[4-(2-morpholinoethoxy)benzyl]acetamide **867216-62-4P**, 2,2-Dichloro-N-[2-[3-(2,6-dichlorophenyl)isoxazol-5-yl]pyridin-4-yl]-N-[4-(4-ethylpiperazin-1-yl)benzyl]acetamide **867216-64-6P**, 2,2-Dichloro-N-[2-[3-(2,6-dichlorophenyl)isoxazol-5-yl]pyridin-4-yl]-N-(2-morpholinoethyl)acetamide **867216-70-4P**, 2,2-Dichloro-N-[2-[3-(2,6-dichlorophenyl)isoxazol-5-yl]pyridin-4-yl]-N-[(5-neopentyl-2-oxo-1,3-dioxol-4-yl)methyl]acetamide **867216-71-5P**, 4-[3-[2,2-Dichloro-N-[2-[3-(2,6-dichlorophenyl)isoxazol-5-yl]pyridin-4-yl]acetamido]propyl]phenyl diethyl phosphate **867216-72-6P**, tert-Butyl 4-[4-[3-[2,2-Dichloro-N-[2-[3-(2,6-dichlorophenyl)isoxazol-5-yl]pyridin-4-yl]acetamido]propyl]phenyl]piperazine-1-carboxylate **867216-73-7P**, tert-Butyl 4-[3-[2,2-Dichloro-N-[2-[3-(2,6-dichlorophenyl)isoxazol-5-yl]pyridin-4-yl]acetamido]propyl]benzoate **867216-74-8P**, 2,2-Dichloro-N-[2-[3-(2,6-dichlorophenyl)isoxazol-5-yl]pyridin-4-yl]-N-[3-[4-(piperazin-1-yl)phenyl]propyl]acetamide **867216-82-8P 867217-01-4P 867217-04-7P 867217-10-5P 867217-15-0P 867217-19-4P 867217-23-0P 867217-34-3P 867217-41-2P 867217-42-3P 867217-43-4P 867217-44-5P**

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU

(Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(drug candidate; preparation of substituted heterocyclic prodrugs for treating HCV infection)

RN 667931-30-8 CAPLUS
CN Acetamide, 2,2-dichloro-N-[2-[3-(2,6-dichlorophenyl)-5-isoxazolyl]-4-pyridinyl]- (9CI) (CA INDEX NAME)



RN 867215-60-9 CAPLUS
CN Propanoic acid, 2,2-dichloro-3-[[2-[3-(2,6-dichlorophenyl)-5-isoxazolyl]-4-pyridinyl]amino]-3-oxo-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 867215-64-3 CAPLUS
CN Propanoic acid, 2,2-dichloro-3-[[3-[3-[4-chloro-2-(dimethylamino)-3-pyridinyl]-5-isoxazolyl]phenyl]amino]-3-oxo-, methyl ester (9CI) (CA INDEX NAME)



RN 867215-72-3 CAPLUS
CN Acetamide, 2,2-dichloro-N-[3-[3-(2,4-dichloro-3-pyridinyl)-5-isoxazolyl]phenyl]-N-[(5-methyl-2-oxo-1,3-dioxol-4-yl)methyl]- (9CI) (CA INDEX NAME)



RN 867215-73-4 CAPLUS
CN Acetamide, 2,2-dichloro-N-[3-[3-[4-chloro-2-(dimethylamino)-3-pyridinyl]-5-isoxazolyl]phenyl]-N-[(5-methyl-2-oxo-1,3-dioxol-4-yl)methyl]- (9CI) (CA INDEX NAME)



RN 867215-75-6 CAPLUS
CN Acetamide, 2,2-dichloro-N-[3-[3-[4-chloro-2-(dimethylamino)-3-pyridinyl]-5-isoxazolyl]phenyl]-N-[[5-(1-methylethyl)-2-oxo-1,3-dioxol-4-yl]methyl]-

(9CI) (CA INDEX NAME)



RN 867215-81-4 CAPLUS
CN Acetamide, 2,2-dichloro-N-[2-[3-(2,6-dichlorophenyl)-5-isoxazolyl]-4-pyridinyl]-N-[(5-methyl-2-oxo-1,3-dioxol-4-yl)methyl]- (9CI) (CA INDEX NAME)



RN 867215-82-5 CAPLUS
CN Acetamide, 2,2-dichloro-N-[2-[3-(2,6-dichlorophenyl)-5-isoxazolyl]-4-pyridinyl]-N-[[5-(1-methylethyl)-2-oxo-1,3-dioxol-4-yl]methyl]- (9CI) (CA INDEX NAME)



RN 867215-84-7 CAPLUS
CN Acetamide, 2,2-dichloro-N-[2-[3-(2,6-dichlorophenyl)-5-isoxazolyl]-4-pyridinyl]-N-[(2-oxo-5-pentyl-1,3-dioxol-4-yl)methyl]- (9CI) (CA INDEX NAME)



RN 867215-89-2 CAPLUS
CN Acetamide, 2,2-dichloro-N-[2-[3-(2,6-dichlorophenyl)-5-isoxazolyl]-4-pyridinyl]-N-[3-oxo-3-(3-pyridinyl)propyl]- (9CI) (CA INDEX NAME)



RN 867215-92-7 CAPLUS
CN Benzoic acid, 4-[3-[(dichloroacetyl)[2-[3-(2,6-dichlorophenyl)-5-isoxazolyl]-4-pyridinyl]amino]-1-oxopropyl]- (9CI) (CA INDEX NAME)



RN 867215-96-1 CAPLUS
CN Acetamide, 2,2-dichloro-N-[2-[3-(2,6-dichlorophenyl)-5-isoxazolyl]-4-pyridinyl]-N-[3-(4-morpholinyl)-3-oxopropyl]- (9CI) (CA INDEX NAME)



RN 867216-01-1 CAPLUS
CN Acetamide, N-(4-amino-3-oxo-5-phenylpentyl)-2,2-dichloro-N-[2-[3-(2,6-dichlorophenyl)-5-isoxazolyl]-4-pyridinyl]- (9CI) (CA INDEX NAME)



RN 867216-02-2 CAPLUS
CN Acetamide, 2,2-dichloro-N-[2-[3-(2,6-dichlorophenyl)-5-isoxazolyl]-4-pyridinyl]-N-[3-oxo-3-(4-piperidinyl)propyl]- (9CI) (CA INDEX NAME)



RN 867216-03-3 CAPLUS
CN Acetamide, 2,2-dichloro-N-[2-[3-(2,6-dichlorophenyl)-5-isoxazolyl]-4-pyridinyl]-N-[3-oxo-3-(2-pyrrolidinyl)propyl]- (9CI) (CA INDEX NAME)



RN 867216-04-4 CAPLUS
CN 1-Piperidinecarboxylic acid, 3-[3-[(dichloroacetyl)[2-[3-(2,6-dichlorophenyl)-5-isoxazolyl]-4-pyridinyl]amino]-1-oxopropyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 867216-06-6 CAPLUS
CN Acetamide, 2,2-dichloro-N-[2-[3-(2,6-dichlorophenyl)-5-isoxazolyl]-4-pyridinyl]-N-[3-oxo-3-(3-piperidinyl)propyl]- (9CI) (CA INDEX NAME)



RN 867216-07-7 CAPLUS
CN 1-Piperazinecarboxylic acid, 4-[4-[3-[(dichloroacetyl)[2-[3-(2,6-dichlorophenyl)-5-isoxazolyl]-4-pyridinyl]amino]-1-oxopropyl]phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 867216-08-8 CAPLUS
CN Carbamic acid, propyl-, 4-[[(dichloroacetyl)[2-[3-(2,6-dichlorophenyl)-5-isoxazolyl]-4-pyridinyl]amino]methyl]-2,6-dimethylphenyl ester (9CI) (CA INDEX NAME)



RN 867216-32-8 CAPLUS

CN Acetamide, 2,2-dichloro-N-[2-[3-(2,6-dichlorophenyl)-5-isoxazolyl]-4-pyridinyl]-N-[[2-(2-pyridinyl)ethoxy]methyl]- (9CI) (CA INDEX NAME)



RN 867216-40-8 CAPLUS
CN Acetamide, 2,2-dichloro-N-[2-[3-(2,6-dichlorophenyl)-5-isoxazolyl]-4-pyridinyl]-N-[(1-methyl-1H-imidazol-2-yl)methyl]- (9CI) (CA INDEX NAME)



RN 867216-42-0 CAPLUS
CN Phosphonic acid, [[4-[3-[(dichloroacetyl)[2-[3-(2,6-dichlorophenyl)-5-isoxazolyl]-4-pyridinyl]amino]propyl]phenyl]methyl]- (9CI) (CA INDEX NAME)



RN 867216-60-2 CAPLUS
CN Benzoic acid, 4-[[(dichloroacetyl)[2-[3-(2,6-dichlorophenyl)-5-isoxazolyl]-4-pyridinyl]amino]methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 867216-61-3 CAPLUS
CN Acetamide, 2,2-dichloro-N-[2-[3-(2,6-dichlorophenyl)-5-isoxazolyl]-4-pyridinyl]-N-[[4-[2-(4-morpholinyl)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)



RN 867216-62-4 CAPLUS
CN Acetamide, 2,2-dichloro-N-[2-[3-(2,6-dichlorophenyl)-5-isoxazolyl]-4-pyridinyl]-N-[[4-(4-ethyl-1-piperazinyl)phenyl]methyl]- (9CI) (CA INDEX NAME)



RN 867216-64-6 CAPLUS
CN Acetamide, 2,2-dichloro-N-[2-[3-(2,6-dichlorophenyl)-5-isoxazolyl]-4-pyridinyl]-N-[2-(4-morpholinyl)ethyl]- (9CI) (CA INDEX NAME)



RN 867216-70-4 CAPLUS
CN Acetamide, 2,2-dichloro-N-[2-[3-(2,6-dichlorophenyl)-5-isoxazolyl]-4-pyridinyl]-N-[[5-(2,2-dimethylpropyl)-2-oxo-1,3-dioxol-4-yl]methyl]- (9CI) (CA INDEX NAME)



RN 867216-71-5 CAPLUS
CN Phosphoric acid, 4-[3-[(dichloroacetyl)[2-[3-(2,6-dichlorophenyl)-5-isoxazolyl]-4-pyridinyl]amino]propyl]phenyl diethyl ester (9CI) (CA INDEX NAME)



RN 867216-72-6 CAPLUS
CN 1-Piperazinecarboxylic acid, 4-[4-[3-[(dichloroacetyl)[2-[3-(2,6-dichlorophenyl)-5-isoxazolyl]-4-pyridinyl]amino]propyl]phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 867216-73-7 CAPLUS
CN Benzoic acid, 4-[3-[(dichloroacetyl)[2-[3-(2,6-dichlorophenyl)-5-isoxazolyl]-4-pyridinyl]amino]propyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 867216-74-8 CAPLUS
CN Acetamide, 2,2-dichloro-N-[2-[3-(2,6-dichlorophenyl)-5-isoxazolyl]-4-pyridinyl]-N-[3-[4-(1-piperazinyl)phenyl]propyl]- (9CI) (CA INDEX NAME)



RN 867216-82-8 CAPLUS
CN Acetamide, 2,2-dichloro-N-[2-[3-(2,6-dichlorophenyl)-5-isoxazolyl]-4-pyridinyl]-N-[3-(4-fluorophenyl)-3-oxopropyl]- (9CI) (CA INDEX NAME)



RN 867217-01-4 CAPLUS
CN Acetamide, 2,2-dichloro-N-[2-[3-(2,6-dichlorophenyl)-5-isoxazolyl]-4-pyridinyl]-N-[(4-fluorophenyl)methyl]- (9CI) (CA INDEX NAME)



RN 867217-04-7 CAPLUS
CN Acetamide, 2,2-dichloro-N-[2-[3-(2,6-dichlorophenyl)-5-isoxazolyl]-4-pyridinyl]-N-[2-(4-fluorophenyl)ethyl]- (9CI) (CA INDEX NAME)



RN 867217-10-5 CAPLUS
CN Acetamide, N-[[4-(acetyloxy)-3,5-dimethylphenyl]methyl]-2,2-dichloro-N-[2-[3-(2,6-dichlorophenyl)-5-isoxazolyl]-4-pyridinyl]- (9CI) (CA INDEX NAME)



RN 867217-15-0 CAPLUS
CN Glycine, N,N-dimethyl-, 4-[[(dichloroacetyl)[2-[3-(2,6-dichlorophenyl)-5-isoxazolyl]-4-pyridinyl]amino]methyl]-2,6-dimethylphenyl ester (9CI) (CA INDEX NAME)



RN 867217-19-4 CAPLUS
CN Glycine, N-[(1,1-dimethylethoxy)carbonyl]-N-methyl-, 4-

[[(dichloroacetyl)[2-[3-(2,6-dichlorophenyl)-5-isoxazolyl]-4-pyridinyl]amino]methyl]-2,6-dimethylphenyl ester (9CI) (CA INDEX NAME)



RN 867217-23-0 CAPLUS
CN Glycine, N-methyl-, 4-[[(dichloroacetyl)[2-[3-(2,6-dichlorophenyl)-5-isoxazolyl]-4-pyridinyl]amino]methyl]-2,6-dimethylphenyl ester (9CI) (CA INDEX NAME)



RN 867217-34-3 CAPLUS
CN Acetamide, 2,2-dichloro-N-[2-[3-(2,6-dichlorophenyl)-5-isoxazolyl]-4-pyridinyl]-N-[3-(4-fluorophenyl)propyl]- (9CI) (CA INDEX NAME)



RN 867217-41-2 CAPLUS
CN Propanoic acid, 2,2-dichloro-3-[[3-[3-[2-chloro-4-(4-morpholinyl)-3-pyridinyl]-5-isoxazolyl]phenyl]amino]-3-oxo-, cyclohexyl ester (9CI) (CA INDEX NAME)



RN 867217-42-3 CAPLUS
CN Propanoic acid, 2,2-dichloro-3-[[3-[3-[2-chloro-4-(4-morpholinyl)-3-pyridinyl]-5-isoxazolyl]phenyl]amino]-3-oxo-, ethyl ester (9CI) (CA INDEX NAME)



RN 867217-43-4 CAPLUS
CN Propanoic acid, 2,2-dichloro-3-[[3-[3-[2-chloro-4-(4-morpholinyl)-3-pyridinyl]-5-isoxazolyl]phenyl]amino]-3-oxo-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 867217-44-5 CAPLUS
CN Propanoic acid, 2,2-dichloro-3-[[2-[3-(2,6-dichlorophenyl)-5-isoxazolyl]-4-pyridinyl]amino]-3-oxo-, cyclohexyl ester (9CI) (CA INDEX NAME)



REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L50 ANSWER 5 OF 15 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2005:979648 CAPLUS
DOCUMENT NUMBER: 143:266935
TITLE: Preparation of isoxazolylphenyl oxadiazole derivatives as inhibitors of hepatitis C virus replication
INVENTOR(S): **Goff, Dane**; **Singh, Rajinder**; Li, Hui
PATENT ASSIGNEE(S): Rigel Pharmaceuticals, Inc., USA
SOURCE: PCT Int. Appl., 101 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005082898	A1	20050909	WO 2005-US5528	20050223

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,

LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI,
NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM,
SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM,
AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT,
RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML,
MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: US 2004-547009P P 20040223
OTHER SOURCE(S): MARPAT 143:266935
GI



I



II

AB Title compds. represented by the formula I [wherein ring B = (aromatic) heterocyclic ring; X, Y, Z = independently C, CH, (un)substituted N, S or N, provided X and Y are not both O; U, T = independently C, CH or N; R1-R6 = independently H, OH, SH, halo, etc.; n = 0-4; R7 is a leaving group; and pharmaceutically acceptable salts, hydrates, solvates, N-oxides, and prodrugs thereof] were prepared as inhibitors of hepatitis C virus (HCV) replication for the treatment of HCV infections. For example, II was given in a multi-step synthesis starting from 2,6-dichlorobenzaldoxime. I were tested for inhibition of HCV replication using a quant. Western blot anal.

IC ICM C07D413-10
ICS A61K031-4245; A61P031-00

CC 28-10 (Heterocyclic Compounds (More Than One Hetero Atom))
Section cross-reference(s): 1

REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L50 ANSWER 6 OF 15 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2004:996145 CAPLUS
DOCUMENT NUMBER: 141:424168
TITLE: Preparation of 1,3-diaryl-substituted five-membered aromatic heterocycles and their di- and tetrahydro derivatives as inhibitors of hepatitis C virus

replication for treatment of hepatitis C infection

INVENTOR(S): **Singh, Rajinder; Goff, Dane; Partridge, John J.**

PATENT ASSIGNEE(S): Rigel Pharmaceuticals, Inc., USA

SOURCE: PCT Int. Appl., 210 pp.
CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004099165	A2	20041118	WO 2004-US13452	20040430
WO 2004099165	A3	20051103		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 2004254227	A1	20041216	US 2004-836561	20040430
EP 1620412	A2	20060201	EP 2004-751046	20040430
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR				

PRIORITY APPLN. INFO.: US 2003-467650P P 20030502
WO 2004-US13452 W 20040430

OTHER SOURCE(S): MARPAT 141:424168

GI



I



II

AB 1,3-Diaryl-substituted five-membered heterocycles I [B ring = aromatic, partially saturated, or fully saturated heterocycle; X, Y, Z = C, CH, N, NR, O, S; U, T = C, CH, N; U, T are not both C, X and Y are not O; Z = CH when X = Y = N; R = H, (un)substituted alkyl, cycloalkyl, heterocycloalkyl, haloalkyl, alkoxy, alkylthio, monohalomethyl, dihalomethyl, trihalomethyl, etc.; R2, R3, R4, R5, R6, R8, R9, R10, R13 = H, HO, HS, NC, O2N, N3, halo, (un)substituted alkyl, cycloalkyl, cycloheteroalkyl, etc.; R11 = H, alkyl; R12 = monohalomethyl, dihalomethyl] such as II are prepared as replication inhibitors for the hepatitis C virus for treatment of hepatitis C infection. 2,6-Dichlorophenylacetylene and 3-nitro-N-hydroxybenzenecarboximidoyl chloride undergo thermal cycloaddn. to an isoxazole; reduction of the nitro group to an amine and acylation with dichloroacetyl chloride yields II. The title compds. inhibit hepatitis C replication (no data).

IC ICM C07D263-32
ICS C07D271-06; C07D275-02; C07D277-10; A61K031-00

CC 28-1 (Heterocyclic Compounds (More Than One Hetero Atom))
Section cross-reference(s): 1

L50 ANSWER 7 OF 15 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2004:996144 CAPLUS
DOCUMENT NUMBER: 141:410935
TITLE: Preparation of substituted diphenyl isoxazoles, pyrazoles and oxadiazoles for treating HCV infection
INVENTOR(S): **Singh, Rajinder**; **Goff, Dane**; **Partridge, John**
PATENT ASSIGNEE(S): Rigel Pharmaceuticals, Inc., USA
SOURCE: PCT Int. Appl., 188 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent

LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004099164	A1	20041118	WO 2004-US13492	20040503

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

US 2004266840	A1	20041230	US 2004-838133	20040503
PRIORITY APPLN. INFO.:			US 2003-467811P	P 20030502

OTHER SOURCE(S): MARPAT 141:410935
GI



I

AB The present invention relates to substituted di-Ph heterocycle compds. I [X, Y = N, O, provided that X and Y are not both O; Z = N, CH, provided that Z = CH when X and Y are both N; R2-R5, R8-R10, R13 = H, OH, SH, CN, etc.; R11 = H, alkyl; R12 = dihalomethyl; R6 = (un)substituted piperazino, piperidino, pyrrolidino, etc.] and pharmaceutical compns. thereof that inhibit replication of HCV virus. E.g., a 3-step synthesis of 2,2-dichloro-N-{3-[3-(2,6-dichlorophenyl)-5-isoxazolyl]phenyl}acetamide, starting from 2,6-dichlorobenzaldoxime, was given. Exemplary compds. I were tested in HCV replicon assay and/or in Western blot assay (biol. data given). The present invention also relates to the use of the compds. and/or compns. (such as liposome suspension) to inhibit HCV replication and/or proliferation and to treat or prevent HCV infections.

IC ICM C07D261-08
ICS C07D271-06; A61K031-42; A61K031-4245
CC 28-10 (Heterocyclic Compounds (More Than One Hetero Atom))
Section cross-reference(s): 1, 63
REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L50 ANSWER 8 OF 15 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2003:376833 CAPLUS
DOCUMENT NUMBER: 138:368880
TITLE: Preparation of substituted diphenyl heterocycles for treating HCV infection
INVENTOR(S): **Singh, Rajinder**; **Goff, Dane**; Lu, Henry; Issankani, Sarkiz D.; Sun, Thomas
PATENT ASSIGNEE(S): Rigel Pharmaceuticals, Inc., USA
SOURCE: PCT Int. Appl., 103 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003040112	A1	20030515	WO 2002-US35131	20021101
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2465189	AA	20030515	CA 2002-2465189	20021101
US 2003165561	A1	20030904	US 2002-286017	20021101
US 6759538	B2	20040706		
BR 2002006266	A	20031230	BR 2002-6266	20021101
EP 1451162	A1	20040901	EP 2002-784378	20021101
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK				
JP 2005511604	T2	20050428	JP 2003-542158	20021101
NZ 532317	A	20051028	NZ 2002-532317	20021101
US 2004236112	A1	20041125	US 2004-873914	20040622

PRIORITY APPLN. INFO.:

US 2001-350107P	P	20011102
US 2002-405472P	P	20020823
US 2002-286017	A3	20021101
WO 2002-US35131	W	20021101

OTHER SOURCE(S): MARPAT 138:368880
GI



I

AB The title compds. [I; X, Y = N, O, provided that X and Y are not both O; Z = N, CH, provided that Z = CH when X and Y are both N; R2-R6, R8-R10, R13 = H, OH, SH, etc.; R11 = alkyl; R12 = monohalomethyl, dihalomethyl] that inhibit replication of HCV virus, were prepared and formulated. Thus,

reacting 2,6-dichloro-N-hydroxybenzenecarboximidoyl chloride with 2,2-dichloro-N-(3-ethynylphenyl)acetamide (prepns. given) in the presence of Et3N in THF afforded I [X = N; Y = O; Z = CH; R2 = Cl; R3-R5 = H; R6 = Cl; R8-R11 = H; R12 = CHCl2; R13 = H] which was evaluated for in rats by both s.c. and i.v. administration, and doses as high as 30 mg/kg/day were well tolerated.

IC ICM C07D261-08
ICS A61K031-42

CC 28-6 (Heterocyclic Compounds (More Than One Hetero Atom))
Section cross-reference(s): 1, 63

REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L50 ANSWER 9 OF 15 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 1997:218872 CAPLUS
DOCUMENT NUMBER: 126:293272
TITLE: Developing a general strategy for the solid supported synthesis of heterocycles: applications to the generation of molecular diversity and drug discovery
AUTHOR(S): Nuss, John M.; Desai, Manoj C.; Zuckermann, Ronald N.; **Singh, Rajinder**; Renhowe, Paul A.; **Goff, Dane A.**; Chinn, Jason P.; Wang, Liang; Dorr, Hilary; Brown, Edward G.; Subramanian, Sharadha
CORPORATE SOURCE: Chiron Corp., Emeryville, CA, 94608, USA
SOURCE: Pure and Applied Chemistry (1997), 69(3), 447-452
CODEN: PACHAS; ISSN: 0033-4545
PUBLISHER: Blackwell
DOCUMENT TYPE: Journal; General Review
LANGUAGE: English

AB The development of a general strategy for the generation of mol. diversity in the form of novel, non-amide based heterocyclic structures is described with 19 refs. The generation of diverse peptide and peptidomimetic libraries, the automation of these strategies and computational approaches to diversity generation are also discussed. The main focus of this lecture is the progression of these concepts into a strategy for small mol. library generation, and hence the generation of small mol. therapeutic leads.

CC 28-0 (Heterocyclic Compounds (More Than One Hetero Atom))
Section cross-reference(s): 34

REFERENCE COUNT: 22 THERE ARE 22 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L50 ANSWER 10 OF 15 USPATFULL on STN

ACCESSION NUMBER: 2005:275188 USPATFULL
TITLE: Heterocyclic anti-viral compounds comprising metabolizable moieties and their uses
INVENTOR(S): **Singh, Rajinder**, Belmont, CA, UNITED STATES
Goff, Dane, Redwood City, CA, UNITED STATES
Kolluri, Rao S. S., Foster City, CA, UNITED STATES
Darwish, Ihab S., San Mateo, CA, UNITED STATES
Partridge, John J., Chapel Hill, NC, UNITED STATES
Cooper, Robin, St. George Island, FL, UNITED STATES
Lu, Henry H., Foster City, CA, UNITED STATES
Park, Gary, Moss Beach, CA, UNITED STATES
PATENT ASSIGNEE(S): Rigel Pharmaceuticals, Inc., South San Francisco, CA, UNITED STATES (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2005239751	A1	20051027
APPLICATION INFO.:	US 2005-90823	A1	20050325 (11)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2004-556625P	20040326 (60)
	US 2004-582903P	20040624 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: MCDONNELL BOEHNEN HULBERT & BERGHOFF LLP, 300 S. WACKER DRIVE, 32ND FLOOR, CHICAGO, IL, 60606, US
NUMBER OF CLAIMS: 54
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 24 Drawing Page(s)
LINE COUNT: 4411
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to substituted prodrug and compositions thereof useful for treating or preventing Hepatitis C virus (HCV) infections. In particular, the present invention relates to prodrugs of substituted diphenyl-, diheteroaryl- and mixed phenyl heteroaryl substituted five-membered heterocycle compounds, compositions comprising the compounds and the use of such compounds and compositions to inhibit HCV replication and/or proliferation as a therapeutic approach towards the treatment and/or prevention of HCV infections in humans and animals.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT **867215-83-6P**, 2,2-Dichloro-N-[2-[3-(2,6-dichlorophenyl)-5-isoxazolyl]-4-pyridyl]-N-[(5-tert-butyl-2-oxo-1,3-dioxol-4-yl)methyl]acetamide
(drug candidate; preparation of substituted heterocyclic prodrugs for treating HCV infection)
RN 867215-83-6 USPATFULL
CN Acetamide, 2,2-dichloro-N-[2-[3-(2,6-dichlorophenyl)-5-isoxazolyl]-4-pyridinyl]-N-[[5-(1,1-dimethylethyl)-2-oxo-1,3-dioxol-4-yl]methyl]- (9CI) (CA INDEX NAME)



IT **867215-95-0P**, tert-Butyl 4-[3-[2,2-Dichloro-N-[2-[3-(2,6-dichlorophenyl)isoxazol-5-yl]pyridin-4-yl]acetamido]propanoyl]benzoate
867216-46-4P, Di-tert-butyl [[4-[3-[2,2-Dichloro-N-[2-[3-(2,6-dichlorophenyl)isoxazol-5-yl]pyridin-4-yl]acetamido]propyl]phenyl]methyl] phosphonate

(drug candidate; preparation of substituted heterocyclic prodrugs for treating HCV infection)

RN 867215-95-0 USPATFULL

CN Benzoic acid, 4-[3-[(dichloroacetyl)[2-[3-(2,6-dichlorophenyl)-5-isoxazolyl]-4-pyridinyl]amino]-1-oxopropyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 867216-46-4 USPATFULL

CN Phosphonic acid, [[4-[3-[(dichloroacetyl)[2-[3-(2,6-dichlorophenyl)-5-isoxazolyl]-4-pyridinyl]amino]propyl]phenyl]methyl]-, bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)



IT **667931-30-8P 867215-60-9P**, 2,2-Dichloro-2-(tert-butoxycarbonyl)-N-[2-[3-(2,6-dichlorophenyl)-5-isoxazolyl]-4-pyridyl]acetamide **867215-64-3P**, 2,2-Dichloro-2-(methoxycarbonyl)-N-[3-[3-(4-chloro-2-dimethylaminopyridin-3-yl)-5-isoxazolyl]phenyl]acetamide **867215-72-3P**, 2,2-Dichloro-N-[3-[3-(2,4-dichloropyridin-3-yl)-5-isoxazolyl]phenyl]-N-[(5-methyl-2-oxo-1,3-dioxol-4-yl)methyl]acetamide **867215-73-4P**, 2,2-Dichloro-N-[3-[3-(4-chloro-2-dimethylaminopyridin-3-yl)-5-isoxazolyl]phenyl]-N-[(5-methyl-2-oxo-1,3-dioxol-4-yl)methyl]acetamide **867215-75-6P**, 2,2-Dichloro-N-[3-[3-(4-chloro-2-dimethylaminopyridin-3-yl)-5-isoxazolyl]phenyl]-N-[(5-isopropyl-2-oxo-1,3-dioxol-4-yl)methyl]acetamide **867215-81-4P**, 2,2-Dichloro-N-[2-[3-(2,6-dichlorophenyl)-5-isoxazolyl]-4-pyridyl]-N-[(5-methyl-2-oxo-1,3-dioxol-4-yl)methyl]acetamide **867215-82-5P**, 2,2-Dichloro-N-[2-[3-(2,6-dichlorophenyl)-5-isoxazolyl]-4-pyridyl]-N-[(5-isopropyl-2-oxo-1,3-dioxol-

4-yl)methyl]acetamide **867215-84-7P**, 2,2-Dichloro-N-[2-[3-(2,6-dichlorophenyl)-5-isoxazolyl]-4-pyridyl]-N-[(5-pentyl-2-oxo-1,3-dioxol-4-yl)methyl]acetamide **867215-89-2P**, 2,2-Dichloro-N-[2-[3-(2,6-dichlorophenyl)isoxazol-5-yl]pyridin-4-yl]-N-[3-oxo-3-(pyridin-3-yl)propyl]acetamide **867215-92-7P**, 4-[3-[2,2-Dichloro-N-[2-[3-(2,6-dichlorophenyl)isoxazol-5-yl]pyridin-4-yl]acetamido]propanoyl]benzoic Acid **867215-96-1P**, 2,2-Dichloro-N-[2-[3-(2,6-dichlorophenyl)isoxazol-5-yl]pyridin-4-yl]-N-[3-(morpholino)-3-oxopropyl]acetamide **867216-01-1P**, N-(4-Amino-3-oxo-5-phenylpentyl)-2,2-dichloro-N-[2-[3-(2,6-dichlorophenyl)isoxazol-5-yl]pyridin-4-yl]acetamide **867216-02-2P**, 2,2-Dichloro-N-[2-[3-(2,6-dichlorophenyl)isoxazol-5-yl]pyridin-4-yl]-N-[3-oxo-3-(piperidin-4-yl)propyl]acetamide **867216-03-3P**, 2,2-Dichloro-N-[2-[3-(2,6-dichlorophenyl)isoxazol-5-yl]pyridin-4-yl]-N-[3-oxo-3-(pyrrolidin-2-yl)propyl]acetamide **867216-04-4P**, tert-Butyl 3-[3-[2,2-Dichloro-N-[2-[3-(2,6-dichlorophenyl)isoxazol-5-yl]pyridin-4-yl]acetamido]propanoyl]piperidine-1-carboxylate **867216-06-6P**, 2,2-Dichloro-N-[2-[3-(2,6-dichlorophenyl)isoxazol-5-yl]pyridin-4-yl]-N-[3-oxo-3-(piperidin-3-yl)propyl]acetamide **867216-07-7P**, tert-Butyl 4-[4-[3-[2,2-Dichloro-N-[2-[3-(2,6-dichlorophenyl)isoxazol-5-yl]pyridin-4-yl]acetamido]propanoyl]phenyl]piperazine-1-carboxylate **867216-08-8P**, 4-[[2,2-Dichloro-N-[2-[3-(2,6-dichlorophenyl)isoxazol-5-yl]pyridin-4-yl]acetamido]methyl]-2,6-dimethylphenyl propylcarbamate **867216-32-8P**, 2,2-Dichloro-N-[2-[3-(2,6-dichlorophenyl)isoxazol-5-yl]pyridin-4-yl]-N-[[2-(pyridin-2-yl)ethoxy]methyl]acetamide **867216-40-8P**, 2,2-Dichloro-N-[2-[3-(2,6-Dichlorophenyl)isoxazol-5-yl]pyridin-4-yl]-N-[(1-methyl-1H-imidazol-2-yl)methyl]acetamide **867216-42-0P**, [4-[3-[2,2-Dichloro-N-[2-[3-(2,6-dichlorophenyl)isoxazol-5-yl]pyridin-4-yl]acetamido]propyl]benzyl]phosphonic Acid **867216-60-2P**, tert-Butyl 4-[[2,2-Dichloro-N-[2-[3-(2,6-dichlorophenyl)isoxazol-5-yl]pyridin-4-yl]acetamido]methyl]benzoate **867216-61-3P**, 2,2-Dichloro-N-[2-[3-(2,6-dichlorophenyl)isoxazol-5-yl]pyridin-4-yl]-N-[4-(2-morpholinoethoxy)benzyl]acetamide **867216-62-4P**, 2,2-Dichloro-N-[2-[3-(2,6-dichlorophenyl)isoxazol-5-yl]pyridin-4-yl]-N-[4-(4-ethylpiperazin-1-yl)benzyl]acetamide **867216-64-6P**, 2,2-Dichloro-N-[2-[3-(2,6-dichlorophenyl)isoxazol-5-yl]pyridin-4-yl]-N-(2-morpholinoethyl)acetamide **867216-70-4P**, 2,2-Dichloro-N-[2-[3-(2,6-dichlorophenyl)isoxazol-5-yl]pyridin-4-yl]-N-[(5-neopentyl-2-oxo-1,3-dioxol-4-yl)methyl]acetamide **867216-71-5P**, 4-[3-[2,2-Dichloro-N-[2-[3-(2,6-dichlorophenyl)isoxazol-5-yl]pyridin-4-yl]acetamido]propyl]phenyl diethyl phosphate **867216-72-6P**, tert-Butyl 4-[4-[3-[2,2-Dichloro-N-[2-[3-(2,6-dichlorophenyl)isoxazol-5-yl]pyridin-4-yl]acetamido]propyl]phenyl]piperazine-1-carboxylate **867216-73-7P**, tert-Butyl 4-[3-[2,2-Dichloro-N-[2-[3-(2,6-dichlorophenyl)isoxazol-5-yl]pyridin-4-yl]acetamido]propyl]benzoate **867216-74-8P**, 2,2-Dichloro-N-[2-[3-(2,6-dichlorophenyl)isoxazol-5-yl]pyridin-4-yl]-N-[3-[4-(piperazin-1-yl)phenyl]propyl]acetamide **867216-82-8P 867217-01-4P 867217-04-7P 867217-10-5P 867217-15-0P 867217-19-4P 867217-23-0P 867217-34-3P 867217-41-2P 867217-42-3P 867217-43-4P 867217-44-5P**
(drug candidate; preparation of substituted heterocyclic prodrugs for treating HCV infection)

RN 667931-30-8 USPATFULL

CN Acetamide, 2,2-dichloro-N-[2-[3-(2,6-dichlorophenyl)-5-isoxazolyl]-4-pyridinyl]- (9CI) (CA INDEX NAME)



RN 867215-60-9 USPATFULL
CN Propanoic acid, 2,2-dichloro-3-[[2-[3-(2,6-dichlorophenyl)-5-isoxazolyl]-4-pyridinyl]amino]-3-oxo-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 867215-64-3 USPATFULL
CN Propanoic acid, 2,2-dichloro-3-[[3-[3-[4-chloro-2-(dimethylamino)-3-pyridinyl]-5-isoxazolyl]phenyl]amino]-3-oxo-, methyl ester (9CI) (CA INDEX NAME)



RN 867215-72-3 USPATFULL
CN Acetamide, 2,2-dichloro-N-[3-[3-(2,4-dichloro-3-pyridinyl)-5-isoxazolyl]phenyl]-N-[(5-methyl-2-oxo-1,3-dioxol-4-yl)methyl]- (9CI) (CA INDEX NAME)



RN 867215-73-4 USPATFULL
CN Acetamide, 2,2-dichloro-N-[3-[3-[4-chloro-2-(dimethylamino)-3-pyridinyl]-5-isoxazolyl]phenyl]-N-[(5-methyl-2-oxo-1,3-dioxol-4-yl)methyl]- (9CI) (CA INDEX NAME)



RN 867215-75-6 USPATFULL
CN Acetamide, 2,2-dichloro-N-[3-[3-[4-chloro-2-(dimethylamino)-3-pyridinyl]-5-isoxazolyl]phenyl]-N-[[5-(1-methylethyl)-2-oxo-1,3-dioxol-4-yl]methyl]- (9CI) (CA INDEX NAME)



RN 867215-81-4 USPATFULL
CN Acetamide, 2,2-dichloro-N-[2-[3-(2,6-dichlorophenyl)-5-isoxazolyl]-4-pyridinyl]-N-[(5-methyl-2-oxo-1,3-dioxol-4-yl)methyl]- (9CI) (CA INDEX

NAME)



RN 867215-82-5 USPATFULL
CN Acetamide, 2,2-dichloro-N-[2-[3-(2,6-dichlorophenyl)-5-isoxazolyl]-4-pyridinyl]-N-[[5-(1-methylethyl)-2-oxo-1,3-dioxol-4-yl]methyl]- (9CI) (CA INDEX NAME)



RN 867215-84-7 USPATFULL
CN Acetamide, 2,2-dichloro-N-[2-[3-(2,6-dichlorophenyl)-5-isoxazolyl]-4-pyridinyl]-N-[(2-oxo-5-pentyl-1,3-dioxol-4-yl)methyl]- (9CI) (CA INDEX NAME)



RN 867215-89-2 USPATFULL
CN Acetamide, 2,2-dichloro-N-[2-[3-(2,6-dichlorophenyl)-5-isoxazolyl]-4-pyridinyl]-N-[3-oxo-3-(3-pyridinyl)propyl]- (9CI) (CA INDEX NAME)



RN 867215-92-7 USPATFULL
CN Benzoic acid, 4-[3-[(dichloroacetyl)[2-[3-(2,6-dichlorophenyl)-5-isoxazolyl]-4-pyridinyl]amino]-1-oxopropyl]- (9CI) (CA INDEX NAME)



RN 867215-96-1 USPATFULL
CN Acetamide, 2,2-dichloro-N-[2-[3-(2,6-dichlorophenyl)-5-isoxazolyl]-4-pyridinyl]-N-[3-(4-morpholinyl)-3-oxopropyl]- (9CI) (CA INDEX NAME)



RN 867216-01-1 USPATFULL
CN Acetamide, N-(4-amino-3-oxo-5-phenylpentyl)-2,2-dichloro-N-[2-[3-(2,6-dichlorophenyl)-5-isoxazolyl]-4-pyridinyl]- (9CI) (CA INDEX NAME)



RN 867216-02-2 USPATFULL
CN Acetamide, 2,2-dichloro-N-[2-[3-(2,6-dichlorophenyl)-5-isoxazolyl]-4-pyridinyl]-N-[3-oxo-3-(4-piperidinyl)propyl]- (9CI) (CA INDEX NAME)



RN 867216-03-3 USPATFULL
CN Acetamide, 2,2-dichloro-N-[2-[3-(2,6-dichlorophenyl)-5-isoxazolyl]-4-pyridinyl]-N-[3-oxo-3-(2-pyrrolidinyl)propyl]- (9CI) (CA INDEX NAME)



RN 867216-04-4 USPATFULL
CN 1-Piperidinecarboxylic acid, 3-[3-[(dichloroacetyl)[2-[3-(2,6-dichlorophenyl)-5-isoxazolyl]-4-pyridinyl]amino]-1-oxopropyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 867216-06-6 USPATFULL
CN Acetamide, 2,2-dichloro-N-[2-[3-(2,6-dichlorophenyl)-5-isoxazolyl]-4-pyridinyl]-N-[3-oxo-3-(3-piperidinyl)propyl]- (9CI) (CA INDEX NAME)



RN 867216-07-7 USPATFULL
CN 1-Piperazinecarboxylic acid, 4-[4-[3-[(dichloroacetyl)[2-[3-(2,6-dichlorophenyl)-5-isoxazolyl]-4-pyridinyl]amino]-1-oxopropyl]phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 867216-08-8 USPATFULL
CN Carbamic acid, propyl-, 4-[[(dichloroacetyl)[2-[3-(2,6-dichlorophenyl)-5-isoxazolyl]-4-pyridinyl]amino]methyl]-2,6-dimethylphenyl ester (9CI) (CA INDEX NAME)



RN 867216-32-8 USPATFULL
CN Acetamide, 2,2-dichloro-N-[2-[3-(2,6-dichlorophenyl)-5-isoxazolyl]-4-pyridinyl]-N-[[2-(2-pyridinyl)ethoxy]methyl]- (9CI) (CA INDEX NAME)



RN 867216-40-8 USPATFULL
CN Acetamide, 2,2-dichloro-N-[2-[3-(2,6-dichlorophenyl)-5-isoxazolyl]-4-pyridinyl]-N-[(1-methyl-1H-imidazol-2-yl)methyl]- (9CI) (CA INDEX NAME)



RN 867216-42-0 USPATFULL
CN Phosphonic acid, [[4-[3-[(dichloroacetyl)[2-[3-(2,6-dichlorophenyl)-5-isoxazolyl]-4-pyridinyl]amino]propyl]phenyl]methyl]- (9CI) (CA INDEX NAME)



RN 867216-60-2 USPATFULL
CN Benzoic acid, 4-[[(dichloroacetyl)[2-[3-(2,6-dichlorophenyl)-5-isoxazolyl]-4-pyridinyl]amino]methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 867216-61-3 USPATFULL

CN Acetamide, 2,2-dichloro-N-[2-[3-(2,6-dichlorophenyl)-5-isoxazolyl]-4-pyridinyl]-N-[[4-[2-(4-morpholinyl)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)



RN 867216-62-4 USPATFULL
CN Acetamide, 2,2-dichloro-N-[2-[3-(2,6-dichlorophenyl)-5-isoxazolyl]-4-pyridinyl]-N-[[4-(4-ethyl-1-piperazinyl)phenyl]methyl]- (9CI) (CA INDEX NAME)



RN 867216-64-6 USPATFULL
CN Acetamide, 2,2-dichloro-N-[2-[3-(2,6-dichlorophenyl)-5-isoxazolyl]-4-pyridinyl]-N-[2-(4-morpholinyl)ethyl]- (9CI) (CA INDEX NAME)



RN 867216-70-4 USPATFULL
CN Acetamide, 2,2-dichloro-N-[2-[3-(2,6-dichlorophenyl)-5-isoxazolyl]-4-pyridinyl]-N-[[5-(2,2-dimethylpropyl)-2-oxo-1,3-dioxol-4-yl]methyl]- (9CI) (CA INDEX NAME)



RN 867216-71-5 USPATFULL
CN Phosphoric acid, 4-[3-[(dichloroacetyl)[2-[3-(2,6-dichlorophenyl)-5-isoxazolyl]-4-pyridinyl]amino]propyl]phenyl diethyl ester (9CI) (CA INDEX NAME)



RN 867216-72-6 USPATFULL
CN 1-Piperazinecarboxylic acid, 4-[4-[3-[(dichloroacetyl)[2-[3-(2,6-dichlorophenyl)-5-isoxazolyl]-4-pyridinyl]amino]propyl]phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 867216-73-7 USPATFULL
CN Benzoic acid, 4-[3-[(dichloroacetyl)[2-[3-(2,6-dichlorophenyl)-5-isoxazolyl]-4-pyridinyl]amino]propyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 867216-74-8 USPATFULL
CN Acetamide, 2,2-dichloro-N-[2-[3-(2,6-dichlorophenyl)-5-isoxazolyl]-4-pyridinyl]-N-[3-[4-(1-piperazinyl)phenyl]propyl]- (9CI) (CA INDEX NAME)



RN 867216-82-8 USPATFULL
CN Acetamide, 2,2-dichloro-N-[2-[3-(2,6-dichlorophenyl)-5-isoxazolyl]-4-pyridinyl]-N-[3-(4-fluorophenyl)-3-oxopropyl]- (9CI) (CA INDEX NAME)



RN 867217-01-4 USPATFULL
CN Acetamide, 2,2-dichloro-N-[2-[3-(2,6-dichlorophenyl)-5-isoxazolyl]-4-pyridinyl]-N-[(4-fluorophenyl)methyl]- (9CI) (CA INDEX NAME)



RN 867217-04-7 USPATFULL
CN Acetamide, 2,2-dichloro-N-[2-[3-(2,6-dichlorophenyl)-5-isoxazolyl]-4-pyridinyl]-N-[2-(4-fluorophenyl)ethyl]- (9CI) (CA INDEX NAME)



RN 867217-10-5 USPATFULL
CN Acetamide, N-[[4-(acetyloxy)-3,5-dimethylphenyl]methyl]-2,2-dichloro-N-[2-[3-(2,6-dichlorophenyl)-5-isoxazolyl]-4-pyridinyl]- (9CI) (CA INDEX NAME)



RN 867217-15-0 USPATFULL
CN Glycine, N,N-dimethyl-, 4-[[(dichloroacetyl)[2-[3-(2,6-dichlorophenyl)-5-isoxazolyl]-4-pyridinyl]amino]methyl]-2,6-dimethylphenyl ester (9CI) (CA INDEX NAME)



RN 867217-19-4 USPATFULL
CN Glycine, N-[(1,1-dimethylethoxy)carbonyl]-N-methyl-, 4-[[(dichloroacetyl)[2-[3-(2,6-dichlorophenyl)-5-isoxazolyl]-4-pyridinyl]amino]methyl]-2,6-dimethylphenyl ester (9CI) (CA INDEX NAME)



RN 867217-23-0 USPATFULL

CN Glycine, N-methyl-, 4-[[(dichloroacetyl)[2-[3-(2,6-dichlorophenyl)-5-isoxazolyl]-4-pyridinyl]amino]methyl]-2,6-dimethylphenyl ester (9CI) (CA INDEX NAME)



RN 867217-34-3 USPATFULL
CN Acetamide, 2,2-dichloro-N-[2-[3-(2,6-dichlorophenyl)-5-isoxazolyl]-4-pyridinyl]-N-[3-(4-fluorophenyl)propyl]- (9CI) (CA INDEX NAME)



RN 867217-41-2 USPATFULL
CN Propanoic acid, 2,2-dichloro-3-[[3-[3-[2-chloro-4-(4-morpholinyl)-3-pyridinyl]-5-isoxazolyl]phenyl]amino]-3-oxo-, cyclohexyl ester (9CI) (CA INDEX NAME)



RN 867217-42-3 USPATFULL

CN Propanoic acid, 2,2-dichloro-3-[[3-[3-[2-chloro-4-(4-morpholinyl)-3-pyridinyl]-5-isoxazolyl]phenyl]amino]-3-oxo-, ethyl ester (9CI) (CA INDEX NAME)



RN 867217-43-4 USPATFULL
CN Propanoic acid, 2,2-dichloro-3-[[3-[3-[2-chloro-4-(4-morpholinyl)-3-pyridinyl]-5-isoxazolyl]phenyl]amino]-3-oxo-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 867217-44-5 USPATFULL
CN Propanoic acid, 2,2-dichloro-3-[[2-[3-(2,6-dichlorophenyl)-5-isoxazolyl]-4-pyridinyl]amino]-3-oxo-, cyclohexyl ester (9CI) (CA INDEX NAME)



L50 ANSWER 11 OF 15 USPATFULL on STN
ACCESSION NUMBER: 2004:335746 USPATFULL
TITLE: Substituted diphenyl isoxazoles, pyrazoles and oxadiazoles useful for treating HCV infection
INVENTOR(S): **Singh, Rajinder**, Belmont, CA, UNITED STATES
Goff, Dane, Redwood City, CA, UNITED STATES
Partridge, John J., Chapel Hill, NC, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004266840	A1	20041230
APPLICATION INFO.:	US 2004-838133	A1	20040503 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2003-467811P	20030502 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: Scott D. Rothenberger, Esq., DORSEY & WHITNEY LLP, Intellectual Property Department, 50 South Sixth Street, Suite 1500, Minneapolis, MN, 55402-1498
NUMBER OF CLAIMS: 33
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 22 Drawing Page(s)
LINE COUNT: 4515
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention relates to substituted diphenyl heterocycle compounds and pharmaceutical compositions thereof that inhibit replication of HCV virus. The present invention also relates to the use of the compounds and/or compositions to inhibit HCV replication and/or proliferation and to treat or prevent HCV infections.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L50 ANSWER 12 OF 15 USPATFULL on STN
ACCESSION NUMBER: 2004:321572 USPATFULL
TITLE: Heterocyclic compounds and hydro isomers thereof
INVENTOR(S): **Singh, Rajinder**, Belmont, CA, UNITED STATES
Goff, Dane, Redwood City, CA, UNITED STATES
Partridge, John J., Chapel Hill, NC, UNITED STATES

	NUMBER	KIND	DATE

PATENT INFORMATION: US 2004254227 A1 20041216
APPLICATION INFO.: US 2004-836561 A1 20040430 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2003-467650P	20030502 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: Scott D. Rothenberger, Esq., DORSEY & WHITNEY LLP, Intellectual Property Department, 50 South Sixth Street, Suite 1500, Minneapolis, MN, 55402-1498
NUMBER OF CLAIMS: 40
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 84 Drawing Page(s)
LINE COUNT: 4269
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention relates to substituted diphenyl heterocycle compounds and pharmaceutical compositions thereof that inhibit replication of HCV virus. The present invention also relates to the use of the compounds and/or compositions to inhibit HCV replication and/or proliferation and to treat or prevent HCV infections.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L50 ANSWER 13 OF 15 USPATFULL on STN
ACCESSION NUMBER: 2004:300242 USPATFULL
TITLE: Substituted diphenyl heterocycles useful for treating HCV infection
INVENTOR(S): **Singh, Rajinder**, Belmont, CA, UNITED STATES
Goff, Dane, Redwood, CA, UNITED STATES
Lu, Henry, Foster, CA, UNITED STATES
Issakani, Sarkiz D., San Jose, CA, UNITED STATES
Sun, Thomas, Fremont, CA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004236112	A1	20041125
APPLICATION INFO.:	US 2004-873914	A1	20040622 (10)

RELATED APPLN. INFO.: Division of Ser. No. US 2002-286017, filed on 1 Nov 2002, GRANTED, Pat. No. US 6759538

	NUMBER	DATE
PRIORITY INFORMATION:	US 2001-350107P	20011102 (60)
	US 2002-405472P	20020823 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: Scott D. Rothenberger, Esq., DORSEY & WHITNEY LLP, Intellectual Property Department, 50 South Sixth Street, Suite 1500, Minneapolis, MN, 55402-1498
NUMBER OF CLAIMS: 18
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 16 Drawing Page(s)
LINE COUNT: 2838
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention relates to substituted diphenyl heterocycle compounds and pharmaceutical compositions thereof that inhibit replication of HCV virus. The present invention also relates to the use of the compounds and/or compositions to inhibit HCV replication and/or proliferation and to treat or prevent HCV infections.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L50 ANSWER 14 OF 15 USPATFULL on STN
ACCESSION NUMBER: 2004:166007 USPATFULL
TITLE: Pyridyl substituted heterocycles useful for treating or preventing HCV infection
INVENTOR(S): **Singh, Rajinder**, Belmont, CA, UNITED STATES
Goff, Dane, Redwood City, CA, UNITED STATES
Partridge, John, Chapel Hill, NC, UNITED STATES

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2004127497	A1	20040701	
APPLICATION INFO.:	US 2003-646348	A1	20030822	(10)

	NUMBER	DATE	
PRIORITY INFORMATION:	US 2002-405467P	20020823	(60)
	US 2002-417837P	20021011	(60)
	US 2003-471373P	20030515	(60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: Scott D. Rothenberger, DORSEY & WHITNEY LLP, Intellectual Property Department, 50 South Sixth Street, Suite 1500, Minneapolis, MN, 55402-1498
NUMBER OF CLAIMS: 58
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 84 Drawing Page(s)
LINE COUNT: 2422
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention relates to pyridyl substituted heterocycles and hydro isomers thereof and pharmaceutical compositions thereof that inhibit replication and/or proliferation of HCV virus. The present invention also relates to the use of the pyridyl heterocycles and hydro isomers thereof and/or pharmaceutical compositions comprising the compounds to treat or prevent HCV infections.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT **667931-22-8P 667931-24-0P 667931-28-4P**
667931-30-8P 667931-32-0P 667931-34-2P
667931-36-4P 667931-38-6P 667931-40-0P
667931-42-2P 667931-44-4P 667931-46-6P
667931-48-8P 667931-50-2P 667931-52-4P
667931-60-4P 667931-62-6P 667931-64-8P
667931-68-2P 667931-80-8P
(drug candidate; prepare and cytotoxicity of pyridylisoxazoles for treatment of hepatitis C virus infections)
RN 667931-22-8 USPATFULL
CN Acetamide, 2,2-dichloro-N-[2-[3-(2-chloro-6-fluorophenyl)-5-isoxazolyl]-4-pyridinyl]- (9CI) (CA INDEX NAME)



RN 667931-24-0 USPATFULL
CN Acetamide, 2,2-dichloro-N-[2-[3-[2-fluoro-6-(trifluoromethyl)phenyl]-5-isoxazolyl]-4-pyridinyl]- (9CI) (CA INDEX NAME)



RN 667931-28-4 USPATFULL
CN Acetamide, 2,2-dichloro-N-[5-[3-(2,6-dichlorophenyl)-5-isoxazolyl]-3-pyridinyl]- (9CI) (CA INDEX NAME)



RN 667931-30-8 USPATFULL
CN Acetamide, 2,2-dichloro-N-[2-[3-(2,6-dichlorophenyl)-5-isoxazolyl]-4-pyridinyl]- (9CI) (CA INDEX NAME)



RN 667931-32-0 USPATFULL
CN Acetamide, 2,2-dichloro-N-[3-[3-(3,5-dichloro-4-pyridinyl)-5-isoxazolyl]phenyl]- (9CI) (CA INDEX NAME)



RN 667931-34-2 USPATFULL
CN Acetamide, 2,2-dichloro-N-[5-[3-(2-chloro-6-fluorophenyl)-5-isoxazolyl]-3-pyridinyl]- (9CI) (CA INDEX NAME)



RN 667931-36-4 USPATFULL
CN Acetamide, 2,2-dichloro-N-[5-[3-(2-fluoro-6-methoxyphenyl)-5-isoxazolyl]-3-pyridinyl]- (9CI) (CA INDEX NAME)



RN 667931-38-6 USPATFULL
CN Acetamide, 2,2-dichloro-N-[2-[3-(2,6-dimethylphenyl)-5-isoxazolyl]-4-pyridinyl]- (9CI) (CA INDEX NAME)



RN 667931-40-0 USPATFULL
CN Acetamide, 2,2-dichloro-N-[5-[3-(2,6-dimethylphenyl)-5-isoxazolyl]-3-pyridinyl]- (9CI) (CA INDEX NAME)



RN 667931-42-2 USPATFULL
CN Acetamide, 2,2-dichloro-N-[5-[3-(2,6-difluorophenyl)-5-isoxazolyl]-3-pyridinyl]- (9CI) (CA INDEX NAME)



RN 667931-44-4 USPATFULL
CN Acetamide, 2,2-dichloro-N-[5-[3-(2,3-dichlorophenyl)-5-isoxazolyl]-3-pyridinyl]- (9CI) (CA INDEX NAME)



RN 667931-46-6 USPATFULL
CN Acetamide, 2,2-dichloro-N-[2-[3-[2-(4-morpholinyl)-6-(trifluoromethyl)phenyl]-5-isoxazolyl]-4-pyridinyl]- (9CI) (CA INDEX NAME)



RN 667931-48-8 USPATFULL
CN Acetamide, 2,2-dichloro-N-[3-[3-(3-methyl-2-pyridinyl)-5-isoxazolyl]phenyl]- (9CI) (CA INDEX NAME)



RN 667931-50-2 USPATFULL
CN Acetamide, 2,2-dichloro-N-[6-[3-(2,6-dichlorophenyl)-5-isoxazolyl]-2-pyridinyl]- (9CI) (CA INDEX NAME)



RN 667931-52-4 USPATFULL
CN Acetamide, 2,2-dichloro-N-[5-[3-[2-fluoro-6-(trifluoromethyl)phenyl]-5-isoxazolyl]-3-pyridinyl]- (9CI) (CA INDEX NAME)



RN 667931-60-4 USPATFULL
CN Acetamide, 2,2-dichloro-N-[2-[3-[2-fluoro-6-(4-morpholinylsulfonyl)phenyl]-5-isoxazolyl]-4-pyridinyl]- (9CI) (CA INDEX NAME)



RN 667931-62-6 USPATFULL
CN Acetamide, 2,2-dichloro-N-[2-[3-[2-methoxy-6-(trifluoromethyl)phenyl]-5-isoxazolyl]-4-pyridinyl]- (9CI) (CA INDEX NAME)



RN 667931-64-8 USPATFULL
CN Acetamide, 2,2-dichloro-N-[2-[3-(2,6-dichlorophenyl)-5-isoxazolyl]-4-pyridinyl]-N-methyl- (9CI) (CA INDEX NAME)



RN 667931-68-2 USPATFULL
CN Acetamide, 2,2-dichloro-N-[5-[3-[2-methoxy-6-(trifluoromethyl)phenyl]-5-isoxazolyl]-3-pyridinyl]- (9CI) (CA INDEX NAME)



RN 667931-80-8 USPATFULL
CN Acetamide, 2,2-dichloro-N-[5-[3-[2-chloro-6-[4-(2-pyridinyl)-1-piperazinyl]phenyl]-5-isoxazolyl]-3-pyridinyl]- (9CI) (CA INDEX NAME)



IT **667931-26-2P 667931-56-8P 667931-58-0P**
667931-66-0P 667931-70-6P 667931-72-8P
667931-74-0P 667931-78-4P 667931-82-0P
667931-84-2P 667931-87-5P 667931-89-7P
667931-91-1P 667931-92-2P 667931-94-4P
667931-96-6P 667931-98-8P 667932-00-5P
667932-02-7P 667932-04-9P 667932-06-1P
667932-08-3P 667932-10-7P 667932-12-9P
667932-14-1P 667932-16-3P
(drug candidate; prepare and cytotoxicity of pyridylisoxazoles for treatment of hepatitis C virus infections)
RN 667931-26-2 USPATFULL
CN Acetamide, 2,2-dichloro-N-[2-[3-(2-fluoro-6-methoxyphenyl)-5-isoxazolyl]-4-pyridinyl]- (9CI) (CA INDEX NAME)



RN 667931-56-8 USPATFULL
CN Acetamide, 2,2-dichloro-N-[2-[3-(2,6-dichlorophenyl)-5-isoxazolyl]-1-oxido-4-pyridinyl]- (9CI) (CA INDEX NAME)



RN 667931-58-0 USPATFULL
CN 3-Pyridinecarboxylic acid, 2-[5-[3-[(dichloroacetyl)amino]phenyl]-3-isoxazolyl]-, ethyl ester (9CI) (CA INDEX NAME)



RN 667931-66-0 USPATFULL
CN Acetamide, 2,2-dichloro-N-[2-[3-[2-chloro-6-[4-(2-pyridinyl)-1-piperazinyl]phenyl]-5-isoxazolyl]-4-pyridinyl]- (9CI) (CA INDEX NAME)



RN 667931-70-6 USPATFULL
CN Acetamide, 2,2-dichloro-N-[5-[3-[2-[4-(2-pyridinyl)-1-piperazinyl]-6-(trifluoromethyl)phenyl]-5-isoxazolyl]-3-pyridinyl]- (9CI) (CA INDEX NAME)



RN 667931-72-8 USPATFULL
CN Acetamide, N-[5-[3-[2-(4-acetyl-1-piperazinyl)-6-chlorophenyl]-5-isoxazolyl]-3-pyridinyl]-2,2-dichloro- (9CI) (CA INDEX NAME)



RN 667931-74-0 USPATFULL
CN Acetamide, 2,2-dichloro-N-[5-[3-[2-chloro-6-(4-ethyl-1-piperazinyl)phenyl]-5-isoxazolyl]-3-pyridinyl]- (9CI) (CA INDEX NAME)



RN 667931-78-4 USPATFULL
CN Acetamide, 2,2-dichloro-N-[5-[3-[2-(trifluoromethyl)phenyl]-5-isoxazolyl]-3-pyridinyl]- (9CI) (CA INDEX NAME)



RN 667931-82-0 USPATFULL
CN 1-Piperazinecarboxylic acid, 4-[3-chloro-2-[5-[5-[(dichloroacetyl)amino]-3-pyridinyl]-3-isoxazolyl]phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 667931-84-2 USPATFULL
CN Acetamide, 2,2-dichloro-N-[5-[3-[2-chloro-6-(1-piperazinyl)phenyl]-5-isoxazolyl]-3-pyridinyl]- (9CI) (CA INDEX NAME)



RN 667931-87-5 USPATFULL
CN Acetamide, 2,2-dichloro-N-[5-[3-[2-chloro-6-[[(1,1-dimethylethyl)dimethylsilyl]oxy]phenyl]-5-isoxazolyl]-3-pyridinyl]- (9CI) (CA INDEX NAME)



RN 667931-89-7 USPATFULL
CN Acetamide, 2,2-dichloro-N-[5-[3-(2-chloro-6-hydroxyphenyl)-5-isoxazolyl]-3-pyridinyl]- (9CI) (CA INDEX NAME)



RN 667931-91-1 USPATFULL
CN Carbamic acid, ethyl-, 3-chloro-2-[5-[5-[(dichloroacetyl)amino]-3-pyridinyl]-3-isoxazolyl]phenyl ester (9CI) (CA INDEX NAME)



RN 667931-92-2 USPATFULL

CN 1-Piperazinecarboxamide, 4-[3-chloro-2-[5-[5-[(dichloroacetyl)amino]-3-pyridinyl]-3-isoxazolyl]phenyl]-N-ethyl- (9CI) (CA INDEX NAME)



RN 667931-94-4 USPATFULL
CN Acetamide, 2,2-dichloro-N-[2-[3-[2-chloro-6-[[(1,1-dimethylethyl)dimethylsilyl]oxy]phenyl]-5-isoxazolyl]-4-pyridinyl]- (9CI) (CA INDEX NAME)



RN 667931-96-6 USPATFULL
CN Carbamic acid, propyl-, 3-chloro-2-[5-[4-[(dichloroacetyl)amino]-2-pyridinyl]-3-isoxazolyl]phenyl ester (9CI) (CA INDEX NAME)



RN 667931-98-8 USPATFULL
CN Acetamide, 2,2-dichloro-N-[2-[3-[2-chloro-6-(methoxymethoxy)phenyl]-5-isoxazolyl]-4-pyridinyl]- (9CI) (CA INDEX NAME)



RN 667932-00-5 USPATFULL
CN Acetamide, 2,2-dichloro-N-[2-[3-(2-chloro-6-hydroxyphenyl)-5-isoxazolyl]-4-pyridinyl]- (9CI) (CA INDEX NAME)



RN 667932-02-7 USPATFULL
CN Acetamide, 2,2-dichloro-N-[3-[3-[4-chloro-2-(dimethylamino)-3-pyridinyl]-5-isoxazolyl]phenyl]- (9CI) (CA INDEX NAME)



RN 667932-04-9 USPATFULL
CN Acetamide, 2,2-dichloro-N-[3-[3-(2,4-dichloro-3-pyridinyl)-5-isoxazolyl]phenyl]- (9CI) (CA INDEX NAME)



RN 667932-06-1 USPATFULL
CN Acetamide, 2,2-dichloro-N-[3-[3-[2-chloro-4-(4-morpholinyl)-3-pyridinyl]-5-isoxazolyl]phenyl]- (9CI) (CA INDEX NAME)



RN 667932-08-3 USPATFULL
CN Acetamide, N-[3-[3-(6-bromo-2-pyridinyl)-5-isoxazolyl]phenyl]-2,2-dichloro- (9CI) (CA INDEX NAME)



RN 667932-10-7 USPATFULL
CN Acetamide, 2,2-dichloro-N-[2-[3-(2,6-dichlorophenyl)-5-isoxazolyl]-4-pyridinyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 667932-12-9 USPATFULL
CN Acetamide, 2,2-dichloro-N-[2-[3-(2,6-dichlorophenyl)-5-isoxazolyl]-4-pyridinyl]-, mono(4-methylbenzenesulfonate) (9CI) (CA INDEX NAME)

CM 1

CRN 667931-30-8
CMF C16 H9 Cl4 N3 O2



RN 667932-16-3 USPATFULL
CN Acetamide, 2,2-dichloro-N-[2-[3-(2,6-dichlorophenyl)-5-isoxazolyl]-4-pyridinyl]-, mononitrate (9CI) (CA INDEX NAME)

CM 1

CRN 667931-30-8
CMF C16 H9 Cl4 N3 O2



CM 2

CRN 7697-37-2
CMF H N O3



L50 ANSWER 15 OF 15 USPATFULL on STN
ACCESSION NUMBER: 2003:237404 USPATFULL
TITLE: Substituted diphenyl heterocycles useful for treating HCV infection
INVENTOR(S): **Singh, Rajinder**, Belmont, CA, UNITED STATES
Goff, Dane, Redwood, CA, UNITED STATES
Lu, Henry, Foster City, CA, UNITED STATES
Issakani, Sarkiz D., San Jose, CA, UNITED STATES
Sun, Thomas, Fremont, CA, UNITED STATES

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2003165561	A1	20030904	
	US 6759538	B2	20040706	
APPLICATION INFO.:	US 2002-286017	A1	20021101	(10)



CM 2

CRN 104-15-4
CMF C7 H8 O3 S



RN 667932-14-1 USPATFULL
CN Ethanesulfonic acid, compd. with 2,2-dichloro-N-[2-[3-(2,6-dichlorophenyl)-5-isoxazolyl]-4-pyridinyl]acetamide (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 667931-30-8
CMF C16 H9 Cl4 N3 O2



CM 2

CRN 594-45-6
CMF C2 H6 O3 S

	NUMBER	DATE
PRIORITY INFORMATION:	US 2001-350107P	20011102 (60)
	US 2002-405472P	20020823 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	DORSEY & WHITNEY LLP, INTELLECTUAL PROPERTY DEPARTMENT, 4 EMBARCADERO CENTER, SUITE 3400, SAN FRANCISCO, CA, 94111	
NUMBER OF CLAIMS:	37	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	16 Drawing Page(s)	
LINE COUNT:	2867	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to substituted diphenyl heterocycle compounds and pharmaceutical compositions thereof that inhibit replication of HCV virus. The present invention also relates to the use of the compounds and/or compositions to inhibit HCV replication and/or proliferation and to treat or prevent HCV infections.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

STRUCTURE SEARCH

=> □

```
=> file registry
FILE 'REGISTRY' ENTERED AT 11:38:43 ON 17 FEB 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2006 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES:   15 FEB 2006  HIGHEST RN 874326-73-5
DICTIONARY FILE UPDATES:  15 FEB 2006  HIGHEST RN 874326-73-5

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH JULY 14, 2005

  Please note that search-term pricing does apply when
  conducting SmartSELECT searches.

*********************************************************************
*                                                                   *
* The CA roles and document type information have been removed from *
* the IDE default display format and the ED field has been added,   *
* effective March 20, 2005.  A new display format, IDERL, is now    *
* available and contains the CA role and document type information. *
*                                                                   *
*********************************************************************

Structure search iteration limits have been increased.  See HELP SLIMITS
for details.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document.  For information
on property searching in REGISTRY, refer to:

http://www.cas.org/ONLINE/UG/regprops.html

=> d stat que L19

L1              STR
```

C 77 N 78







Page 1-A





Page 1-B





Page 2-A



Page 2-B





Page 3-A



Page 3-B
VAR G1=5/11/17/23
VAR G2=77/78
VAR G3=33/39/45/51/61
NODE ATTRIBUTES:

NSPEC	IS R	AT	1
NSPEC	IS R	AT	2
NSPEC	IS R	AT	3
NSPEC	IS R	AT	4
NSPEC	IS R	AT	5
NSPEC	IS R	AT	6
NSPEC	IS R	AT	7
NSPEC	IS R	AT	8
NSPEC	IS R	AT	9
NSPEC	IS R	AT	10
NSPEC	IS R	AT	11
NSPEC	IS R	AT	12
NSPEC	IS R	AT	13
NSPEC	IS R	AT	14
NSPEC	IS R	AT	15
NSPEC	IS R	AT	16
NSPEC	IS R	AT	17
NSPEC	IS R	AT	18
NSPEC	IS R	AT	19
NSPEC	IS R	AT	20
NSPEC	IS R	AT	21
NSPEC	IS R	AT	22
NSPEC	IS R	AT	23
NSPEC	IS R	AT	24
NSPEC	IS C	AT	25
NSPEC	IS R	AT	26
NSPEC	IS R	AT	27
NSPEC	IS R	AT	28
NSPEC	IS R	AT	29
NSPEC	IS R	AT	30
NSPEC	IS R	AT	31
NSPEC	IS R	AT	32
NSPEC	IS R	AT	33
NSPEC	IS R	AT	34

```
NSPEC   IS R      AT  35
NSPEC   IS R      AT  36
NSPEC   IS R      AT  37
NSPEC   IS R      AT  38
NSPEC   IS R      AT  39
NSPEC   IS R      AT  40
NSPEC   IS R      AT  41
NSPEC   IS R      AT  42
NSPEC   IS R      AT  43
NSPEC   IS R      AT  44
NSPEC   IS R      AT  45
NSPEC   IS R      AT  46
NSPEC   IS R      AT  47
NSPEC   IS R      AT  48
NSPEC   IS R      AT  49
NSPEC   IS R      AT  50
NSPEC   IS R      AT  51
NSPEC   IS R      AT  52
NSPEC   IS R      AT  53
NSPEC   IS R      AT  54
NSPEC   IS C      AT  55
NSPEC   IS C      AT  56
NSPEC   IS C      AT  57
NSPEC   IS C      AT  58
NSPEC   IS R      AT  59
NSPEC   IS R      AT  60
NSPEC   IS R      AT  61
NSPEC   IS R      AT  62
NSPEC   IS R      AT  63
NSPEC   IS R      AT  64
NSPEC   IS C      AT  65
NSPEC   IS C      AT  66
NSPEC   IS C      AT  67
NSPEC   IS C      AT  68
NSPEC   IS C      AT  69
NSPEC   IS C      AT  70
NSPEC   IS C      AT  71
NSPEC   IS C      AT  72
NSPEC   IS C      AT  73
NSPEC   IS C      AT  74
NSPEC   IS C      AT  75
NSPEC   IS C      AT  76
CONNECT IS E3  RC AT  66
CONNECT IS E3  RC AT  67
CONNECT IS E3  RC AT  68
CONNECT IS E3  RC AT  69
CONNECT IS E3  RC AT  70
CONNECT IS E1  RC AT  71
CONNECT IS E1  RC AT  72
CONNECT IS E1  RC AT  73
CONNECT IS E1  RC AT  74
CONNECT IS E1  RC AT  75
DEFAULT MLEVEL IS ATOM
MLEVEL  IS CLASS  AT  55 56 57 58 65 66 67 68 69 70 71 72 73 74 75
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS  78
```

STEREO ATTRIBUTES: NONE
L2 (4356201) SEA FILE=REGISTRY ABB=ON PLU=ON NC5/ESS
L3 281 SEA FILE=REGISTRY SUB=L2 SSS FUL L1
L10 STR

C 107 N 108



Page 1-A





Page 1-B



Page 2-A



Page 2-B



Page 3-A



Page 3-B
VAR G1=5/11/17/23
VAR G2=107/108
VAR G3=32/38/44/50/60
VAR G4=27/78/90
NODE ATTRIBUTES:
NSPEC IS R AT 1
NSPEC IS R AT 2
NSPEC IS R AT 3
NSPEC IS R AT 4
NSPEC IS R AT 5
NSPEC IS R AT 6
NSPEC IS R AT 7
NSPEC IS R AT 8
NSPEC IS R AT 9
NSPEC IS R AT 10
NSPEC IS R AT 11
NSPEC IS R AT 12
NSPEC IS R AT 13
NSPEC IS R AT 14
NSPEC IS R AT 15
NSPEC IS R AT 16
NSPEC IS R AT 17
NSPEC IS R AT 18
NSPEC IS R AT 19
NSPEC IS R AT 20
NSPEC IS R AT 21
NSPEC IS R AT 22
NSPEC IS R AT 23
NSPEC IS R AT 24
NSPEC IS R AT 25
NSPEC IS R AT 26
NSPEC IS R AT 27
NSPEC IS R AT 28
NSPEC IS R AT 29
NSPEC IS R AT 30

```
NSPEC   IS R      AT  31
NSPEC   IS R      AT  32
NSPEC   IS R      AT  33
NSPEC   IS R      AT  34
NSPEC   IS R      AT  35
NSPEC   IS R      AT  36
NSPEC   IS R      AT  37
NSPEC   IS R      AT  38
NSPEC   IS R      AT  39
NSPEC   IS R      AT  40
NSPEC   IS R      AT  41
NSPEC   IS R      AT  42
NSPEC   IS R      AT  43
NSPEC   IS R      AT  44
NSPEC   IS R      AT  45
NSPEC   IS R      AT  46
NSPEC   IS R      AT  47
NSPEC   IS R      AT  48
NSPEC   IS R      AT  49
NSPEC   IS R      AT  50
NSPEC   IS R      AT  51
NSPEC   IS R      AT  52
NSPEC   IS R      AT  53
NSPEC   IS C      AT  54
NSPEC   IS C      AT  55
NSPEC   IS C      AT  56
NSPEC   IS C      AT  57
NSPEC   IS R      AT  58
NSPEC   IS R      AT  59
NSPEC   IS R      AT  60
NSPEC   IS R      AT  61
NSPEC   IS R      AT  62
NSPEC   IS R      AT  63
NSPEC   IS C      AT  64
NSPEC   IS C      AT  65
NSPEC   IS C      AT  66
NSPEC   IS C      AT  67
NSPEC   IS C      AT  68
NSPEC   IS C      AT  69
NSPEC   IS C      AT  70
NSPEC   IS C      AT  71
NSPEC   IS C      AT  72
NSPEC   IS C      AT  73
NSPEC   IS C      AT  74
NSPEC   IS C      AT  75
NSPEC   IS R      AT  76
NSPEC   IS R      AT  77
NSPEC   IS R      AT  78
NSPEC   IS R      AT  79
NSPEC   IS R      AT  80
NSPEC   IS R      AT  81
NSPEC   IS R      AT  82
NSPEC   IS R      AT  83
NSPEC   IS R      AT  84
NSPEC   IS R      AT  85
NSPEC   IS C      AT  86
NSPEC   IS C      AT  87
NSPEC   IS R      AT  88
NSPEC   IS R      AT  89
NSPEC   IS R      AT  90
```

```
NSPEC   IS R       AT  91
NSPEC   IS R       AT  92
NSPEC   IS R       AT  93
NSPEC   IS R       AT  94
NSPEC   IS R       AT  95
NSPEC   IS R       AT  96
NSPEC   IS R       AT  97
NSPEC   IS R       AT  98
NSPEC   IS R       AT  99
NSPEC   IS R       AT 100
NSPEC   IS R       AT 101
NSPEC   IS R       AT 102
NSPEC   IS R       AT 103
NSPEC   IS R       AT 104
NSPEC   IS R       AT 105
NSPEC   IS C       AT 106
CONNECT IS E3  RC AT  65
CONNECT IS E3  RC AT  66
CONNECT IS E3  RC AT  67
CONNECT IS E3  RC AT  68
CONNECT IS E3  RC AT  69
CONNECT IS E1  RC AT  70
CONNECT IS E1  RC AT  71
CONNECT IS E1  RC AT  72
CONNECT IS E1  RC AT  73
CONNECT IS E1  RC AT  74
CONNECT IS E2  RC AT 100
CONNECT IS E2  RC AT 102
DEFAULT MLEVEL IS ATOM
MLEVEL  IS CLASS  AT  54 55 56 57 64 65 66 67 68 69 70 71 72 73 74
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS 108

STEREO ATTRIBUTES: NONE
L12          180 SEA FILE=REGISTRY SUB=L3 SSS FUL L10
L13            1 SEA FILE=REGISTRY ABB=ON  PLU=ON  "CARBAMIC ACID, (3-(5-(3,4-BI
                 S(PHENYLMETHOXY)PHENYL)-1-(2-PYRIDINYL)-1H-PYRAZOL-3-YL)PHENYL)
                 -, PHENYLMETHYL ESTER"/CN
L14            1 SEA FILE=REGISTRY ABB=ON  PLU=ON  "BENZAMIDE, N-(4-(2-(2-CHLORO
                 PHENYL)-4-(3-METHYLPHENYL)-5-THIAZOLYL)-2-PYRIDINYL)-"/CN
L15            1 SEA FILE=REGISTRY ABB=ON  PLU=ON  "BENZENEACETAMIDE, N-(4-(2-(2
                 -CHLOROPHENYL)-4-(3-METHYLPHENYL)-5-THIAZOLYL)-2-PYRIDINYL)-"/C
                 N
L16            1 SEA FILE=REGISTRY ABB=ON  PLU=ON  "BENZENEPROPANAMIDE,
                 N-(4-(2-(2-CHLOROPHENYL)-4-(3-METHYLPHENYL)-5-THIAZOLYL)-2-PYRI
                 DINYL)-"/CN
L17            4 SEA FILE=REGISTRY ABB=ON  PLU=ON  (L13 OR L14 OR L15 OR L16)
L18          101 SEA FILE=REGISTRY ABB=ON  PLU=ON  L3 NOT L12
L19          105 SEA FILE=REGISTRY ABB=ON  PLU=ON  L18 OR L17

=> d L21

L21          ANALYZE L19 1- LC :        4 TERMS

TERM #    # OCC   # DOC   % DOC LC
------ -------- ------- ------- ---------------
```

```
     1      104     104  99.05 CA
     2      104     104  99.05 CAPLUS
     3      102     102  97.14 USPATFULL
     4       49      49  46.67 TOXCENTER
*********  END OF L21***


=> file caplus

FILE 'CAPLUS' ENTERED AT 11:38:46 ON 17 FEB 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)


Copyright of the articles to which records in this database refer is
held by the publishers listed in the PUBLISHER (PB) field (available
for records published or updated in Chemical Abstracts after December
26, 1996), unless otherwise indicated in the original publications.
The CA Lexicon is the copyrighted intellectual property of the
American Chemical Society and is provided to assist you in searching
databases on STN.  Any dissemination, distribution, copying, or storing
of this information, without the prior written consent of CAS, is
strictly prohibited.

FILE COVERS 1907 - 17 Feb 2006  VOL 144 ISS 9
FILE LAST UPDATED: 16 Feb 2006  (20060216/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply.
They are available for your review at:

http://www.cas.org/infopolicy.html
'OBI' IS DEFAULT SEARCH FIELD FOR 'CAPLUS' FILE

=> d que nos L20

L1              STR
L2  (   4356201)SEA FILE=REGISTRY ABB=ON  PLU=ON  NC5/ESS
L3          281 SEA FILE=REGISTRY SUB=L2 SSS FUL L1
L10             STR
L12         180 SEA FILE=REGISTRY SUB=L3 SSS FUL L10
L13           1 SEA FILE=REGISTRY ABB=ON  PLU=ON  "CARBAMIC ACID, (3-(5-(3,4-BI
                S(PHENYLMETHOXY)PHENYL)-1-(2-PYRIDINYL)-1H-PYRAZOL-3-YL)PHENYL)
                -, PHENYLMETHYL ESTER"/CN
L14           1 SEA FILE=REGISTRY ABB=ON  PLU=ON  "BENZAMIDE, N-(4-(2-(2-CHLORO
                PHENYL)-4-(3-METHYLPHENYL)-5-THIAZOLYL)-2-PYRIDINYL)-"/CN
L15           1 SEA FILE=REGISTRY ABB=ON  PLU=ON  "BENZENEACETAMIDE, N-(4-(2-(2
                -CHLOROPHENYL)-4-(3-METHYLPHENYL)-5-THIAZOLYL)-2-PYRIDINYL)-"/C
                N
L16           1 SEA FILE=REGISTRY ABB=ON  PLU=ON  "BENZENEPROPANAMIDE,
                N-(4-(2-(2-CHLOROPHENYL)-4-(3-METHYLPHENYL)-5-THIAZOLYL)-2-PYRI
                DINYL)-"/CN
L17           4 SEA FILE=REGISTRY ABB=ON  PLU=ON  (L13 OR L14 OR L15 OR L16)
L18         101 SEA FILE=REGISTRY ABB=ON  PLU=ON  L3 NOT L12
L19         105 SEA FILE=REGISTRY ABB=ON  PLU=ON  L18 OR L17
L20          14 SEA FILE=CAPLUS ABB=ON  PLU=ON  L19


=> s L20 not L47
```

L51 12 L20 NOT L47 printed with author search

=> file uspatfull

FILE 'USPATFULL' ENTERED AT 11:38:48 ON 17 FEB 2006
CA INDEXING COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

FILE COVERS 1971 TO PATENT PUBLICATION DATE: 16 Feb 2006 (20060216/PD)
FILE LAST UPDATED: 16 Feb 2006 (20060216/ED)
HIGHEST GRANTED PATENT NUMBER: US7000250
HIGHEST APPLICATION PUBLICATION NUMBER: US2006037120
CA INDEXING IS CURRENT THROUGH 14 Feb 2006 (20060214/UPCA)
ISSUE CLASS FIELDS (/INCL) CURRENT THROUGH: 16 Feb 2006 (20060216/PD)
REVISED CLASS FIELDS (/NCL) LAST RELOADED: Dec 2005
USPTO MANUAL OF CLASSIFICATIONS THESAURUS ISSUE DATE: Dec 2005

=> d que nos L22

L1 STR
L2 (4356201) SEA FILE=REGISTRY ABB=ON PLU=ON NC5/ESS
L3 281 SEA FILE=REGISTRY SUB=L2 SSS FUL L1
L10 STR
L12 180 SEA FILE=REGISTRY SUB=L3 SSS FUL L10
L13 1 SEA FILE=REGISTRY ABB=ON PLU=ON "CARBAMIC ACID, (3-(5-(3,4-BIS(PHENYLMETHOXY)PHENYL)-1-(2-PYRIDINYL)-1H-PYRAZOL-3-YL)PHENYL)-, PHENYLMETHYL ESTER"/CN
L14 1 SEA FILE=REGISTRY ABB=ON PLU=ON "BENZAMIDE, N-(4-(2-(2-CHLOROPHENYL)-4-(3-METHYLPHENYL)-5-THIAZOLYL)-2-PYRIDINYL)-"/CN
L15 1 SEA FILE=REGISTRY ABB=ON PLU=ON "BENZENEACETAMIDE, N-(4-(2-(2-CHLOROPHENYL)-4-(3-METHYLPHENYL)-5-THIAZOLYL)-2-PYRIDINYL)-"/CN
L16 1 SEA FILE=REGISTRY ABB=ON PLU=ON "BENZENEPROPANAMIDE, N-(4-(2-(2-CHLOROPHENYL)-4-(3-METHYLPHENYL)-5-THIAZOLYL)-2-PYRIDINYL)-"/CN
L17 4 SEA FILE=REGISTRY ABB=ON PLU=ON (L13 OR L14 OR L15 OR L16)
L18 101 SEA FILE=REGISTRY ABB=ON PLU=ON L3 NOT L12
L19 105 SEA FILE=REGISTRY ABB=ON PLU=ON L18 OR L17
L22 13 SEA FILE=USPATFULL ABB=ON PLU=ON L19

=> s L22 not L48

L52 11 L22 NOT L48 printed with author search

=> file toxcenter

FILE 'TOXCENTER' ENTERED AT 11:38:50 ON 17 FEB 2006
COPYRIGHT (C) 2006 ACS

FILE COVERS 1907 TO 14 Feb 2006 (20060214/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TOXCENTER has been enhanced with new files segments and search fields.
See HELP CONTENT for more information.

```
TOXCENTER thesauri in the /CN, /CT, and /MN fields incorporate the
MeSH 2006 vocabulary.
See http://www.nlm.nih.gov/mesh/
    http://www.nlm.nih.gov/pubs/techbull/nd05/nd05_med_data_changes.html
    http://www.nlm.nih.gov/pubs/techbull/nd05/nd05_2006_MeSH.html
for a description of changes.

=> d que nos L23

L1              STR
L2  (   4356201)SEA FILE=REGISTRY ABB=ON  PLU=ON  NC5/ESS
L3          281 SEA FILE=REGISTRY SUB=L2 SSS FUL L1
L10             STR
L12         180 SEA FILE=REGISTRY SUB=L3 SSS FUL L10
L13           1 SEA FILE=REGISTRY ABB=ON  PLU=ON  "CARBAMIC ACID, (3-(5-(3,4-BI
                S(PHENYLMETHOXY)PHENYL)-1-(2-PYRIDINYL)-1H-PYRAZOL-3-YL)PHENYL)
                -, PHENYLMETHYL ESTER"/CN
L14           1 SEA FILE=REGISTRY ABB=ON  PLU=ON  "BENZAMIDE, N-(4-(2-(2-CHLORO
                PHENYL)-4-(3-METHYLPHENYL)-5-THIAZOLYL)-2-PYRIDINYL)-"/CN
L15           1 SEA FILE=REGISTRY ABB=ON  PLU=ON  "BENZENEACETAMIDE, N-(4-(2-(2
                -CHLOROPHENYL)-4-(3-METHYLPHENYL)-5-THIAZOLYL)-2-PYRIDINYL)-"/C
                N
L16           1 SEA FILE=REGISTRY ABB=ON  PLU=ON  "BENZENEPROPANAMIDE,
                N-(4-(2-(2-CHLOROPHENYL)-4-(3-METHYLPHENYL)-5-THIAZOLYL)-2-PYRI
                DINYL)-"/CN
L17           4 SEA FILE=REGISTRY ABB=ON  PLU=ON  (L13 OR L14 OR L15 OR L16)
L18         101 SEA FILE=REGISTRY ABB=ON  PLU=ON  L3 NOT L12
L19         105 SEA FILE=REGISTRY ABB=ON  PLU=ON  L18 OR L17
L23           4 SEA FILE=TOXCENTER ABB=ON  PLU=ON  L19


=> s L23 not L49
L53           3 L23 NOT L49
```

printed with author search

```
=> => dup rem L51 L52 L53
FILE 'CAPLUS' ENTERED AT 11:39:50 ON 17 FEB 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'USPATFULL' ENTERED AT 11:39:50 ON 17 FEB 2006
CA INDEXING COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'TOXCENTER' ENTERED AT 11:39:50 ON 17 FEB 2006
COPYRIGHT (C) 2006 ACS
PROCESSING COMPLETED FOR L51
PROCESSING COMPLETED FOR L52
PROCESSING COMPLETED FOR L53
L54          23 DUP REM L51 L52 L53 (3 DUPLICATES REMOVED)
                ANSWERS '1-12' FROM FILE CAPLUS
                ANSWERS '13-23' FROM FILE [illegible]

=> d ibib abs hitind hitstr L54 1-12; d ibib abs hitstr L54 13-23

L54  ANSWER 1 OF 23  CAPLUS  COPYRIGHT 2006 ACS on STN DUPLICATE 1
ACCESSION NUMBER:        2005:612074  CAPLUS
DOCUMENT NUMBER:         143:109761
TITLE:                   Compositions and methods for treating hepatitis C
```

virus (HCV) infection with haloalkylamide antiviral agents and for protecting the antiviral agent from hydrolases

INVENTOR(S): Holsztynska, Elzbieta J.; Lo, Ray; Sun, Thomas W.; Wang, Steven X.
PATENT ASSIGNEE(S): Rigel Pharmaceuticals, Inc., USA
SOURCE: PCT Int. Appl., 98 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005063225	A1	20050714	WO 2004-US42717	20041218
WO 2005063225	C1	20050825		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 2005249805	A1	20051110	US 2004-17531	20041218

PRIORITY APPLN. INFO.: US 2003-531543P P 20031219
OTHER SOURCE(S): MARPAT 143:109761
GI



I

AB Provided are compns. and methods for protecting a compound comprising a haloalkylamide moiety from metabolic transformation by hydrolases. In one aspect, the disclosure is directed to increasing the bioavailability and tissue delivery of a anti-HCV compound comprising a haloalkylamide moiety by protecting the compound from inactivation by carboxylesterases. Specific approaches for limiting metabolic transformation include use of carboxylesterase inhibitors to inhibit metabolism of the compound, or use of orally administered compns. designed to deliver the compound to the small intestine or large intestine. Further provided are methods of treating or preventing HCV infection in a subject. Sodium fluoride and bis(p-nitrophenyl)phosphate gave complete inhibition of I degradation by human liver microsomes.

IC ICM A61K031-16
CC 1-5 (Pharmacology)
IT 286841-27-8 **667931-30-8**
RL: BSU (Biological study, unclassified); PAC (Pharmacological activity);

PKT (Pharmacokinetics); THU (Therapeutic use); BIOL (Biological study);
USES (Uses)
(as antiviral agent; treatment of hepatitis C virus infection with antiviral haloalkylamide agents and inhibitors for protecting the antiviral agent from inactivation by hydrolases)

IT **667931-30-8**
RL: BSU (Biological study, unclassified); PAC (Pharmacological activity); PKT (Pharmacokinetics); THU (Therapeutic use); BIOL (Biological study);
USES (Uses)
(as antiviral agent; treatment of hepatitis C virus infection with antiviral haloalkylamide agents and inhibitors for protecting the antiviral agent from inactivation by hydrolases)

RN 667931-30-8 CAPLUS
CN Acetamide, 2,2-dichloro-N-[2-[3-(2,6-dichlorophenyl)-5-isoxazolyl]-4-pyridinyl]- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L54 ANSWER 2 OF 23 CAPLUS COPYRIGHT 2006 ACS on STN DUPLICATE 2
ACCESSION NUMBER: 2005:14218 CAPLUS
DOCUMENT NUMBER: 142:109454
TITLE: Methods of identifying hepatitis C virus gene NS5B polymerase inhibitors and their uses
INVENTOR(S): Lu, Henry
PATENT ASSIGNEE(S): Rigel Pharmaceuticals, Inc., USA
SOURCE: PCT Int. Appl., 96 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005000308	A2	20050106	WO 2004-US15665	20040517
WO 2005000308	A3	20050324		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK,

EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

US 2005009877 A1 20050113 US 2004-847822 20040517
PRIORITY APPLN. INFO.: US 2003-471444P P 20030515
OTHER SOURCE(S): MARPAT 142:109454
GI



I

AB The present invention relates to a variety of screening methods, utilizing both biochem. and cellular assays as well as in silico assays, for use in the discovery of agents active in the treating or preventing Hepatitis C virus (HCV) infections. The invention further relates to methods of inhibiting an HCV NS5B polymerase and to the treatment and/or prevention of HCV infections with compds. having specified binding properties. The compds. bind to a region identified as the Rigel pocket, which is defined by the amino acid residues at positions 142, 148, 213, 316, 444, 445, 447, 451, 452, and 465 of NS5B. Four claimed structures are representative of these pocket-binding inhibitors (I; A ring = (substituted)Ph or pyridyl; five-membered B ring is saturated, unsatd., or aromatic; X, Y, Z = NH, N, O, S, except that X and Y are not simultaneously O; the C ring = Ph, pyridyl, R11 = H, alkyl; R12 = ClCH2, Cl2CH). One of these structures is 2,2-dichloro-N-[2-[3-[2-(4-morpholinyl)-6-(trifluoromethyl)phenyl]-5-is oxazolyl]-4-pyridinyl]acetamide (I; A ring = trifluoromethyl and morpholino-substituted Ph; B ring = isoxazole; C ring = pyridine; R11 = H; R12 = Cl2CH). The examples describe a replicon assay that was used to identify compds. A-C and counterscreens to identify resistant replicons and to investigate a mechanism of action for the compds.

IC ICM A61K031-443
ICS A61K031-4439; A61P031-12

CC 7-3 (Enzymes)
Section cross-reference(s): 1, 3, 10, 28

IT 286841-27-8 **667931-24-0 667931-30-8 667931-46-6**
RL: PEP (Physical, engineering or chemical process); PYP (Physical process); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)
(methods of identifying hepatitis C virus gene NS5B polymerase inhibitors and their uses)

IT **667931-24-0 667931-30-8 667931-46-6**
RL: PEP (Physical, engineering or chemical process); PYP (Physical process); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)
(methods of identifying hepatitis C virus gene NS5B polymerase inhibitors and their uses)

RN 667931-24-0 CAPLUS
CN Acetamide, 2,2-dichloro-N-[2-[3-[2-fluoro-6-(trifluoromethyl)phenyl]-5-isoxazolyl]-4-pyridinyl]- (9CI) (CA INDEX NAME)



RN 667931-30-8 CAPLUS
CN Acetamide, 2,2-dichloro-N-[2-[3-(2,6-dichlorophenyl)-5-isoxazolyl]-4-pyridinyl]- (9CI) (CA INDEX NAME)



RN 667931-46-6 CAPLUS
CN Acetamide, 2,2-dichloro-N-[2-[3-[2-(4-morpholinyl)-6-(trifluoromethyl)phenyl]-5-isoxazolyl]-4-pyridinyl]- (9CI) (CA INDEX NAME)



L54 ANSWER 3 OF 23 CAPLUS COPYRIGHT 2006 ACS on STN DUPLICATE 3
ACCESSION NUMBER: 2002:504649 CAPLUS
DOCUMENT NUMBER: 137:83638
TITLE: Concomitant drugs of p38MAP kinase inhibitors and/or TNF-α production inhibitors with other specified agents
INVENTOR(S): Ohkawa, Shigenori; Naruo, Kenichi; Miwatashi, Seiji
PATENT ASSIGNEE(S): Takeda Chemical Industries, Ltd., Japan
SOURCE: PCT Int. Appl., 278 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002051442	A1	20020704	WO 2001-JP11353	20011225
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2436739	AA	20020704	CA 2001-2436739	20011225
JP 2002302458	A2	20021018	JP 2001-392778	20011225
EP 1354603	A1	20031022	EP 2001-271876	20011225
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
US 2004097555	A1	20040520	US 2003-451839	20030625
PRIORITY APPLN. INFO.:			JP 2000-396220 A	20001226
			JP 2001-27572 A	20010202
			WO 2001-JP11353 W	20011225

OTHER SOURCE(S): MARPAT 137:83638

AB Drugs comprising a combination of one or more p38MAP kinase inhibitors and/or TNF-α production inhibitors with one or more agents selected from the group consisting of: (1) nonsteroidal anti-inflammatory agents; (2) disease-modification antirheumatics; (3) anti-cytokine drugs; (4) immunomodulators; (5) steroidal drugs; and (6) c-JUN N-terminal kinase inhibitors. These concomitant drugs are useful as preventives and remedies for diseases such as rheumatism and arthritis and other diseases. For example, tablets containing [4-(3,5-dimethylphenyl)-5-(2-phenylmethyloxy-4-pyridyl)-1,3-thiazol-2-yl]amine 50 mg/tablet are administered with tablets containing rofecoxib 5 mg/tablet.

IC ICM A61K045-06
ICS A61K031-4439; A61K031-4545; A61K031-497; A61K031-506; A61K031-5377; A61P001-04; A61P001-16; A61P003-10; A61P007-06; A61P009-02; A61P009-04; A61P009-10; A61P011-00; A61P011-06; A61P013-12; A61P017-04; A61P017-06; A61P019-02; A61P019-10

CC 63-6 (Pharmaceuticals)
Section cross-reference(s): 1

IT 224039-49-0P 224039-51-4P 224039-54-7P 224039-55-8P 224039-56-9P 224039-57-0P 224039-58-1P 224039-59-2P 224039-60-5P 224039-61-6P 224039-63-8P 224039-64-9P 224039-65-0P 224039-66-1P 224039-67-2P 224039-68-3P 224039-70-7P 224039-72-9P 224039-73-0P 224039-74-1P 224039-76-3P 224039-77-4P 224039-78-5P 224039-79-6P 224039-81-0P

224039-82-1P 224039-83-2P 224039-85-4P 224039-86-5P 224039-87-6P
224039-88-7P 224039-90-1P 224039-91-2P 224039-92-3P 224039-93-4P
224039-95-6P 224039-96-7P 224039-97-8P 224039-99-0P 224040-00-0P
224040-01-1P 224040-02-2P 224040-03-3P 224040-04-4P 224040-06-6P
224040-07-7P 224040-08-8P 224040-10-2P 224040-11-3P 224040-12-4P
224040-13-5P 224040-14-6P 224040-16-8P 224040-17-9P 224040-18-0P
224040-19-1P 224040-21-5P 224040-22-6P 224040-23-7P 224040-24-8P
224040-26-0P 224040-27-1P 224040-28-2P 224040-30-6P 224040-31-7P
224040-33-9P 224040-34-0P 224040-36-2P 224040-37-3P 224040-38-4P
224040-40-8P 224040-41-9P 224040-42-0P 224040-43-1P 224040-44-2P
224040-45-3P 224040-46-4P 224040-47-5P 224040-57-7P 252198-63-3P
252198-66-6P 252198-74-6P 252198-75-7P 252198-97-3P 284486-00-6P
303162-67-6P 303162-68-7P 303162-69-8P 303162-70-1P 303162-71-2P
303162-72-3P 303162-73-4P 303162-74-5P 303162-75-6P 303162-76-7P
303162-77-8P 303162-78-9P 303162-79-0P 303162-80-3P
303162-81-4P 303162-82-5P 303162-84-7P 303162-85-8P 303162-86-9P
303162-87-0P 303162-88-1P 303162-89-2P 303162-90-5P
303162-91-6P 303162-92-7P 303162-93-8P 303162-94-9P
303162-95-0P 303162-96-1P 303162-97-2P 303162-98-3P 303162-99-4P
303163-00-0P 303163-01-1P 303163-02-2P 303163-03-3P 303163-04-4P
303163-05-5P 303163-06-6P 303163-07-7P 303163-08-8P 303163-09-9P
303163-10-2P 303163-11-3P 303163-12-4P 303163-13-5P 303163-14-6P
303163-15-7P 303163-16-8P 303163-17-9P 303163-18-0P 303163-19-1P
303163-20-4P 303163-21-5P 303163-22-6P 303163-23-7P 303163-24-8P
303163-25-9P 303163-26-0P 303163-27-1P 303163-28-2P 303163-29-3P
303163-30-6P 303163-31-7P 303163-32-8P 303163-33-9P 303163-34-0P
303163-35-1P 303163-36-2P 303163-37-3P 303163-38-4P 303163-39-5P
303163-40-8P 303163-41-9P 303163-42-0P 303163-43-1P 303163-44-2P
303787-77-1P 303787-98-6P 325767-68-8P 325767-69-9P 325767-71-3P
325767-72-4P 325767-73-5P 325767-74-6P 325767-75-7P 325767-76-8P
325767-77-9P 325767-79-1P 325767-80-4P 325767-81-5P 325767-82-6P
325767-83-7P 325767-84-8P 325767-85-9P 325767-86-0P 325767-87-1P
325767-88-2P 325767-89-3P 325767-90-6P 325767-91-7P 325767-92-8P
325767-93-9P 325767-94-0P 325767-95-1P 325767-96-2P 325767-97-3P
325767-99-5P 325768-00-1P 325768-02-3P 325768-03-4P 325768-04-5P
325768-05-6P 325768-06-7P 325768-07-8P 325768-08-9P 325768-09-0P
325768-10-3P 325768-11-4P 325768-12-5P 325768-13-6P 325768-14-7P
325768-15-8P 325768-16-9P 325768-17-0P 325768-18-1P 325768-19-2P
325768-20-5P 325768-21-6P 325768-22-7P 325768-23-8P 325768-24-9P
325768-25-0P 325768-27-2P 325768-28-3P 325768-29-4P 325768-30-7P
325768-31-8P 325768-32-9P 325768-33-0P 325768-34-1P 325768-35-2P
325768-36-3P 325768-37-4P 325768-38-5P 325768-40-9P 325768-41-0P
325768-42-1P 325768-43-2P 325768-44-3P
RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(combination drugs containing p38MAP kinase inhibitors and/or TNF-α production inhibitors with other specified agents)

IT **303162-77-8P 303162-91-6P 303162-92-7P**
RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(combination drugs containing p38MAP kinase inhibitors and/or TNF-α production inhibitors with other specified agents)

RN 303162-77-8 CAPLUS
CN Benzeneacetamide, N-[4-[2-(2-chlorophenyl)-4-(3-methylphenyl)-5-thiazolyl]-2-pyridinyl]- (9CI) (CA INDEX NAME)



RN 303162-91-6 CAPLUS
CN Benzamide, N-[4-[2-(2-chlorophenyl)-4-(3-methylphenyl)-5-thiazolyl]-2-pyridinyl]- (9CI) (CA INDEX NAME)



RN 303162-92-7 CAPLUS
CN Benzenepropanamide, N-[4-[2-(2-chlorophenyl)-4-(3-methylphenyl)-5-thiazolyl]-2-pyridinyl]- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 58 THERE ARE 58 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L54 ANSWER 4 OF 23 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2006:54669 CAPLUS
DOCUMENT NUMBER: 144:135282
TITLE: A manufacturing method for solid dispersions of p38 MAP kinase inhibitors
INVENTOR(S): Omachi, Yoshihiro; Kurasawa, Takashi
PATENT ASSIGNEE(S): Takeda Pharmaceutical Company Limited, Japan

SOURCE: PCT Int. Appl., 98 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006006691	A2	20060119	WO 2005-JP13099	20050708

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW

RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

PRIORITY APPLN. INFO.: JP 2004-203799 A 20040709

AB The present invention provides a solid dispersion containing (i) a drug, (ii) polymeric carrier(s), (iii) plasticizer(s), and (iv) drug release-controlling component(s). According to the present invention, the solubility of poorly soluble or insol. drugs, such as p38 MAP kinase inhibitors, can be improved and a drug release-controlling function can be provided simultaneously in a single manufacturing process, and a solid dispersion having a uniform composition and permitting sustained release of drugs can be provided. Thus, N-[4-[2-ethyl-4-(3-methylphenyl)-1,3-thiazol-5-yl]-2-pyridyl]benzamide 4 g was mixed with hydroxypropyl Me cellulose phthalate (HP-55) 6 g, hydroxypropyl Me cellulose (TC-5) 3 g, and polyethylene oxide 7 g, and the mixture was extruded at a barrel temperature of 90° and a screw rotation speed of 80 rpm to give an extruded product of a solid dispersion. The extruded product obtained was cut into a length of about 10 mm to give a pellet sample. The oral absorption of pellet solid dispersion obtained and the comparative film-coated tablet was evaluated in dogs. The solid dispersion showed an AUC that was not much different from that of the comparative film-coated tablet, but a Cmax decreased to about 40%, and a Tmax was prolonged to about 5 h and an MRT to about 3 h, thus exhibiting clear sustained drug release.

IC ICM A61K009-16
ICS A61K031-4439

CC 63-6 (Pharmaceuticals)
Section cross-reference(s): 1

IT 303162-57-4 303162-58-5 303162-59-6 303162-60-9 303162-61-0
303162-62-1 303162-67-6 303162-68-7 303162-69-8 303162-70-1
303162-71-2 303162-72-3 303162-73-4 303162-74-5 303162-75-6
303162-76-7 **303162-77-8** 303162-78-9 303162-79-0
303162-80-3 303162-81-4 303162-82-5 303162-85-8 303162-86-9
303162-87-0 303162-88-1 303162-89-2 303162-90-5 **303162-91-6**
303162-92-7 303162-93-8 303162-94-9 303162-95-0
303162-96-1 303162-97-2 303162-98-3 303162-99-4 303163-00-0
303163-01-1 303163-02-2 303163-03-3 303163-04-4 303163-05-5
303163-06-6 303163-07-7 303163-08-8 303163-09-9 303163-10-2
303163-11-3 303163-12-4 303163-13-5 303163-14-6 303163-15-7
303163-16-8 303163-17-9 303163-18-0 303163-19-1 303163-20-4
303163-21-5 303163-22-6 303163-23-7 303163-24-8 303163-25-9

303163-26-0 303163-28-2 303163-29-3 303163-30-6 303163-31-7
303163-32-8 303163-33-9 303163-34-0 303163-35-1 303163-36-2
303163-37-3 303163-38-4 303163-39-5 303163-40-8 303163-41-9
303163-42-0 303163-43-1 303163-44-2 365430-63-3 365430-65-5
RL: PKT (Pharmacokinetics); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(solid dispersions for sustained release of p38 MAP kinase inhibitors)

IT **303162-77-8 303162-91-6 303162-92-7**
RL: PKT (Pharmacokinetics); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(solid dispersions for sustained release of p38 MAP kinase inhibitors)

RN 303162-77-8 CAPLUS
CN Benzeneacetamide, N-[4-[2-(2-chlorophenyl)-4-(3-methylphenyl)-5-thiazolyl]-2-pyridinyl]- (9CI) (CA INDEX NAME)



RN 303162-91-6 CAPLUS
CN Benzamide, N-[4-[2-(2-chlorophenyl)-4-(3-methylphenyl)-5-thiazolyl]-2-pyridinyl]- (9CI) (CA INDEX NAME)



RN 303162-92-7 CAPLUS
CN Benzenepropanamide, N-[4-[2-(2-chlorophenyl)-4-(3-methylphenyl)-5-thiazolyl]-2-pyridinyl]- (9CI) (CA INDEX NAME)



L54 ANSWER 5 OF 23 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2005:471983 CAPLUS
DOCUMENT NUMBER: 143:13356
TITLE: Synergistically effective combinations of dihaloacetamide compounds and interferon or ribavirin against HCV infections
INVENTOR(S): Lu, Henry
PATENT ASSIGNEE(S): Rigel Pharmaceuticals, Inc., USA
SOURCE: PCT Int. Appl., 32 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005049065	A2	20050602	WO 2004-US39011	20041119
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 2005129659	A1	20050616	US 2004-993212	20041119

PRIORITY APPLN. INFO.: US 2003-523405P P 20031119
OTHER SOURCE(S): MARPAT 143:13356

AB The present invention relates to anti-HCV dihaloacetamide compds. in synergistic combination with an interferon and/or ribavirin and pharmaceutical compns. thereof for inhibition of the replication of HCV virus. The present invention also relates to the use of the compns. to inhibit HCV replication and/or proliferation and to treat or prevent HCV infections.

IC ICM A61K038-00
CC 63-6 (Pharmaceuticals)
Section cross-reference(s): 15
IT 286841-27-8 **667931-30-8**
RL: PAC (Pharmacological activity); PEP (Physical, engineering or chemical process); PYP (Physical process); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)

(synergistically effective combinations of dihaloacetamide compds. and interferon or ribavirin against HCV infections)

IT **667931-30-8**
RL: PAC (Pharmacological activity); PEP (Physical, engineering or chemical process); PYP (Physical process); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)
(synergistically effective combinations of dihaloacetamide compds. and interferon or ribavirin against HCV infections)

RN 667931-30-8 CAPLUS
CN Acetamide, 2,2-dichloro-N-[2-[3-(2,6-dichlorophenyl)-5-isoxazolyl]-4-pyridinyl]- (9CI) (CA INDEX NAME)



L54 ANSWER 6 OF 23 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2004:1124567 CAPLUS
DOCUMENT NUMBER: 142:74572
TITLE: Preparation of heterocyclic compounds for treating hepatitis C virus
INVENTOR(S): Vourloumis, Dionisios; Takahashi, Masayuki; Winters, Geoff; Zhou, Jinglan; Duchene, Russell
PATENT ASSIGNEE(S): Anadys Pharmaceuticals, Inc., USA
SOURCE: PCT Int. Appl., 416 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004110351	A2	20041223	WO 2004-US15249	20040514
WO 2004110351	A3	20050428		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 2005075375	A1	20050407	US 2004-845587	20040514
PRIORITY APPLN. INFO.:			US 2003-470200P P	20030514

OTHER SOURCE(S): MARPAT 142:74572
GI



I



II

AB The title compds. I [X, Y, Z = C, N; W = N, O, S; R1, R3-R5 = H, halo, NO2, etc.; R2 = H, alkyl], useful for treating Hepatitis C virus, were prepared E.g., a multi-step synthesis of II, starting from 2'-hydroxy-5'-methoxyacetophenone, was given. The compds. I were tested for inhibition of HCV replication in in vitro assays (the results of EC50 assay are given for 640 compds. I). The pharmaceutical composition comprising the compound I is disclosed.

IC ICM A61K

CC 28-10 (Heterocyclic Compounds (More Than One Hetero Atom))
Section cross-reference(s): 1, 63

IT 814256-93-4P 814257-49-3P 814258-88-3P 814258-89-4P 814258-90-7P
814258-95-2P 814258-96-3P 814259-02-4P 814259-03-5P 814259-04-6P
814259-05-7P **814259-16-0P** 814259-17-1P 814259-20-6P
814259-26-2P 814259-28-4P 814262-17-4P 814262-19-6P 814263-49-5P
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of disubstituted pyrazoles, oxadiazoles and triazoles for treating hepatitis C virus)

IT 814258-70-3P 814258-71-4P 814258-72-5P 814258-73-6P 814258-74-7P
814258-75-8P 814258-76-9P 814258-77-0P 814258-78-1P 814258-79-2P
814258-80-5P 814258-81-6P 814258-82-7P 814258-83-8P 814258-84-9P
814258-85-0P 814258-86-1P 814258-87-2P 814258-91-8P 814258-92-9P
814258-93-0P 814258-94-1P 814258-97-4P 814258-98-5P 814258-99-6P
814259-00-2P 814259-01-3P 814259-06-8P 814259-07-9P 814259-08-0P
814259-09-1P 814259-10-4P 814259-11-5P 814259-12-6P 814259-13-7P
814259-14-8P 814259-15-9P 814259-18-2P 814259-19-3P 814259-21-7P
814259-22-8P 814259-23-9P 814259-24-0P **814259-25-1P**
814259-29-5P 814259-30-8P 814259-31-9P 814259-32-0P 814259-33-1P
814259-34-2P 814259-35-3P 814259-36-4P 814259-37-5P 814259-38-6P
814259-39-7P 814259-40-0P **814259-41-1P** 814259-42-2P
814259-43-3P 814259-44-4P 814259-45-5P 814259-46-6P 814259-47-7P
814259-48-8P **814259-49-9P** 814259-50-2P 814259-51-3P
814259-52-4P 814259-53-5P 814259-54-6P 814259-55-7P 814259-56-8P
814259-57-9P 814259-58-0P 814259-59-1P 814259-60-4P 814259-61-5P
814259-62-6P 814259-63-7P 814259-64-8P 814259-65-9P 814259-66-0P
814259-67-1P 814259-68-2P 814259-69-3P 814259-70-6P 814259-71-7P
814259-72-8P 814259-73-9P 814259-74-0P 814259-75-1P 814259-76-2P
814259-77-3P 814259-78-4P 814259-79-5P 814259-80-8P 814259-81-9P
814259-82-0P 814259-83-1P 814259-84-2P 814259-85-3P 814259-86-4P

814259-87-5P 814259-88-6P 814259-89-7P 814259-90-0P 814259-91-1P
814259-92-2P 814259-93-3P 814259-94-4P 814259-95-5P 814259-96-6P
814259-97-7P 814259-98-8P 814259-99-9P 814260-00-9P 814260-01-0P
814260-02-1P 814260-03-2P 814260-04-3P 814260-05-4P 814260-06-5P
814260-07-6P 814260-08-7P 814260-09-8P 814260-10-1P 814260-11-2P
814260-12-3P 814260-13-4P 814260-14-5P 814260-15-6P 814260-16-7P
814260-17-8P 814260-18-9P 814260-19-0P 814260-20-3P 814260-21-4P
814260-22-5P 814260-23-6P 814260-24-7P 814260-25-8P 814260-26-9P
814260-27-0P 814260-28-1P 814260-29-2P 814260-30-5P 814260-31-6P
814260-32-7P 814260-33-8P 814260-34-9P 814260-35-0P 814260-36-1P
814260-37-2P 814260-38-3P 814260-39-4P 814260-40-7P 814260-41-8P
814260-42-9P 814260-43-0P 814260-44-1P 814260-45-2P 814260-46-3P
814260-47-4P 814260-48-5P 814260-49-6P 814260-50-9P 814260-51-0P
814260-52-1P 814260-53-2P 814260-54-3P 814260-55-4P 814260-56-5P
814260-57-6P 814260-58-7P 814260-59-8P 814260-60-1P 814260-61-2P
814260-62-3P 814260-63-4P 814260-64-5P 814260-65-6P 814260-66-7P
814260-67-8P 814260-68-9P 814260-69-0P 814260-70-3P 814260-71-4P
814260-72-5P 814260-73-6P 814260-74-7P 814260-75-8P 814260-76-9P
814260-77-0P 814260-78-1P 814260-79-2P 814260-80-5P 814260-81-6P
814260-82-7P 814260-83-8P 814260-84-9P 814260-85-0P 814260-86-1P
814260-87-2P 814260-88-3P 814260-89-4P 814260-90-7P 814260-91-8P
814260-92-9P 814260-93-0P 814260-94-1P 814260-95-2P 814260-96-3P
814260-97-4P 814260-98-5P 814260-99-6P 814261-00-2P 814261-01-3P
814261-02-4P 814261-03-5P 814261-04-6P 814261-05-7P 814261-06-8P
814261-07-9P 814261-08-0P 814261-09-1P 814261-10-4P 814261-11-5P
814261-12-6P 814261-13-7P 814261-14-8P 814261-15-9P 814261-16-0P
814261-17-1P 814261-18-2P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of disubstituted pyrazoles, oxadiazoles and triazoles for treating hepatitis C virus)

IT **814259-16-0P**

RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of disubstituted pyrazoles, oxadiazoles and triazoles for treating hepatitis C virus)

RN 814259-16-0 CAPLUS

CN Carbamic acid, [4-hydroxy-3-[3-(3-methyl-2-pyridinyl)-1,2,4-oxadiazol-5-yl]phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



IT **814259-25-1P 814259-41-1P 814259-49-9P**

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of disubstituted pyrazoles, oxadiazoles and triazoles for

treating hepatitis C virus)
RN 814259-25-1 CAPLUS
CN Acetamide, N-[4-hydroxy-3-[3-(3-methyl-2-pyridinyl)-1,2,4-oxadiazol-5-yl]phenyl]- (9CI) (CA INDEX NAME)



RN 814259-41-1 CAPLUS
CN Benzamide, N-[4-hydroxy-3-[3-(3-methyl-2-pyridinyl)-1,2,4-oxadiazol-5-yl]phenyl]- (9CI) (CA INDEX NAME)



RN 814259-49-9 CAPLUS
CN Carbamic acid, [2-hydroxy-3-[3-(3-methyl-2-pyridinyl)-1,2,4-oxadiazol-5-yl]phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



L54 ANSWER 7 OF 23 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2004:333699 CAPLUS
DOCUMENT NUMBER: 140:357334
TITLE: Preparation of pyrazole derivatives as antifungal agents
INVENTOR(S): Konno, Fujiko; Nakazawa, Kyoko; Hirota, Hiroyuki; Ishida, Kazuya; Kaneko, Yasushi; Okouchi, Hisako
PATENT ASSIGNEE(S): SSP Co., Ltd., Japan
SOURCE: PCT Int. Appl., 102 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004033432	A1	20040422	WO 2003-JP12856	20031008

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: JP 2002-296127 A 20021009

OTHER SOURCE(S): MARPAT 140:357334

GI



I

AB The title compds. I [R1 = alkyl, etc.; R3 = H, alkyl, etc.; R2 = H, halo, etc.; R4, R5 = H, acyl, etc.; or OR4 and OR5 together form alkylenedioxy; and X represents a methine group or a nitrogen atom] are prepared Compds. of this invention in vitro showed MIC values of 0.5 μg/mL to 4 μg/mL against Candida albicans ATCC 90028, vs. MIC of 0.25 μg/mL shown by fluconazole. Two compds. of this invention showed MIC value of 1 μg/mL against Aspergillus fumigatus IFM 41935, vs. MIC of > 64 μg/mL shown by fluconazole.

IC ICM C07D231-12
ICS C07D401-04; C07D401-14; C07D409-14; C07D417-04; C07D403-04; A61K031-415; A61K031-428; A61K031-4439; A61K031-444; A61K031-454; A61K031-496; A61K031-506; A61K031-5377; A61K031-4545; A61P031-10

CC 28-8 (Heterocyclic Compounds (More Than One Hetero Atom))
Section cross-reference(s): 1, 10

IT 60-34-4 94-02-0, Ethyl 3-oxo-3-phenylpropanoate 98-80-6, Phenylboronic acid 98-86-2, Acetophenone, reactions 100-63-0 108-24-7, Acetic anhydride 110-91-8, Morpholine, reactions 302-01-2, Hydrazine, reactions 616-45-5, 2-Pyrrolidinone 630-08-0, Carbon monoxide, reactions 1073-70-7 1120-90-7, 3-Iodopyridine 2458-26-6, 3-Phenylpyrazole 2859-78-1, 4-Bromo-1,2-dimethoxybenzene 3054-95-3, 3,3-Diethoxypropene 3453-00-7, Diethyl 2-oxo-2-phenylethylphosphonate 4487-59-6, 2-Bromo-5-nitropyridine 4930-98-7, 2-Hydrazinopyridine 5447-02-9, 3,4-Bis(benzyloxy)benzaldehyde 7681-82-5, Sodium iodide, reactions 25620-54-6, Bromochloroethane 58045-88-8 62885-51-2 112334-44-8 133115-72-7 204847-72-3 681234-50-4 681234-55-9 681234-59-3 681234-61-7 681234-63-9 681234-67-3 681234-69-5 **681234-75-3**
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of pyrazole derivs. as antifungal agents)

IT **681234-75-3**
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of pyrazole derivs. as antifungal agents)
RN 681234-75-3 CAPLUS
CN Carbamic acid, [3-[5-[3,4-bis(phenylmethoxy)phenyl]-1-(2-pyridinyl)-1H-pyrazol-3-yl]phenyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)



REFERENCE COUNT: 29 THERE ARE 29 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L54 ANSWER 8 OF 23 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2004:287841 CAPLUS
DOCUMENT NUMBER: 140:321349
TITLE: Preparation of pyrazole derivatives as p38 MAP kinase inhibitors and cytokine production inhibitors
INVENTOR(S): Hagihara, Masahiko; Shibakawa, Nobuhiko; Nishihara, Masamichi; Shirai, Toshiyuki; Shimizu, Motohisa; Hasegawa, Tohru; Tokunaga, Yasunori; Suzuki, Naoto; Wada, Yukinori
PATENT ASSIGNEE(S): Ube Industries, Ltd., Japan
SOURCE: PCT Int. Appl., 276 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004029043	A1	20040408	WO 2003-JP12254	20030925
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2500225	AA	20040408	CA 2003-2500225	20030925
EP 1553096	A1	20050713	EP 2003-798497	20030925

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK

PRIORITY APPLN. INFO.: JP 2002-279385 A 20020925
WO 2003-JP12254 W 20030925

OTHER SOURCE(S): MARPAT 140:321349

GI



I

AB The title compds. I [R1 is optionally substituted phenyl; R2 is H, halogeno, alkyl, alkoxy, alkylthio, alkylsulfinyl, alkylsulfonyl, or substituted amino; Q is CH or N; R3 is H, alkyl, or amino; and R4 is a group represented by the general formula Q1, etc.; R7 is H or alkyl; R8 is H, alkyl, or substituted amino; R9 is H or alkyl] are prepared Compds. of this invention in vitro showed IC50 values of 0.2 nM to 8.8 nM against p38 MAP kinase. Formulations are given.

IC ICM C07D401-14
ICS C07D403-14; C07D487-04; A61K031-501; A61K031-5025; A61K031-506; A61P001-04; A61P003-10; A61P009-10; A61P017-06; A61P019-02; A61P019-10; A61P025-00; A61P029-00; A61P037-08; A61P043-00

CC 28-8 (Heterocyclic Compounds (More Than One Hetero Atom))
Section cross-reference(s): 1, 63

IT 148671-39-0P, 3-Dimethylamino-1-(4-fluorophenyl)-2-(pyridin-4-yl)-2-propen-1-one 216504-75-5P 216505-71-4P 216506-58-0P 216506-68-2P
677319-68-5P 677319-70-9P 677319-72-1P 677319-74-3P 677319-76-5P
677319-78-7P 677319-81-2P 677319-84-5P 677319-86-7P 677319-88-9P
677319-90-3P 677319-92-5P 677319-94-7P 677319-97-0P 677319-99-2P
677320-01-3P 677320-03-5P 677320-05-7P 677320-07-9P 677320-09-1P
677320-11-5P 677320-13-7P 677320-15-9P 677320-17-1P 677320-19-3P
677320-21-7P 677320-23-9P 677320-25-1P 677320-27-3P 677320-29-5P
677320-31-9P 677320-33-1P 677320-35-3P 677320-37-5P 677320-39-7P
677320-41-1P **677320-43-3P** 677320-45-5P 677320-47-7P
677320-49-9P 677320-51-3P 677320-53-5P 677320-55-7P 677320-57-9P
677320-59-1P 677320-61-5P 677320-63-7P 677320-66-0P 677320-68-2P
677320-70-6P 677320-72-8P 677320-74-0P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of pyrazole derivs. as p38 MAP kinase inhibitors and cytokine production inhibitors)

IT **677320-43-3P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of pyrazole derivs. as p38 MAP kinase inhibitors and cytokine production inhibitors)

RN 677320-43-3 CAPLUS

CN Carbamic acid, [4-[1-(6-chloro-4-methyl-3-pyridinyl)-3-(4-fluorophenyl)-1H-pyrazol-4-yl]-2-pyridinyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



REFERENCE COUNT: 59 THERE ARE 59 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L54 ANSWER 9 OF 23 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2003:282532 CAPLUS
DOCUMENT NUMBER: 138:287681
TITLE: Preparation of heteroaryl substituted tetrazole modulators of metabotropic glutamate receptor-5
INVENTOR(S): Cosford, Nicholas D.; Roppe, Jeffrey; Chen, Chixu; Smith, Nicholas; Reger, Thomas
PATENT ASSIGNEE(S): Merck & Co., Inc., USA
SOURCE: PCT Int. Appl., 119 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 5
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003029210	A2	20030410	WO 2002-US31294	20021001
WO 2003029210	A3	20031120		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2462289	AA	20030410	CA 2002-2462289	20021001
EP 1434773	A2	20040707	EP 2002-776076	20021001
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK				
JP 2005508344	T2	20050331	JP 2003-532460	20021001
WO 2004030637	A2	20040415	WO 2003-US9717	20030331
WO 2004030637	A3	20040923		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

US 2004186295	A1	20040923	US 2004-491613	20040402
PRIORITY APPLN. INFO.:			US 2001-327132P	P 20011004
			WO 2002-US31294	W 20021001
			WO 2002-US40147	A 20021213
			WO 2002-US41720	A 20021213
			WO 2002-US40237	A 20021216
			WO 2002-US40486	A 20021217

OTHER SOURCE(S): MARPAT 138:287681

GI



I



II

AB Title compds. I [X, Y = (un)substituted (hetero)aryl; A, B = alkyl, alkyl-SO-alkyl, alkyl-SO2-alkyl, etc.] are prepared For instance, 2-formylpyridine is condensed with toluenesulfonyl hydrazide to form the hydrazone. 3-Chloroaniline is converted to the diazonium salt and reacted with the hydrazone to form 2-[2-(3-chlorophenyl)-2H-tetrazol-5-yl]pyridine (II) as a pale orange solid. Compds. of the invention have IC50 < 10μM for mGluR5 in the calcium flux assay. I are mGluR5 modulators useful in the treatment of psychiatric and mood disorders such as, schizophrenia, anxiety, depression, and panic, as well as in the treatment of pain and other diseases.

IC ICM C07D

CC 28-10 (Heterocyclic Compounds (More Than One Hetero Atom))
Section cross-reference(s): 1

IT 507268-12-4P, 2-[2-(3-Chlorophenyl)-2H-tetrazol-5-yl]pyridine
507268-13-5P, 3-(5-Pyridin-2-yl-2H-tetrazol-2-yl)benzonitrile
507268-14-6P, 2-(2-Pyridin-3-yl-2H-tetrazol-5-yl)pyridine 507268-15-7P, 2-(3-Chlorophenyl)-5-(2-methyl-1,3-thiazol-4-yl)-2H-tetrazole
507268-16-8P, 3-[5-(2-Methylthiazol-4-yl)-2H-tetrazol-2-yl]benzonitrile
507268-17-9P, 2-[5-(3-Bromophenyl)-2H-tetrazol-2-yl]pyridine
507268-18-0P, 2-[5-(3-Chlorophenyl)-2H-tetrazol-2-yl]pyridine
507268-19-1P, 3-(2-Pyridin-2-yl-2H-tetrazol-5-yl)benzonitrile
507268-20-4P, 2-[2-(3,5-Difluorophenyl)-2H-tetrazol-5-yl]pyridine
507268-21-5P, 2-[2-(3-Methoxyphenyl)-2H-tetrazol-5-yl]pyridine
507268-22-6P, 2-[2-(3-Trifluoromethylphenyl)-2H-tetrazol-5-yl]pyridine
507268-23-7P, 2-[2-(3-Iodophenyl)-2H-tetrazol-5-yl]pyridine
507268-24-8P, 2-[2-(3-Bromophenyl)-2H-tetrazol-5-yl]pyridine
507268-25-9P, 2-[2-(3-Methylmercaptophenyl)-2H-tetrazol-5-yl]pyridine
507268-26-0P, 2-[2-(4-Fluorophenyl)-2H-tetrazol-5-yl]pyridine
507268-27-1P, 2-[2-(3-Fluorophenyl)-2H-tetrazol-5-yl]pyridine
507268-28-2P, 2-[2-(2-Methoxyphenyl)-2H-tetrazol-5-yl]pyridine
507268-29-3P, 2-[2-(3-Ethylphenyl)-2H-tetrazol-5-yl]pyridine
507268-30-6P, 2-[2-(3-Methylphenyl)-2H-tetrazol-5-yl]pyridine
507268-31-7P, 2-[2-(2-Chloro-3-pyridyl)-2H-tetrazol-5-yl]pyridine
507268-32-8P, 2-[2-(3,5-Dichlorophenyl)-2H-tetrazol-5-yl]pyridine
507268-33-9P, 2-[2-(2-Chlorophenyl)-2H-tetrazol-5-yl]pyridine
507268-34-0P, 2-[2-(4-Methoxyphenyl)-2H-tetrazol-5-yl]pyridine

507268-35-1P, 2-[2-(4-Pyridyl)-2H-tetrazol-5-yl]pyridine 507268-36-2P, 2-[2-(3,5-Dimethylphenyl)-2H-tetrazol-5-yl]pyridine 507268-37-3P, 3-[5-(6-Methylpyridin-2-yl)-2H-tetrazol-2-yl]benzonitrile 507268-38-4P, 3-[5-(4-Methylpyridin-2-yl)-2H-tetrazol-2-yl]benzonitrile 507268-39-5P, 2-[2-(3-Isopropylphenyl)-2H-tetrazol-5-yl]pyridine 507268-40-8P, 2-[2-[3-(Trifluoromethoxy)phenyl]-2H-tetrazol-5-yl]pyridine 507268-41-9P, 2-[2-(3-Ethoxyphenyl)-2H-tetrazol-5-yl]pyridine 507268-42-0P, 2-[2-[3-Methoxy-5-(trifluoromethyl)phenyl]-2H-tetrazol-5-yl]pyridine 507268-43-1P, 3-[5-(1,3-Thiazol-2-yl)-2H-tetrazol-2-yl]benzonitrile 507268-44-2P, 3-[5-(5-Methylpyridin-2-yl)-2H-tetrazol-2-yl]benzonitrile 507268-45-3P, 3-[5-(3-Methylpyridin-2-yl)-2H-tetrazol-2-yl]benzonitrile 507268-46-4P, 3-[5-(1-Methyl-1H-imidazol-2-yl)-2H-tetrazol-2-yl]benzonitrile 507268-47-5P, 2-[2-(3,4-Dimethylphenyl)-2H-tetrazol-5-yl]pyridine 507268-48-6P, 2-[2-(3,4,5-Trichlorophenyl)-2H-tetrazol-5-yl]pyridine 507268-49-7P, 3-[5-(1,3-Thiazol-4-yl)-2H-tetrazol-2-yl]benzonitrile 507268-50-0P, 2-[2-(2,5-Dichlorophenyl)-2H-tetrazol-5-yl]pyridine 507268-51-1P, 2-[2-(3,4-Difluorophenyl)-2H-tetrazol-5-yl]pyridine 507268-52-2P, 2-[2-(3-Chloro-4-methylphenyl)-2H-tetrazol-5-yl]pyridine 507268-53-3P, 2-[2-(2,3-Dichlorophenyl)-2H-tetrazol-5-yl]pyridine 507268-54-4P, 2-[2-[3-Methyl-5-(trifluoromethyl)phenyl]-2H-tetrazol-5-yl]pyridine 507268-55-5P, 2-[2-(3-Bromo-4-methylphenyl)-2H-tetrazol-5-yl]pyridine 507268-56-6P, 2-[2-(3-Chloro-4-iodophenyl)-2H-tetrazol-5-yl]pyridine 507268-58-8P, 2-[2-[3-Fluoro-5-(trifluoromethyl)phenyl]-2H-tetrazol-5-yl]pyridine 507268-59-9P, 3-(5-Pyrazin-2-yl-2H-tetrazol-2-yl)benzonitrile 507268-60-2P, 2-[2-(2,3-Dihydro-1H-inden-5-yl)-2H-tetrazol-5-yl]pyridine 507268-61-3P, 2-[2-(1,3-Dihydro-2-benzofuran-5-yl)-2H-tetrazol-5-yl]pyridine 507268-62-4P, 2-[2-(4-Methoxy-2-naphthyl)-2H-tetrazol-5-yl]pyridine 507268-63-5P, 2-[2-(1-Naphthyl)-2H-tetrazol-5-yl]pyridine 507268-64-6P, 2-[2-(3,5-Dimethoxyphenyl)-2H-tetrazol-5-yl]pyridine 507268-66-8P, 2-[2-(4-Phenoxyphenyl)-2H-tetrazol-5-yl]pyridine 507268-67-9P, 3-[5-(3-Fluoropyridin-2-yl)-2H-tetrazol-2-yl]benzonitrile 507268-68-0P, 3-(5-(Isoxazol-3-yl)-2H-tetrazol-2-yl)benzonitrile 507268-69-1P, 3-[5-(1-Methyl-1H-pyrazol-3-yl)-2H-tetrazol-2-yl]benzonitrile 507268-70-4P, 3-(5-(Oxazol-4-yl)-2H-tetrazol-2-yl)benzonitrile 507268-71-5P 507268-72-6P, 3-[5-(1H-Imidazol-2-yl)-2H-tetrazol-2-yl]benzonitrile 507268-73-7P, 3-[5-(5-Hydroxypyridin-2-yl)-2H-tetrazol-2-yl]benzonitrile 507268-74-8P, 3-[5-(5-Bromopyridin-2-yl)-2H-tetrazol-2-yl]-5-fluorobenzonitrile 507268-75-9P, 3-Fluoro-5-[5-(3-fluoropyridin-2-yl)-2H-tetrazol-2-yl]benzonitrile 507268-76-0P, 3-Fluoro-5-[5-(oxazol-2-yl)-2H-tetrazol-2-yl]benzonitrile 507268-77-1P, 3-[3-Fluoro-5-[5-(1H-imidazol-2-yl)-2H-tetrazol-2-yl]phenoxy]pyridine 507268-78-2P, 3-Fluoro-5-[5-(4-methyl-1H-imidazol-2-yl)-2H-tetrazol-2-yl]benzonitrile 507268-79-3P, 3-[3-Fluoro-5-[5-(1H-[1,2,3]triazol-4-yl)-2H-tetrazol-2-yl]phenoxy]pyridine 507268-80-6P, 2-[2-[3-Fluoro-5-(pyridin-3-yloxy)phenyl]-2H-tetrazol-5-yl]pyrimidine 507268-81-7P, 3-[3-Fluoro-5-[5-(1H-pyrazol-3-yl)-2H-tetrazol-2-yl]phenoxy]pyridine 507268-82-8P, 3-[3-Fluoro-5-[5-(1-methyl-1H-pyrazol-3-yl)-2H-tetrazol-2-yl]phenoxy]pyridine 507268-83-9P, 3-Fluoro-5-[5-(1-methyl-1H-pyrazol-3-yl)-2H-tetrazol-2-yl]benzonitrile 507268-84-0P, N-[4-(5-Pyridin-2-yl-2H-tetrazol-2-yl)phenyl]pyridin-3-amine 507268-85-1P, 2-[2-[4-(Pyridin-3-ylmethyl)phenyl]-2H-tetrazol-5-yl]pyridine 507268-86-2P, N-[3-(5-Pyridin-2-yl-2H-tetrazol-2-yl)phenyl]pyridin-3-amine 507268-87-3P, N-[3-(5-Pyridin-2-yl-2H-tetrazol-2-yl)phenyl]pyridin-2-amine 507268-88-4P, 2-[2-[3-(Pyridin-2-yloxy)phenyl]-2H-tetrazol-5-yl]pyridine 507268-89-5P, 2-[2-(3-Ethynylphenyl)-2H-tetrazol-5-yl]pyridine 507268-90-8P, 2-[2-[4-(Pyridin-3-yloxy)phenyl]-2H-tetrazol-5-yl]pyridine 507268-91-9P, 2-[2-[3-(Pyridin-3-yloxy)phenyl]-2H-tetrazol-5-yl]pyridine 507268-92-0P, 2-[2-(3-Nitrophenyl)-2H-tetrazol-5-yl]pyridine 507268-93-1P, 2-Methyl-3-[3-(5-pyridin-2-yl-2H-tetrazol-2-

yl)phenoxy]pyridine 507268-94-2P, 2-Methyl-N-[3-(5-pyridin-2-yl-2H-tetrazol-2-yl)phenyl]pyridin-3-amine 507268-95-3P, N-Methyl-N-[3-(5-pyridin-2-yl-2H-tetrazol-2-yl)phenyl]pyridin-3-amine 507268-96-4P, N-[3-Fluoro-5-(5-pyridin-2-yl-2H-tetrazol-2-yl)phenyl]-N-methylpyridin-3-amine 507268-97-5P, 2-[2-[3-Fluoro-5-(pyridin-3-yloxy)phenyl]-2H-tetrazol-5-yl]pyridine 507268-98-6P, N-[3-Fluoro-5-(5-pyridin-2-yl-2H-tetrazol-2-yl)phenyl]pyridin-3-amine 507268-99-7P, N-[3-[5-(5-Bromopyridin-2-yl)-2H-tetrazol-2-yl]-5-fluorophenyl]pyridin-3-amine 507269-00-3P, 2-[2-[3-Fluoro-5-(pyridin-3-ylmethyl)phenyl]-2H-tetrazol-5-yl]pyridine 507269-01-4P, 5-[3-Fluoro-5-(5-pyridin-2-yl-2H-tetrazol-2-yl)benzyl]-2-methylpyridine 507269-02-5P, 3-[3-Fluoro-5-[5-(1,3-thiazol-2-yl)-2H-tetrazol-2-yl]phenoxy]pyridine 507269-03-6P, 2-[2-[3-Fluoro-5-(pyridin-3-ylthio)phenyl]-2H-tetrazol-5-yl]pyridine 507269-04-7P, 2-[2-[3-Fluoro-5-[(pyridin-3-yloxy)methyl]phenyl]-2H-tetrazol-5-yl]pyridine 507269-05-8P, 3-Fluoro-2-[2-[3-fluoro-5-(pyridin-3-yloxy)phenyl]-2H-tetrazol-5-yl]pyridine 507269-06-9P, 2-[2-[3-Fluoro-5-(pyridin-3-yloxy)phenyl]-2H-tetrazol-5-yl]-6-methylpyridine 507269-07-0P 507269-08-1P, 3-Bromo-5-(5-pyridin-2-yl-2H-tetrazol-2-yl)pyridine 507269-09-2P, 2-[2-[4-(Allyloxy)-3-methoxyphenyl]-2H-tetrazol-5-yl]pyridine 507269-10-5P, 2-Methoxy-4-(5-pyridin-2-yl-2H-tetrazol-2-yl)phenol 507269-11-6P 507269-12-7P, 2-[2-(4-Bromo-3-methoxyphenyl)-2H-tetrazol-5-yl]pyridine 507269-13-8P, 2-[2-[3-Methoxy-4-(pyridin-2-yloxy)phenyl]-2H-tetrazol-5-yl]pyridine 507269-14-9P, 5-(5-Pyridin-2-yl-2H-tetrazol-2-yl)nicotinonitrile 507269-15-0P, [3-(5-Pyridin-2-yl-2H-tetrazol-2-yl)phenoxy]acetonitrile 507269-16-1P, N-Pyridin-3-yl-5-(5-pyridin-2-yl-2H-tetrazol-2-yl)pyridin-3-amine 507269-17-2P, 3-(Pyridin-3-yloxy)-5-(5-pyridin-2-yl-2H-tetrazol-2-yl)pyridine 507269-18-3P, 3-Bromo-5-[5-(1H-imidazol-2-yl)-2H-tetrazol-2-yl]pyridine 507269-19-4P, 2-(Pyridin-3-yloxy)-5-(5-pyridin-2-yl-2H-tetrazol-2-yl)pyridine 507269-20-7P, 2-[(5-Chloropyridin-3-yl)oxy]-5-(5-pyridin-2-yl-2H-tetrazol-2-yl)pyridine 507269-21-8P, 2-Methyl-5-[[5-(5-pyridin-2-yl-2H-tetrazol-2-yl)pyridin-2-yl]oxy]pyridine 507269-22-9P, 2-Methyl-3-[[5-(5-pyridin-2-yl-2H-tetrazol-2-yl)pyridin-2-yl]oxy]pyridine 507269-23-0P, 2-[(4-Methylpyridin-3-yl)oxy]-5-(5-pyridin-2-yl-2H-tetrazol-2-yl)pyridine 507269-24-1P, 2-(Pyridin-4-yloxy)-5-(5-pyridin-2-yl-2H-tetrazol-2-yl)pyridine 507269-25-2P, 2-Bromo-5-(5-pyridin-2-yl-2H-tetrazol-2-yl)benzonitrile 507269-26-3P, 3-(5-Pyridin-2-yl-2H-tetrazol-2-yl)aniline 507269-27-4P, 3-Fluoro-5-(5-pyridin-2-yl-2H-tetrazol-2-yl)benzonitrile 507269-28-5P, 2-[2-[3-Bromo-5-(trifluoromethyl)phenyl]-2H-tetrazol-5-yl]pyridine 507269-29-6P, 3-(5-(Pyridin-2-yl)-2H-tetrazol-2-yl)-5-(trifluoromethyl)benzonitrile 507269-30-9P, 3-Nitro-5-(5-pyridin-2-yl-2H-tetrazol-2-yl)benzonitrile 507269-31-0P, 3-Amino-5-(5-pyridin-2-yl-2H-tetrazol-2-yl)benzonitrile 507269-32-1P, 3-Chloro-5-(5-pyridin-2-yl-2H-tetrazol-2-yl)benzonitrile 507269-33-2P 507269-34-3P 507269-35-4P, 2-[5-[3-Chloro-5-(pyridin-3-yloxy)phenyl]-2H-tetrazol-2-yl]pyridine 507269-36-5P, 2-[5-(3-Bromo-5-chlorophenyl)-2H-tetrazol-2-yl]pyridine 507269-37-6P, 3-Chloro-5-(2-pyridin-2-yl-2H-tetrazol-5-yl)benzonitrile 507269-38-7P, 3-Methyl-5-(2-pyridin-2-yl-2H-tetrazol-5-yl)benzonitrile 507269-39-8P, [3-(5-Pyridin-2-yl-2H-tetrazol-2-yl)phenyl]methanol 507269-40-1P, [3-(5-Pyridin-2-yl-2H-tetrazol-2-yl)phenyl]acetonitrile 507269-41-2P, N-Methyl-3-(5-pyridin-2-yl-2H-tetrazol-2-yl)aniline 507269-42-3P, 2-[2-[3-(1H-Imidazol-1-ylmethyl)phenyl]-2H-tetrazol-5-yl]pyridine 507269-43-4P, 2-Methoxy-N-[3-(5-pyridin-2-yl-2H-tetrazol-2-yl)phenyl]aniline 507269-44-5P, 2-[2-(3-Fluoro-5-iodophenyl)-2H-tetrazol-5-yl]pyridine 507269-45-6P, 3-Fluoro-5-[5-(1H-imidazol-2-yl)-2H-tetrazol-2-yl]benzonitrile 507269-47-8P, 3-[5-(4,5-Dibromo-1H-imidazol-2-yl)-2H-tetrazol-2-yl]-5-fluorobenzonitrile 507269-49-0P, 2-[2-[3-Fluoro-5-(pyridin-3-ylmethoxy)phenyl]-2H-tetrazol-5-yl]pyridine 507269-50-3P, 2-[[3-Fluoro-5-(5-pyridin-2-yl-2H-tetrazol-2-yl)phenoxy]methyl]benzonitril

e 507269-51-4P, N-[3-Fluoro-5-[5-(1H-imidazol-2-yl)-2H-tetrazol-2-yl]phenyl]-N-methylpyridin-3-amine 507269-52-5P, 3-Chloro-5-[5-(1H-imidazol-2-yl)-2H-tetrazol-2-yl]benzonitrile 507269-53-6P, 3-[3-Fluoro-5-[5-(1-methyl-1H-imidazol-2-yl)-2H-tetrazol-2-yl]phenoxy]pyridine 507269-54-7P, 4-Chloro-2-(5-pyridin-2-yl-2H-tetrazol-2-yl)benzonitrile 507269-55-8P, 2-[2-(2,4-Dichlorophenyl)-2H-tetrazol-5-yl]pyridine 507269-56-9P, 2-[2-(5-Chloro-2-methoxyphenyl)-2H-tetrazol-5-yl]pyridine 507269-57-0P, 3-[5-(2-Methyl-2H-pyrazol-3-yl)-2H-tetrazol-2-yl]benzonitrile 507269-58-1P, 3-[5-(1H-Imidazol-4-yl)-2H-tetrazol-2-yl]benzonitrile 507269-59-2P, 3-[5-(5-Methoxypyridin-2-yl)-2H-tetrazol-2-yl]benzonitrile 507269-60-5P, 3-[5-(1H-Benzimidazol-2-yl)-2H-tetrazol-2-yl]benzonitrile 507269-61-6P, 4-Bromo-3-fluoro-5-[5-(3-fluoropyridin-2-yl)-2H-tetrazol-2-yl]benzonitrile 507269-62-7P, 3-[3-[5-(4,5-Dibromo-1H-imidazol-2-yl)-2H-tetrazol-2-yl]-5-fluorophenoxy]pyridine 507269-63-8P, 7-[2-[3-Fluoro-5-(pyridin-3-yloxy)phenyl]-2H-tetrazol-5-yl]pyrazolo[1,5-a]pyridine 507269-64-9P, 2-[2-(5-Methylisoxazol-3-yl)-2H-tetrazol-5-yl]pyridine 507269-65-0P, N-Phenyl-N-[4-(5-pyridin-2-yl-2H-tetrazol-2-yl)phenyl]amine 507269-66-1P, N-[4-(5-Pyridin-2-yl-2H-tetrazol-2-yl)phenyl]pyridin-2-amine 507269-67-2P, N-Phenyl-N-[3-(5-pyridin-2-yl-2H-tetrazol-2-yl)phenyl]amine 507269-68-3P, 2-[2-[4-(Pyridin-2-yloxy)phenyl]-2H-tetrazol-5-yl]pyridine 507269-69-4P, 2-[2-[3-(3-Methoxyphenoxy)phenyl]-2H-tetrazol-5-yl]pyridine 507269-70-7P, 2-Bromo-6-[2-[3-fluoro-5-(pyridin-3-yloxy)phenyl]-2H-tetrazol-5-yl]pyridine 507269-71-8P, 2-[2-[3-Fluoro-5-(pyridin-3-yloxy)phenyl]-2H-tetrazol-5-yl]-6-methoxypyridine 507269-72-9P 507269-73-0P, 2-Chloro-5-(5-pyridin-2-yl-2H-tetrazol-2-yl)pyridine 507269-74-1P, 3-[5-(1H-Imidazol-2-yl)-2H-tetrazol-2-yl]pyridine 507269-75-2P, 2-(2-Pyridin-2-yl-2H-tetrazol-5-yl)pyridine 507269-76-3P, N,N-Dimethyl-5-(5-pyridin-2-yl-2H-tetrazol-2-yl)pyridin-2-amine 507269-77-4P, N-Pyridin-2-yl-5-(5-pyridin-2-yl-2H-tetrazol-2-yl)pyridin-2-amine 507269-78-5P, N-Pyridin-3-yl-5-(5-pyridin-2-yl-2H-tetrazol-2-yl)pyridin-2-amine 507269-79-6P, 3-Chloro-N-[5-(5-(pyridin-2-yl)-2H-tetrazol-2-yl)pyridin-2-yl]-5-(trifluoromethyl)pyridin-2-amine 507269-80-9P, 3-(5-Quinolin-2-yl-2H-tetrazol-2-yl)benzonitrile 507269-81-0P, 3-(5-Isoquinolin-3-yl-2H-tetrazol-2-yl)benzonitrile 507269-82-1P, 2-[2-(4-Bromo-3-fluorophenyl)-2H-tetrazol-5-yl]pyridine 507269-83-2P, 2-[2-[3,5-Bis(trifluoromethyl)phenyl]-2H-tetrazol-5-yl]pyridine 507269-84-3P, 2-[2-[4-Bromo-3-(trifluoromethyl)phenyl]-2H-tetrazol-5-yl]pyridine 507269-85-4P 507269-86-5P, 2-[3-(5-Pyridin-2-yl-2H-tetrazol-2-yl)phenoxy]ethylamine 507269-87-6P, 2-[2-[3-Fluoro-5-(pyridin-2-ylmethoxy)phenyl]-2H-tetrazol-5-yl]pyridine 507269-88-7P, 2-[2-(2,6-Dichlorophenyl)-2H-tetrazol-5-yl]pyridine 507269-89-8P, [3-(5-Pyridin-2-yl-2H-tetrazol-2-yl)phenyl]acetic acid 507269-90-1P, 2-[2-(3-Iodo-4-methylphenyl)-2H-tetrazol-5-yl]pyridine 507269-91-2P, 2-[2-(4-Chloro-3-methylphenyl)-2H-tetrazol-5-yl]pyridine 507269-92-3P, 2-[2-(1,3-Benzodioxol-5-yl)-2H-tetrazol-5-yl]pyridine 507269-93-4P, 2-[2-[2-Chloro-5-(trifluoromethyl)phenyl]-2H-tetrazol-5-yl]pyridine 507269-94-5P, 2-Chloro-4-(5-pyridin-2-yl-2H-tetrazol-2-yl)benzonitrile 507269-95-6P, 2-[2-(4-Bromo-3-methylphenyl)-2H-tetrazol-5-yl]pyridine 507269-96-7P, 2-[2-(3,4-Dichlorophenyl)-2H-tetrazol-5-yl]pyridine 507269-97-8P, 2-[2-(3-Chloro-4-fluorophenyl)-2H-tetrazol-5-yl]pyridine 507269-98-9P, 2-[2-(3-Fluoro-4-methylphenyl)-2H-tetrazol-5-yl]pyridine 507269-99-0P, 1-[3-(5-Pyridin-2-yl-2H-tetrazol-2-yl)phenyl]ethanol 507270-00-0P, 1-[3-(5-Pyridin-2-yl-2H-tetrazol-2-yl)phenyl]ethanone 507270-01-1P, 2-[2-(3-Phenoxyphenyl)-2H-tetrazol-5-yl]pyridine 507270-02-2P, 2-[2-[3-(Benzyloxy)phenyl]-2H-tetrazol-5-yl]pyridine 507270-03-3P, 2-[2-[3-(Methylsulfonyl)phenyl]-2H-tetrazol-5-yl]pyridine **507270-04-4P**, N-[3-(5-Pyridin-2-yl-2H-tetrazol-2-yl)phenyl]acetamide 507270-05-5P, 2-(5-Pyridin-2-yl-2H-tetrazol-2-yl)benzonitrile 507270-06-6P, 2-(2-Phenyl-2H-tetrazol-5-yl)pyridine

507270-07-7P, [2-Methoxy-4-(5-pyridin-2-yl-2H-tetrazol-2-yl)phenyl]acetonitrile 507270-08-8P, 2-[2-(3-Methoxy-4-methylphenyl)-2H-tetrazol-5-yl]pyridine 507270-09-9P, 2-[2-Methoxy-4-(5-(pyridin-2-yl)-2H-tetrazol-2-yl)phenyl]-2-methylpropanenitrile 507270-10-2P, 2-[Cyano[2-methoxy-4-(5-pyridin-2-yl-2H-tetrazol-2-yl)phenyl]methyl]nicotinonitrile 507270-11-3P, 2-[2-Methoxy-4-(5-pyridin-2-yl-2H-tetrazol-2-yl)phenyl]succinonitrile 507270-12-4P, 2-[2-Methoxy-4-(5-pyridin-2-yl-2H-tetrazol-2-yl)phenyl]propane-1,2,3-tricarbonitrile 507270-13-5P, 2-[2-Methoxy-4-(5-pyridin-2-yl-2H-tetrazol-2-yl)phenyl]propanenitrile 507270-14-6P 507270-15-7P, (6-Fluoropyridin-2-yl)[2-methoxy-4-(5-pyridin-2-yl-2H-tetrazol-2-yl)phenyl]acetonitrile 507270-16-8P, [2-Methoxy-4-(5-pyridin-2-yl-2H-tetrazol-2-yl)phenyl](pyridin-2-yl)acetonitrile 507270-17-9P, 2-[2-[4-(Methylthio)phenyl]-2H-tetrazol-5-yl]pyridine 507270-18-0P, 2-[[4-(Trifluoromethoxy)phenyl]-2H-tetrazol-5-yl]pyridine 507270-19-1P, 4-[5-Pyridin-2-yl-2H-tetrazol-2-yl]benzonitrile 507270-20-4P, 2-[2-(4-Chlorophenyl)-2H-tetrazol-5-yl]pyridine 507270-21-5P, 2-[2-(2-Naphthyl)-2H-tetrazol-5-yl]pyridine 507270-22-6P, 2-[2-(3,5-Di-(tert-butyl)phenyl)-2H-tetrazol-5-yl]pyridine 507270-23-7P, 2-Fluoro-5-(5-pyridin-2-yl-2H-tetrazol-2-yl)benzonitrile 507270-24-8P, 2-[2-[4-(Bromomethyl)-3-methoxyphenyl]-2H-tetrazol-5-yl]pyridine 507270-25-9P, 2-Methoxy-4-(5-pyridin-2-yl-2H-tetrazol-2-yl)benzoic acid 507270-26-0P, 2-[2-Methoxy-4-(5-pyridin-2-yl-2H-tetrazol-2-yl)phenyl]ethanamine 507270-27-1P 507270-28-2P, 2-[2-Methoxy-4-(5-pyridin-2-yl-2H-tetrazol-2-yl)phenyl]propan-2-ol 507270-29-3P, 2-Methoxy-4-(5-pyridin-2-yl-2H-tetrazol-2-yl)benzamide 507270-30-6P, 2-Methoxy-4-(5-pyridin-2-yl-2H-tetrazol-2-yl)benzonitrile 507270-31-7P, 3-Bromo-6-(5-pyridin-2-yl-2H-tetrazol-2-yl)-1H-indole 507270-32-8P, 6-(5-Pyridin-2-yl-2H-tetrazol-2-yl)-1H-indole 507270-33-9P, 6-(5-Pyridin-2-yl-2H-tetrazol-2-yl)-1H-indole-1-carbonitrile 507270-34-0P, 6-(5-Pyridin-2-yl-2H-tetrazol-2-yl)-1H-indole-3-carbonitrile 507270-35-1P, 3-Methoxy-5-(5-pyridin-2-yl-2H-tetrazol-2-yl)benzonitrile 507270-36-2P, 3-[5-(1H-Imidazol-2-yl)-2H-tetrazol-2-yl]-5-methylbenzonitrile 507270-37-3P, 3-[3-Fluoro-5-[5-(4-methyl-1H-imidazol-2-yl)-2H-tetrazol-2-yl]phenoxy]pyridine 507270-38-4P, 3-Methyl-5-[5-(5-methyl-1H-imidazol-2-yl)-2H-tetrazol-2-yl]benzonitrile 507270-39-5P, 3-Chloro-5-[5-(5-methyl-1H-imidazol-2-yl)-2H-tetrazol-2-yl]benzonitrile 507270-40-8P, 3-Fluoro-5-[5-(1,3-thiazol-2-yl)-2H-tetrazol-2-yl]benzonitrile 507270-41-9P, 3-Fluoro-5-[5-(1,3-thiazol-4-yl)-2H-tetrazol-2-yl]benzonitrile 507270-42-0P, 3-[3-Fluoro-5-[5-(1,3-thiazol-4-yl)-2H-tetrazol-2-yl]phenoxy]pyridine 507270-43-1P, 3-Fluoro-5-[5-[4-(trifluoromethyl)-1H-imidazol-2-yl]-2H-tetrazol-2-yl]benzonitrile 507270-44-2P, 3-[5-(4-Methyl-1H-imidazol-2-yl)-2H-tetrazol-2-yl]-5-(pyridin-3-yloxy)benzonitrile 507270-45-3P, 3-Methoxy-5-[5-(4-methyl-1H-imidazol-2-yl)-2H-tetrazol-2-yl]benzonitrile
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of diaryl substituted tetrazole modulators of metabotropic glutamate receptor-5)

IT **507270-04-4P**, N-[3-(5-Pyridin-2-yl-2H-tetrazol-2-yl)phenyl]acetamide
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of diaryl substituted tetrazole modulators of metabotropic glutamate receptor-5)

RN 507270-04-4 CAPLUS

CN Acetamide, N-[3-[5-(2-pyridinyl)-2H-tetrazol-2-yl]phenyl]- (9CI) (CA INDEX NAME)



L54 ANSWER 10 OF 23 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2002:964216 CAPLUS
DOCUMENT NUMBER: 138:33356
TITLE: Medicinal compositions as p38MAP kinase and/or TNF-α production inhibitor for pain
INVENTOR(S): Ohkawa, Shigenori; Naruo, Kenichi; Morimoto, Shigeru; Nagase, Yoshinori; Miwatashi, Seiji
PATENT ASSIGNEE(S): Takeda Chemical Industries, Ltd., Japan
SOURCE: PCT Int. Appl., 563 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002100433	A1	20021219	WO 2002-JP5726	20020610
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2450400	AA	20021219	CA 2002-2450400	20020610
JP 2003063993	A2	20030305	JP 2002-168226	20020610
EP 1402900	A1	20040331	EP 2002-733431	20020610
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
US 2005080113	A1	20050414	US 2003-480551	20020610

PRIORITY APPLN. INFO.:
JP 2001-175224 A 20010611
JP 2001-175273 A 20010611
WO 2002-JP5726 W 20020610

OTHER SOURCE(S): MARPAT 138:33356

AB Prevention/treatment for pain and/or suppression of the activation and/or inhibition of the formation of osteoclasts by using a p38MAP kinase inhibitor and/or a TNF-α production inhibitor. A method of HDL1 relieving a P 450-inhibitory effect of a compound having a pyridyl group or its salt characterized by introducing a substituent into the α-position of the nitrogen atom in the pyridyl group of the above compound or its salt, or for relieving a P 450-inhibitory effect of a compound having a pyridyl group and an aromatic hydrocarbyl group or its salt characterized by introducing a polar group into the aromatic hydrocarbyl group of the above compound or its salt.

IC ICM A61K045-00
ICS A61K045-06; A61K031-4439; A61K031-444; A61K031-4545; A61K031-496; A61K031-5377; A61P029-00; A61P043-00; C07D417-04; C07D417-14

CC 1-11 (Pharmacology)
Section cross-reference(s): 28, 63

IT 224041-28-5, 2-Bromo-1-(3,5-dimethylphenyl)-2-(4-pyridyl)ethanone hydrobromide 224041-29-6, 2-Bromo-1-(3,4-methylenedioxyphenyl)-2-(4-pyridyl)ethanone hydrobromide 224041-30-9, 2-Bromo-1-(2-naphthyl)-2-(4-pyridyl)ethanone hydrobromide 242801-86-1, 4-Phenyl-1-piperazinecarbothioamide 252198-66-6 252198-74-6 252198-75-7 252198-96-2, 1-(4-Cyclohexylphenyl)-2-(4-pyridyl)ethanone 252198-97-3 284486-00-6 303162-27-8 303162-28-9, 2-Bromo-1-(3,5-dimethylphenyl)-2-(2-phenylmethyloxy-4-pyridyl)ethanone hydrobromide 303162-30-3, 2-(2-tert-Butoxycarbonylamino-4-pyridyl)-1-(4-methoxyphenyl)ethanone 303162-31-4, [5-(2-Amino-4-pyridyl)-4-(4-methoxyphenyl)-1,3-thiazol-2-yl]amine 303162-34-7, 2-(2-tert-Butoxycarbonylamino-4-pyridyl)-1-(3,5-dimethylphenyl)ethanone 303162-37-0, 2-(2-tert-Butoxycarbonylamino-4-pyridyl)-1-(3-methylphenyl)ethanone 303162-38-1, 4-[2-Methyl-4-(3-methylphenyl)-1,3-thiazol-5-yl]-2-pyridylamine 303162-39-2, 4-[2-Ethyl-4-(3-methylphenyl)-1,3-thiazol-5-yl]-2-pyridylamine 303162-40-5 303162-41-6, 4-[4-(4-Methoxyphenyl)-2-methyl-1,3-thiazol-5-yl]-2-pyridylamine 303162-43-8, 2-(2-Amino-4-pyridyl)-2-bromo-1-(3-methylphenyl)ethanone hydrobromide 303162-45-0, 4-[2-(4-Fluorophenyl)-4-(3-methylphenyl)-1,3-thiazol-5-yl]-2-pyridylamine 303162-46-1, 4-[2-(2-Chlorophenyl)-4-(3-methylphenyl)-1,3-thiazol-5-yl]-2-pyridylamine 303162-47-2 303162-48-3, 4-[2-Butyl-4-(3-methylphenyl)-1,3-thiazol-5-yl]2-pyridylamine 303162-49-4, 2-(2-Fluoro-4-pyridyl)-1-(3-methylphenyl)ethanone 303162-50-7, 2-(2-Fluoro-4-pyridyl)-1-(3-methoxyphenyl)ethanone 303162-52-9, [5-(2-Fluoro-4-pyridyl)-4-(3-methylphenyl)-1,3-thiazol-2-yl]amine 303162-54-1, [5-(2-Fluoro-4-pyridyl)-4-(3-methoxyphenyl)-1,3-thiazol-2-yl]amine 303162-55-2, 5-(2-Fluoro-4-pyridyl)-4-(3-methylphenyl)-2-[4-(methylthio)phenyl]-1,3-thiazole 303162-57-4, [4-(3,5-Dimethylphenyl)-5-(2-phenylmethyloxy-4-pyridyl)-1,3-thiazol-2-yl]amine 303162-58-5, N-[4-[2-Benzoylamino-4-(4-methoxyphenyl)-1,3-thiazol-5-yl]-2-pyridyl]benzamide 303162-59-6, N-[4-(4-Methoxyphenyl)-5-[2-[(3-pyridinecarbonylamino)]-4-pyridyl]-1,3-thiazol-2-yl]nicotinamide 303162-60-9, N-[4-[2-Amino-4-(4-methoxyphenyl)-1,3-thiazol-5-yl]-2-pyridyl]benzamide 303162-61-0, N-[4-[2-Amino-4-(3,5-dimethylphenyl)-1,3-thiazol-5-yl]-2-pyridyl]benzamide 303162-62-1, N-[4-[2-Amino-4-(3,5-dimethylphenyl)-1,3-thiazol-5-yl]-2-pyridyl]benzylamine 303162-64-3, N-[4-[2-Amino-4-(3,5-dimethylphenyl)-1,3-thiazol-5-yl]-2-pyridyl]benzamide hydrochloride 303162-66-5, N-[4-[2-Amino-4-(3,5-dimethylphenyl)-1,3-thiazol-5-yl]-2-pyridyl]benzylamine dihydrochloride 303162-67-6, N-[5-(2-Benzoylamino-4-pyridyl)-4-(3,5-dimethylphenyl)-1,3-thiazol-2-yl]acetamide 303162-68-7 303162-69-8, N-[4-[4-(4-Methoxyphenyl)-2-methylamino-1,3-thiazol-5-yl]-2-pyridyl]benzamide 303162-70-1, N-[4-[2-Amino-4-(3-methylphenyl)-1,3-thiazol-5-yl]-2-pyridyl]benzamide 303162-71-2, N-[4-[4-(4-Methoxyphenyl)-2-methyl-1,3-thiazol-5-yl]-2-pyridyl]benzamide 303162-72-3, N-[4-[2-(4-Fluorophenyl)-4-(3-methylphenyl)-1,3-thiazol-5-yl]-2-pyridyl]phenylacetamide 303162-73-4, N-[4-[4-(4-Methoxyphenyl)-2-methyl-1,3-thiazol-5-yl]-2-pyridyl]phenylacetamide 303162-74-5, N-[4-[2-Ethyl-4-(3-methylphenyl)-1,3-thiazol-5-yl]-2-pyridyl]phenylacetamide 303162-75-6, N-[4-[4-(3-Methylphenyl)-2-propyl-1,3-thiazol-5-yl]-2-pyridyl]phenylacetamide 303162-76-7, N-[4-[2-Butyl-4-(3-methylphenyl)-1,3-thiazol-5-yl]-2-pyridyl]phenylacetamide **303162-77-8**, N-[4-[2-(2-Chlorophenyl)-4-(3-methylphenyl)-1,3-thiazol-5-yl]-2-pyridyl]phenylacetamide 303162-78-9, N-[4-[4-(3-Methylphenyl)-2-(4-methylthiophenyl)-1,3-thiazol-5-yl]-2-pyridyl]phenylacetamide 303162-79-0 303162-80-3, N-[4-[2-Ethyl-4-(3-methylphenyl)-1,3-thiazol-5-yl]-2-pyridyl]-3-phenylpropionamide 303162-81-4, N-[4-[2-Ethyl-4-(3-methylphenyl)-1,3-thiazol-5-yl]-2-pyridyl]-3-(4-methoxyphenyl)propionamide 303162-82-5,

N-[4-[2-Ethyl-4-(3-methylphenyl)-1,3-thiazol-5-yl]-2-pyridyl]-3-(4-fluorophenyl)propionamide 303162-85-8, N-[4-[4-(3-Methylphenyl)-2-propyl-1,3-thiazol-5-yl]-2-pyridyl]benzamide 303162-86-9, N-[4-[4-(3-Methylphenyl)-2-propyl-1,3-thiazol-5-yl]-2-pyridyl]-3-phenylpropionamide 303162-87-0, N-[4-[2-Butyl-4-(3-methylphenyl)-1,3-thiazol-5-yl]-2-pyridyl]benzamide 303162-88-1, N-[4-[2-Butyl-4-(3-methylphenyl)-1,3-thiazol-5-yl]-2-pyridyl]-3-phenylpropanamide 303162-89-2 303162-90-5, N-[4-[2-(4-Fluorophenyl)-4-(3-methylphenyl)-1,3-thiazol-5-yl]-2-pyridyl]-3-phenylpropanamide **303162-91-6**, N-[4-[2-(2-Chlorophenyl)-4-(3-methylphenyl)-1,3-thiazol-5-yl]-2-pyridyl]benzamide **303162-92-7**, N-[4-[2-(2-Chlorophenyl)-4-(3-methylphenyl)-1,3-thiazol-5-yl]-2-pyridyl]-3-phenylpropionamide 303162-93-8, N-[4-[4-(3-Methylphenyl)-2-(4-methylthiophenyl)-1,3-thiazol-5-yl]-2-pyridyl]benzamide 303162-94-9, N-[4-[4-(3-Methylphenyl)-2-(4-methylthiophenyl)-1,3-thiazol-5-yl]-2-pyridyl]-3-phenylpropionamide 303162-95-0, N-[4-[4-(3-Methylphenyl)-2-(4-methylthiophenyl)-1,3-thiazol-5-yl]-2-pyridyl]-2-thiophencarboxamide 303162-96-1 303162-97-2, N-[4-[2-Ethyl-4-(3-Methylphenyl)-1,3-thiazol-5-yl]-2-pyridyl]-N-methylphenylacetamide 303162-98-3 303162-99-4, N-Benzyl-N-[4-[4-(4-Methoxyphenyl)-2-methyl-1,3-thiazol-5-yl]-2-pyridyl]amine 303163-00-0 303163-01-1, N-[4-[2-Ethyl-4-(3-Methylphenyl)-1,3-thiazol-5-yl]-2-pyridyl]-N-(2-phenylethyl)amine 303163-02-2, N-[4-[2-Ethyl-4-(3-Methylphenyl)-1,3-thiazol-5-yl]-2-pyridyl]-N-(3-phenylpropyl)amine 303163-03-3, N-Benzyl-N-[4-[4-(3-Methylphenyl)-2-propyl-1,3-thiazol-5-yl]-2-pyridyl]amine 303163-04-4, N-[4-[4-(3-Methylphenyl)-2-propyl-1,3-thiazol-5-yl]-2-pyridyl]-N-(2-phenylethyl)amine 303163-05-5, N-[4-[4-(3-Methylphenyl)-2-propyl-1,3-thiazol-5-yl]-2-pyridyl]-N-(3-phenylpropyl)amine 303163-06-6, N-Benzyl-N-[4-[2-butyl-4-(3-Methylphenyl)-1,3-thiazol-5-yl]-2-pyridyl]amine 303163-07-7, N-[4-[2-Butyl-4-(3-Methylphenyl)-1,3-thiazol-5-yl]-2-pyridyl]-N-(2-phenylethyl)amine 303163-08-8, N-[4-[2-Butyl-4-(3-Methylphenyl)-1,3-thiazol-5-yl]-2-pyridyl]-N-(3-phenylpropyl)amine 303163-09-9, N-Benzyl-N-[4-[2-(4-fluorophenyl)-4-(3-Methylphenyl)-1,3-thiazol-5-yl]-2-pyridyl]amine 303163-10-2, N-[4-[2-(4-Fluorophenyl)-4-(3-Methylphenyl)-1,3-thiazol-5-yl]-2-pyridyl]-N-(2-phenylethyl)amine 303163-11-3, N-[4-[2-(4-Fluorophenyl)-4-(3-Methylphenyl)-1,3-thiazol-5-yl]-2-pyridyl]-N-(3-phenylpropyl)amine 303163-12-4, N-Benzyl-N-[4-[2-(2-chlorophenyl)-4-(3-Methylphenyl)-1,3-thiazol-5-yl]-2-pyridyl]amine 303163-13-5, N-[4-[2-(2-Chlorophenyl)-4-(3-Methylphenyl)-1,3-thiazol-5-yl]-2-pyridyl]-N-(2-phenylethyl)amine 303163-14-6, N-[4-[2-(2-Chlorophenyl)-4-(3-Methylphenyl)-1,3-thiazol-5-yl]-2-pyridyl]-N-(3-phenylpropyl)amine 303163-15-7 303163-16-8, N-[4-[4-(3-Methylphenyl)-2-(4-methylthiophenyl)-1,3-thiazol-5-yl]-2-pyridyl]-N-(2-phenylethyl)amine 303163-17-9, N-[4-[4-(3-Methylphenyl)-2-(4-methylthiophenyl)-1,3-thiazol-5-yl]-2-pyridyl]-N-(3-phenylpropyl)amine 303163-18-0, N-[4-[4-(3-Methylphenyl)-2-(4-methylthiophenyl)-1,3-thiazol-5-yl]-2-pyridyl]-N-(2-naphthylmethyl)amine 303163-19-1, N-[4-[4-(3-Methylphenyl)-2-(4-methylsulfonylphenyl)-1,3-thiazol-5-yl]-2-pyridyl]benzamide 303163-20-4, N-[4-[4-(3-Methylphenyl)-2-(4-methylsulfonylphenyl)-1,3-thiazol-5-yl]-2-pyridyl]phenylacetamide 303163-21-5 303163-22-6, N-[4-[4-(3-Methylphenyl)-2-(4-methylsulfonylphenyl)-1,3-thiazol-5-yl]-2-pyridyl]-2-thiophenecarboxamide 303163-23-7 303163-24-8, N-Benzyl-N-[4-[4-(3-Methylphenyl)-2-(4-methylsulfonylphenyl)-1,3-thiazol-5-yl]-2-pyridyl]amine 303163-25-9, N-[4-[4-(3-Methylphenyl)-2-(4-methylsulfonylphenyl)-1,3-thiazol-5-yl]-2-pyridyl]-N-(3-phenylpropyl)amine 303163-26-0, N-[4-[4-(3-Methylphenyl)-2-(4-methylsulfonylphenyl)-1,3-thiazol-5-yl]-2-pyridyl]-N-(2-naphthylmethyl)amine 303163-27-1 303163-28-2, N-[4-[2-Amino-4-(3-Methylphenyl)-1,3-thiazol-5-yl]-2-pyridyl]-N-(4-methoxybenzyl)amine 303163-29-3, N-[4-[2-Amino-4-(3-Methylphenyl)-1,3-thiazol-5-yl]-2-pyridyl]-N-(3-methoxybenzyl)amine 303163-30-6, N-[4-[2-Amino-4-(3-Methylphenyl)-

1,3-thiazol-5-yl]-2-pyridyl]-N-(2-methoxybenzyl)amine 303163-31-7, N-[4-[2-Amino-4-(3-Methylphenyl)-1,3-thiazol-5-yl]-2-pyridyl]-N-(4-chlorobenzyl)amine 303163-32-8, N-[4-[2-Amino-4-(3-Methylphenyl)-1,3-thiazol-5-yl]-2-pyridyl]-N-(3-chlorobenzyl)amine 303163-33-9 303163-34-0, (S) N-[4-[2-Amino-4-(3-Methylphenyl)-1,3-thiazol-5-yl]-2-pyridyl]-N-(1-phenylethyl)amine 303163-35-1, N-[4-[2-Amino-4-(3-Methylphenyl)-1,3-thiazol-5-yl]-2-pyridyl]-N-benzyl-N-methylamine 303163-36-2, N-[4-[2-Amino-4-(3-Methoxyphenyl)-1,3-thiazol-5-yl]-2-pyridyl]-N-benzylamine 303163-37-3, N-[4-[4-(3-Methylphenyl)-2-(4-methylsulfonylphenyl)-1,3-thiazol-5-yl]-2-pyridyl]-N-(2-phenylethyl)amine 303163-38-4, N-(4-Fluorobenzyl)-N-[4-[4-(3-Methylphenyl)-2-(4-methylsulfonylphenyl)-1,3-thiazol-5-yl]-2-pyridyl]amine 303163-39-5, N-Benzyl-N-methyl-N-[4-[4-(3-Methylphenyl)-2-(4-methylsulfonylphenyl)-1,3-thiazol-5-yl]-2-pyridyl]amine 303163-40-8, N-Methyl-N-[4-[4-(3-Methylphenyl)-2-(4-methylsulfonylphenyl)-1,3-thiazol-5-yl]-2-pyridyl]-N-(2-phenylethyl)amine 303163-41-9, N-[4-[4-(3-Methylphenyl)-2-(4-methylsulfonylphenyl)-1,3-thiazol-5-yl]-2-pyridyl]-N-(2-thienylmethyl)amine 303163-42-0, 4-(3-Methylphenyl)-2-(4-methylsulfonylphenyl)-5-(2-phenylthio-4-pyridyl)-1,3-thiazole 303163-43-1, 5-(2-Benzylthio-4-pyridyl)-4-(3-Methylphenyl)-2-(4-methylsulfonylphenyl)-1,3-thiazole 303163-44-2 303787-77-1 303787-79-3, 2-Bromo-1-(4-chlorophenyl)-2-(3-pyridyl)ethanone hydrobromide 303787-81-7 303787-83-9, 2-Bromo-1-(3-methylphenyl)-2-(3-pyridyl)ethanone hydrobromide 303787-85-1, 2-Bromo-1-(3-methoxyphenyl)-2-(3-pyridyl)ethanone hydrobromide 303787-87-3 303787-89-5, 2-Bromo-1-(3-methoxyphenyl)-2-(4-pyridyl)ethanone hydrobromide 303787-91-9, 2-Bromo-2-(4-pyridyl)-1-(4-trifluoromethoxyphenyl)ethanone hydrobromide 303787-98-6 325707-98-0 325767-68-8 325767-69-9 325767-71-3 325767-72-4 325767-73-5 325767-74-6 325767-75-7 325767-77-9 325767-79-1 325767-80-4 325767-81-5 325767-82-6 325767-83-7 325767-84-8 325767-85-9 325767-86-0 325767-87-1 325767-88-2 325767-89-3 325767-90-6 325767-91-7 325767-92-8 325767-93-9 325767-94-0 325767-95-1 325767-96-2 325767-97-3 325767-98-4 325767-99-5 325768-00-1 325768-02-3 325768-03-4 325768-04-5 325768-05-6 325768-06-7 325768-07-8 325768-08-9 325768-09-0 325768-10-3 325768-11-4 325768-12-5 325768-13-6 325768-14-7 325768-15-8 325768-16-9 325768-17-0 325768-18-1 325768-19-2 325768-20-5 325768-21-6 325768-22-7 325768-23-8 325768-24-9 325768-25-0 325768-27-2 325768-28-3 325768-29-4 325768-30-7 325768-31-8 325768-32-9 325768-33-0 325768-34-1 325768-35-2 325768-36-3 325768-37-4 325768-38-5 325768-39-6 325768-40-9 325768-41-0 325768-42-1 325768-43-2 325768-44-3 325768-45-4 325768-46-5 325768-47-6 325768-48-7 325768-49-8 325768-50-1 325768-51-2 325768-52-3 325768-53-4 325768-54-5 325768-55-6 325768-56-7 325768-57-8 325768-58-9 325768-59-0 325768-60-3 325768-61-4 325768-62-5 325768-63-6 325768-64-7 325768-65-8 325768-66-9 325768-67-0 325768-68-1 325768-69-2 325768-70-5 325768-71-6 325768-72-7 325768-73-8 325768-75-0 325768-76-1 325768-77-2 325768-78-3 325768-79-4 325768-80-7 325768-81-8 325768-82-9 325768-83-0 325768-84-1

RL: PAC (Pharmacological activity); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(medicinal compns. as p38MAP kinase and/or TNF-α production inhibitor for pain)

IT **303162-77-8**, N-[4-[2-(2-Chlorophenyl)-4-(3-methylphenyl)-1,3-thiazol-5-yl]-2-pyridyl]phenylacetamide **303162-91-6**, N-[4-[2-(2-Chlorophenyl)-4-(3-methylphenyl)-1,3-thiazol-5-yl]-2-pyridyl]benzamide **303162-92-7**, N-[4-[2-(2-Chlorophenyl)-4-(3-methylphenyl)-1,3-thiazol-5-yl]-2-pyridyl]-3-phenylpropionamide

RL: PAC (Pharmacological activity); PRP (Properties); THU (Therapeutic

use); BIOL (Biological study); USES (Uses)
(medicinal compns. as p38MAP kinase and/or TNF-α production inhibitor for pain)

RN 303162-77-8 CAPLUS
CN Benzeneacetamide, N-[4-[2-(2-chlorophenyl)-4-(3-methylphenyl)-5-thiazolyl]-2-pyridinyl]- (9CI) (CA INDEX NAME)



RN 303162-91-6 CAPLUS
CN Benzamide, N-[4-[2-(2-chlorophenyl)-4-(3-methylphenyl)-5-thiazolyl]-2-pyridinyl]- (9CI) (CA INDEX NAME)



RN 303162-92-7 CAPLUS
CN Benzenepropanamide, N-[4-[2-(2-chlorophenyl)-4-(3-methylphenyl)-5-thiazolyl]-2-pyridinyl]- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 20 THERE ARE 20 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L54 ANSWER 11 OF 23 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2002:449677 CAPLUS
DOCUMENT NUMBER: 137:33288
TITLE: Preparation of substituted thiazole derivatives bearing 3-pyridyl groups as steroid C17,20 lyase inhibitors, process for preparing the same and use thereof
INVENTOR(S): Kusaka, Masami; Kuroda, Noritaka; Nara, Yoshi; Hashiguchi, Shohei; Tasaka, Akihiro; Yamaoka, Masuo; Kaku, Tomohiro
PATENT ASSIGNEE(S): Takeda Chemical Industries, Ltd., Japan
SOURCE: PCT Int. Appl., 190 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002046186	A1	20020613	WO 2001-JP10723	20011207
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ; LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2431171	AA	20020613	CA 2001-2431171	20011207
AU 2002021080	A5	20020618	AU 2002-21080	20011207
JP 2002234843	A2	20020823	JP 2001-375062	20011207
EP 1348706	A1	20031001	EP 2001-999258	20011207
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
US 2004072876	A1	20040415	US 2003-433910	20030604

PRIORITY APPLN. INFO.: JP 2000-373868 A 20001208
WO 2001-JP10723 W 20011207

OTHER SOURCE(S): MARPAT 137:33288
GI



I

AB Disclosed are pharmaceutical compns., more particularly, steroid C17,20 lyase inhibitors characterized by containing a compound of the general formula (I) or a salt or prodrug thereof (wherein A1 is an optionally substituted aromatic hydrocarbon group or an optionally substituted heterocyclic group; and one of A2 or A3 is hydrogen, halogeno, an optionally substituted C1-4 aliphatic hydrocarbon group, or optionally esterified carboxyl, and the other is an optionally substituted heterocyclic group, with the proviso that at

least one of A1, A2, and A3 is optionally substituted 3-pyridyl). These compns. are useful as preventive or therapeutic agents for sex hormone-dependent diseases such as prostatic hypertrophy, virilism, hypertrichosis, male alopecia, male early maturation, endometriosis, hysteromyoma, uterine adenomyosis, mastopathy, and polycystic ovary syndrome. Thus, 2-bromo-1-(4-methylpyridin-3-yl)ethanone hydrobromide and 4-methylpyridine-3-thiocarboxamide were suspended in ethanol and refluxed for 3 h to give 4-methyl-3-[2-(4-methylpyridin-3-yl)-1,3-thiazol-4-yl]pyridine (II). II showed IC50 of <10 nM against rat steroid C17,20 lyase. Pharmaceutical formulations, e.g. a coated tablet containing II, were prepared

IC ICM C07D417-04
ICS C07D417-14; A61K031-4439; A61K031-4545; A61K031-4725; A61P043-00; A61P013-08; A61P015-00; A61P017-14; A61P035-00

CC 28-7 (Heterocyclic Compounds (More Than One Hetero Atom))
Section cross-reference(s): 1, 63

IT 25021-37-8P 71562-73-7P 93209-48-4P 181632-82-6P 222629-41-6P
435271-34-4P 435271-35-5P 435271-36-6P 435271-37-7P 435271-38-8P
435271-39-9P 435271-40-2P 435271-41-3P 435271-42-4P 435271-43-5P
435271-44-6P 435271-45-7P 435271-46-8P 435271-47-9P 435271-48-0P
435271-49-1P 435271-50-4P 435271-51-5P 435271-52-6P 435271-53-7P
435271-54-8P 435271-55-9P 435271-56-0P 435271-57-1P 435271-58-2P
435271-59-3P 435271-60-6P 435271-61-7P 435271-62-8P 435271-63-9P
435271-64-0P 435271-65-1P 435271-66-2P 435271-67-3P 435271-68-4P
435271-69-5P 435271-70-8P 435271-71-9P 435271-72-0P 435271-73-1P
435271-74-2P 435271-75-3P 435271-76-4P 435271-77-5P 435271-78-6P
435271-79-7P 435271-80-0P 435271-81-1P 435271-82-2P 435271-83-3P
435271-84-4P 435271-85-5P 435271-86-6P 435271-87-7P 435271-88-8P
435271-89-9P 435271-90-2P 435271-91-3P 435271-92-4P 435271-93-5P
435271-94-6P 435271-95-7P 435271-96-8P 435271-97-9P 435271-98-0P
435271-99-1P 435272-00-7P 435272-01-8P 435272-02-9P 435272-03-0P
435272-04-1P **435272-05-2P** 435272-06-3P 435272-07-4P
435272-08-5P 435272-09-6P 435272-10-9P 435272-11-0P 435272-12-1P
435272-13-2P 435272-14-3P 435272-15-4P 435272-16-5P 435272-17-6P
435272-18-7P 435272-19-8P 435272-20-1P 435272-21-2P 435272-22-3P
435272-23-4P 435272-24-5P 435272-25-6P 435272-26-7P 435272-27-8P,
4-[3-[4-(4-Chlorophenyl)-1,3-thiazol-2-yl]pyridin-4-yl]morpholine
435272-28-9P 435272-29-0P 435272-30-3P, 2-[3-[4-(4-Chlorophenyl)-1,3-thiazol-2-yl]pyridin-4-yl]propan-2-ol 435272-31-4P, 3-[4-(4-Chlorophenyl)-1,3-thiazol-2-yl]-N,N-dimethylisonicotinamide 435272-32-5P
435272-33-6P 435272-34-7P 435272-35-8P, 3-[5-Chloro-4-(4-chlorophenyl)-1,3-thiazol-2-yl]-4-methylpyridine 435272-36-9P 435272-37-0P
435272-38-1P, 3-[5-Fluoro-4-(4-methylphenyl)-1,3-thiazol-2-yl]-4-methylpyridine 435272-39-2P, 4-[2-(4-Methylpyridin-3-yl)-1,3-thiazol-4-yl]benzenesulfonamide 435272-40-5P, 4-[2-[4-(Trifluoromethyl)pyridin-3-yl]-1,3-thiazol-4-yl]benzenesulfonamide 435272-41-6P,
4-[2-[4-(Trifluoromethyl)pyridin-3-yl]-1,3-thiazol-4-yl]aniline
435272-42-7P, 3-[2-[4-(Trifluoromethyl)pyridin-3-yl]-1,3-thiazol-4-yl]aniline 435272-43-8P, N-(4-[2-[4-(Trifluoromethyl)pyridin-3-yl]-1,3-thiazol-4-yl]phenyl)acetamide 435272-44-9P, N-(4-[2-[4-(Trifluoromethyl)pyridin-3-yl]-1,3-thiazol-4-yl]phenyl)methanesulfonamide hydrochloride 435272-45-0P, N-(3-[2-[4-(Trifluoromethyl)pyridin-3-yl]-1,3-thiazol-4-yl]phenyl)methanesulfonamide hydrochloride 435272-46-1P,
4-[2-[4-(Trifluoromethyl)pyridin-3-yl]-1,3-thiazol-4-yl]benzoic acid
435272-47-2P, 4-[2-(4-Methylpyridin-3-yl)-1,3-thiazol-4-yl]benzoic acid
435272-48-3P, 4-[2-[4-(Trifluoromethyl)pyridin-3-yl]-1,3-thiazol-4-yl]benzamide 435272-49-4P, 4-[2-(4-Methylpyridin-3-yl)-1,3-thiazol-4-yl]benzamide 435272-50-7P, 3-[4-(4-Methylpyridin-3-yl)-1,3-thiazol-2-yl]benzamide 435272-51-8P, N-Methyl-3-[4-(4-methylpyridin-3-yl)-1,3-thiazol-2-yl]benzamide 435272-52-9P, N,N-Dimethyl-3-[4-(4-methylpyridin-

3-yl)-1,3-thiazol-2-yl]benzamide 435272-53-0P, 4-[4-(4-Methylpyridin-3-yl)-1,3-thiazol-2-yl]benzamide 435272-54-1P, N-Methyl-4-[4-(4-methylpyridin-3-yl)-1,3-thiazol-2-yl]benzamide 435272-55-2P, N,4-Dimethyl-3-[4-(4-methylpyridin-3-yl)-1,3-thiazol-2-yl]benzamide 435272-56-3P, N,N,4-Trimethyl-3-[4-(4-methylpyridin-3-yl)-1,3-thiazol-2-yl]benzamide 435272-57-4P, 4-Methyl-3-[2-[2-methyl-5-(pyrrolidin-1-ylcarbonyl)phenyl]-1,3-thiazol-4-yl]pyridine 435272-58-5P, 4-Fluoro-N-methyl-3-[4-(4-methylpyridin-3-yl)-1,3-thiazol-2-yl]benzamide 435272-59-6P, 2-Chloro-N-methyl-5-[4-(4-methylpyridin-3-yl)-1,3-thiazol-2-yl]benzamide **435272-60-9P**, N-[3-[4-(4-Methylpyridin-3-yl)-1,3-thiazol-2-yl]phenyl]acetamide 435272-61-0P, N-[4-[4-(4-Methylpyridin-3-yl)-1,3-thiazol-2-yl]phenyl]acetamide 435272-62-1P, 4-Methyl-3-[4-(4-methylpyridin-3-yl)-1,3-thiazol-2-yl]phenyl]formamide **435272-63-2P**, N-[4-Methyl-3-[4-(4-methylpyridin-3-yl)-1,3-thiazol-2-yl]phenyl]acetamide 435272-64-3P, 4-Methyl-3-[2-(2-pyridyl)-1,3-thiazol-4-yl]pyridine 435272-65-4P, 4-Methyl-3-[2-(3-pyridyl)-1,3-thiazol-4-yl]pyridine 435272-66-5P, 4-Methyl-3-[2-(4-pyridyl)-1,3-thiazol-4-yl]pyridine 435272-67-6P, 5-[4-(4-Methylpyridin-3-yl)-1,3-thiazol-2-yl]nicotinamide 435272-68-7P, N-Methyl-5-[4-(4-methylpyridin-3-yl)-1,3-thiazol-2-yl]nicotinamide 435272-69-8P, N-Ethyl-5-[4-(4-methylpyridin-3-yl)-1,3-thiazol-2-yl]nicotinamide 435272-70-1P, N-Methyl-6-[4-(4-methylpyridin-3-yl)-1,3-thiazol-2-yl]pyridine-2-carboxamide 435272-71-2P, N-Methyl-6-[4-(4-methylpyridin-3-yl)-1,3-thiazol-2-yl]nicotinamide 435272-72-3P, 4-[4-(4-Methylpyridin-3-yl)-1,3-thiazol-2-yl]isoindolin-1-one 435272-73-4P, 2-Methyl-4-[4-(4-methylpyridin-3-yl)-1,3-thiazol-2-yl]isoindolin-1-one 435272-74-5P, 5-[4-(4-Methylpyridin-3-yl)-1,3-thiazol-2-yl]pyridin-2(1H)-one 435272-75-6P, 3-[4-(4-Methylpyridin-3-yl)-1,3-thiazol-2-yl]isoquinoline 435272-76-7P, 1-[4-(4-Methylpyridin-3-yl)-1,3-thiazol-2-yl]isoquinoline 435272-77-8P, 2,4-Dimethoxy-5-[4-(4-methylpyridin-3-yl)-1,3-thiazol-2-yl]pyrimidine 435272-78-9P, 3-[5-Methyl-4-(4-methylpyridin-3-yl)-1,3-thiazol-2-yl]benzamide 435272-79-0P, 3-[5-Isopropyl-4-(4-methylpyridin-3-yl)-1,3-thiazol-2-yl]benzamide 435272-80-3P, 3-[5-Chloro-4-(4-methylpyridin-3-yl)-1,3-thiazol-2-yl]-N,N-dimethylbenzamide 435272-81-4P, 3-[5-Methyl-4-(4-methylpyridin-3-yl)-1,3-thiazol-2-yl]benzenesulfonamide 435272-82-5P, 3-[2-[4-Methylpyridin-3-yl]-1,3-thiazol-4-yl]benzamide 435272-83-6P, 3-[2-[4-(Trifluoromethyl)pyridin-3-yl]-1,3-thiazol-4-yl]benzamide 435272-84-7P, 2-Fluoro-5-[2-[4-(trifluoromethyl)pyridin-3-yl]-1,3-thiazol-4-yl]benzamide 435272-85-8P, 2-Fluoro-N-methyl-5-[2-[4-(trifluoromethyl)pyridin-3-yl]-1,3-thiazol-4-yl]benzamide 435272-86-9P, 2-Fluoro-N,N-dimethyl-5-[2-[4-(trifluoromethyl)pyridin-3-yl]-1,3-thiazol-4-yl]benzamide 435272-87-0P, N-Ethyl-2-fluoro-5-[2-[4-(trifluoromethyl)pyridin-3-yl]-1,3-thiazol-4-yl]benzamide 435272-88-1P, 3-[4-(4-(Ethylpyridin-3-yl)-1,3-thiazol-2-yl]benzamide 435272-89-2P, 3-[4-(4-(Ethylpyridin-3-yl)-1,3-thiazol-2-yl]-N-methylbenzamide 435272-90-5P, 3-[4-(4-(Ethylpyridin-3-yl)-1,3-thiazol-2-yl]-N,N-dimethylbenzamide 435272-91-6P, 3-[4-(4-(Isopropylpyridin-3-yl)-1,3-thiazol-2-yl]benzamide 435272-92-7P, 3-[4-(4-(Isopropylpyridin-3-yl)-1,3-thiazol-2-yl]-N,4-dimethylbenzamide 435272-94-9P, 3-[4-(4-(Isopropylpyridin-3-yl)-1,3-thiazol-2-yl]-N,N-dimethylbenzamide hemifumarate 435272-95-0P, 3-[4-(4-(Ethylpyridin-3-yl)-1,3-thiazol-2-yl]benzenesulfonamide 435272-96-1P, 4-[4-(4-(Ethylpyridin-3-yl)-1,3-thiazol-2-yl]benzenesulfonamide 435273-00-0P, 3-[4-(3-Bromo-4-fluorophenyl)-1,3-thiazol-2-yl]-4-(trifluoromethyl)pyridine 435273-01-1P, Ethyl 2-fluoro-5-[2-[4-trifluoromethyl)pyridin-3-yl]-1,3-thiazol-4-yl]benzoic acid 435273-03-3P, 4-Methyl-3-[2-(4-methyl-pyridin-3-yl)-1,3-thiazol-4-yl]pyridine 435273-04-4P, 4-Methyl-3-[4-(pyridin-4-yl)-1,3-thiazol-2-yl]pyridine 435273-05-5P, N-Methyl-3-[2-(4-methylpyridin-3-yl)-1,3-thiazol-4-yl]benzamide 435273-06-6P, N,N-Dimethyl-3-[2-(4-methylpyridin-3-yl)-1,3-thiazol-4-yl]benzamide

435273-07-7P, N-Ethyl-3-[2-(4-methylpyridin-3-yl)-1,3-thiazol-4-yl]benzamide 435273-08-8P, 3-[4-[3-(1-Azetidinylcarbonyl)phenyl]-1,3-thiazol-2-yl]-4-methylpyridine
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of substituted pyridylthiazole derivs. as steroid C17,20 lyase inhibitors for treatment and prevention of sex hormone-dependent diseases)

IT **435272-05-2P 435272-60-9P**, N-[3-[4-(4-Methylpyridin-3-yl)-1,3-thiazol-2-yl]phenyl]acetamide **435272-63-2P**, N-[4-Methyl-3-[4-(4-methylpyridin-3-yl)-1,3-thiazol-2-yl]phenyl]acetamide
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of substituted pyridylthiazole derivs. as steroid C17,20 lyase inhibitors for treatment and prevention of sex hormone-dependent diseases)

RN 435272-05-2 CAPLUS
CN Acetamide, N-[3-[2-[4-(trifluoromethyl)-3-pyridinyl]-4-thiazolyl]phenyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 435272-60-9 CAPLUS
CN Acetamide, N-[3-[4-(4-methyl-3-pyridinyl)-2-thiazolyl]phenyl]- (9CI) (CA INDEX NAME)



RN 435272-63-2 CAPLUS
CN Acetamide, N-[4-methyl-3-[4-(4-methyl-3-pyridinyl)-2-thiazolyl]phenyl]- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 78 THERE ARE 78 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L54 ANSWER 12 OF 23 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2000:772628 CAPLUS
DOCUMENT NUMBER: 133:321879
TITLE: Preparation of 5-pyridyl-1,3-azole compounds as antagonists of adenosine A3 receptor, process for producing the same and use thereof
INVENTOR(S): Ohkawa, Shigenori; Kanzaki, Naoyuki; Miwatashi, Seiji
PATENT ASSIGNEE(S): Takeda Chemical Industries, Ltd., Japan
SOURCE: PCT Int. Appl., 152 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000064894	A1	20001102	WO 2000-JP2575	20000420
W: AE, AG, AL, AM, AU, AZ, BA, BB, BG, BR, BY, CA, CN, CR, CU, CZ, DM, DZ, EE, GD, GE, HR, HU, ID, IL, IN, IS, JP, KG, KR, KZ, LC, LK, LR, LT, LV, MA, MD, MG, MK, MN, MX, NO, NZ, PL, RO, RU, SG, SI, SK, TJ, TM, TR, TT, UA, US, UZ, VN, YU, ZA				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2370264	AA	20001102	CA 2000-2370264	20000420
EP 1180518	A1	20020220	EP 2000-917375	20000420
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
BR 2000009952	A	20020326	BR 2000-9952	20000420
NZ 515215	A	20030725	NZ 2000-515215	20000420
AU 765473	B2	20030918	AU 2000-38401	20000420
RU 2237062	C2	20040927	RU 2001-131556	20000420
JP 2001114779	A2	20010424	JP 2000-126289	20000421
JP 3333774	B2	20021015		
JP 2002363179	A2	20021218	JP 2002-164744	20000421
TW 220900	B1	20040911	TW 2000-89122035	20001020
NO 2001005156	A	20011218	NO 2001-5156	20011022
NO 320588	B1	20051227		
ZA 2001008996	A	20030131	ZA 2001-8996	20011031

PRIORITY APPLN. INFO.:

JP 1999-116686	A	19990423
JP 1999-224650	A	19990806
WO 2000-JP2575	W	20000420
JP 2000-126289	A3	20000421

OTHER SOURCE(S): MARPAT 133:321879
GI



I

AB Optionally N-oxidized compds. represented by general formula (I) salts thereof [wherein R1 represents hydrogen, hydrocarbyl, a heterocycle, amino or acyl; R2 represents an aromatic group; R3 represents hydrogen, pyridyl or aromatic hydrocarbyl; X represents oxygen or optionally oxidized sulfur; Y represents a bond, oxygen, optionally oxidized sulfur or NR4 (wherein R4 represents hydrogen, hydrocarbyl, or acyl); and Z represents a bond or a divalent chain hydrocarbyl] are prepared These compds. are usable as preventives or remedies for diseases in association with adenosine A3 receptor because of having excellent adenosine A3 receptor antagonism thereof. Moreover, the compds. I or salts thereof exhibit excellent effects of inhibiting p38 MAP kinase and inhibiting TNF-α and, therefore, are also usable as preventives or remedies for diseases in association with p38 MAP kinase or TNF-α. Above diseases include asthma, allergies, brain edema, cerebral vascular disorders, head injuries, inflammation, Addison's disease, autoimmune hemolytic anemia, Crohn's disease, psoriasis, rheumatism, spinal cord injury, multiple sclerosis, Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis, diabetes, arthritis, septicemia, ulcerative colitis, chronic pneumonia, silicosis, lung sarcoidosis, pulmonary tuberculosis, cachexia, arteriosclerosis, Creutzfeldt-Jakob disease, virus infection, atopic dermatitis, systemic lupus erythematosus, AIDS encephalopathy, meningitis, angina pectoris, myocardial infarction, ischemic heart failure, hepatitis, transplant, dialysis hypotension, and frequent disseminated intravascular coagulation. Thus, bromination of 2-(2-benzoylamino-4-pyridyl)-1-(4-methoxyphenyl)ethanone with Br in AcOH at room temperature for 1 h followed by cyclocondensation of the bromination product with thiourea in the presence of Et3N in MeCN at 80° for 5 h gave N-[4-[2-amino-4-(4-methoxyphenyl)-1,3-thiazol-5-yl]-2-pyridyl]benzamide (II). II showed IC50 of 0.020 μM against p38 MAP kinase and 0.014 μM for inhibiting the production of TNF-α in THP-1 cells.

IC ICM C07D417-04
ICS C07D417-14; A61K031-4439; A61P043-00; A61P029-00; A61P031-12; A61P003-10; A61P001-00; A61P009-00; A61P007-00

CC 28-7 (Heterocyclic Compounds (More Than One Hetero Atom))
Section cross-reference(s): 1, 7

IT 303162-57-4P 303162-71-2P 303162-72-3P 303162-74-5P 303162-75-6P
303162-76-7P **303162-77-8P** 303162-78-9P 303162-79-0P
303162-80-3P 303162-85-8P 303162-86-9P 303162-87-0P 303162-88-1P
303162-89-2P 303162-90-5P **303162-91-6P 303162-92-7P**
303162-93-8P 303162-94-9P 303162-95-0P 303162-96-1P 303163-15-7P
303163-17-9P 303163-18-0P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of pyridylazole compds. as antagonists of adenosine A3 receptor and inhibitors of TNF-α and p38 MAP kinase for therapeutics)

IT **303162-77-8P 303162-91-6P 303162-92-7P**

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of pyridylazole compds. as antagonists of adenosine A3 receptor and inhibitors of TNF-α and p38 MAP kinase for therapeutics)

RN 303162-77-8 CAPLUS
CN Benzeneacetamide, N-[4-[2-(2-chlorophenyl)-4-(3-methylphenyl)-5-thiazolyl]-2-pyridinyl]- (9CI) (CA INDEX NAME)



RN 303162-91-6 CAPLUS
CN Benzamide, N-[4-[2-(2-chlorophenyl)-4-(3-methylphenyl)-5-thiazolyl]-2-pyridinyl]- (9CI) (CA INDEX NAME)



RN 303162-92-7 CAPLUS
CN Benzenepropanamide, N-[4-[2-(2-chlorophenyl)-4-(3-methylphenyl)-5-thiazolyl]-2-pyridinyl]- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 20 THERE ARE 20 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L54 ANSWER 13 OF 23 USPATFULL on STN
ACCESSION NUMBER: 2005:286541 USPATFULL
TITLE: Compositions and methods for treating hepatitis C virus (HCV) infection
INVENTOR(S): Holsztynska, Elzbieta J., Half Moon Bay, CA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2005249805	A1	20051110
APPLICATION INFO.:	US 2004-17531	A1	20041218 (11)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2003-531543P	20031219 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: DORSEY & WHITNEY LLP, 555 CALIFORNIA STREET, SUITE 1000, SUITE 1000, SAN FRANCISCO, CA, 94104, US
NUMBER OF CLAIMS: 36
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 32 Drawing Page(s)
LINE COUNT: 2498
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Provided are compositions and methods for protecting a compound comprising a haloalkylamide moiety from metabolic transformation by hydrolases. In one aspect, the disclosure is directed to increasing the bioavailability and tissue delivery of a anti-HCV compound comprising a haloalkylamide moiety by protecting the compound from inactivation by carboxylesterases. Specific approaches for limiting metabolic transformation include use of carboxylesterase inhibitors to inhibit metabolism of the compound, or use of orally administered compositions designed to deliver the compound to the small intestine or large intestine. Further provided are methods of treating or preventing HCV infection in a subject.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT **667931-30-8**
(as antiviral agent; treatment of hepatitis C virus infection with antiviral haloalkylamide agents and inhibitors for protecting the antiviral agent from inactivation by hydrolases)
RN 667931-30-8 USPATFULL
CN Acetamide, 2,2-dichloro-N-[2-[3-(2,6-dichlorophenyl)-5-isoxazolyl]-4-pyridinyl]- (9CI) (CA INDEX NAME)



L54 ANSWER 14 OF 23 USPATFULL on STN

ACCESSION NUMBER:	2005:150748 USPATFULL
TITLE:	Synergistically effective combinations of dihaloacetamide compounds and interferon or ribavirin against HCV infections
INVENTOR(S):	Lu, Henry, Foster City, CA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2005129659	A1	20050616
APPLICATION INFO.:	US 2004-993212	A1	20041119 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2003-523405P	20031119 (60)

DOCUMENT TYPE:	Utility
FILE SEGMENT:	APPLICATION
LEGAL REPRESENTATIVE:	DORSEY & WHITNEY LLP, INTELLECTUAL PROPERTY DEPARTMENT, 50 SOUTH SIXTH STREET, MINNEAPOLIS, MN, 55402-1498, US
NUMBER OF CLAIMS:	17
EXEMPLARY CLAIM:	1
NUMBER OF DRAWINGS:	4 Drawing Page(s)
LINE COUNT:	960

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to anti-HCV dihaloacetamide compounds in synergistic combination with an interferon and/or ribavirin and pharmaceutical compositions thereof for inhibition of the replication of HCV virus. The present invention also relates to the use of the compositions to inhibit HCV replication and/or proliferation and to treat or prevent HCV infections.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT **667931-30-8**
(synergistically effective combinations of dihaloacetamide compds. and interferon or ribavirin against HCV infections)

RN 667931-30-8 USPATFULL

CN Acetamide, 2,2-dichloro-N-[2-[3-(2,6-dichlorophenyl)-5-isoxazolyl]-4-pyridinyl]- (9CI) (CA INDEX NAME)



L54 ANSWER 15 OF 23 USPATFULL on STN
ACCESSION NUMBER: 2005:99595 USPATFULL
TITLE: Heteroaryl substituted pyrrole modulators of metabotropic glutamate receptor-5
INVENTOR(S): Cosford, Nicholas D.P., San Diego, CA, UNITED STATES
Huang, Dehua, San Diego, CA, UNITED STATES
Smith, Nicholas D, San Diego, CA, UNITED STATES

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2005085514	A1	20050421	
APPLICATION INFO.:	US 2003-499393	A1	20021217	(10)
	WO 2002-US40486		20021217	

	NUMBER	DATE
PRIORITY INFORMATION:	US 2003-343262P	20011221 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: MERCK AND CO., INC, P O BOX 2000, RAHWAY, NJ, 07065-0907, US
NUMBER OF CLAIMS: 32
EXEMPLARY CLAIM: 1
LINE COUNT: 2635
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Pyrrole compounds substituted directly, or by a bridge, with a heteroaryl moiety containing N adjacent to the point of connection of the heteroaryl, are mGluR5 modulators useful in the treatment of psychiatric and mood disorders such as, for example, schizophrenia, anxiety, depression, bipolar disorder and panic, as well as in the treatment of pain, circadian rhythm disorders, and other diseases.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT **507270-04-4P**, N-[3-(5-Pyridin-2-yl-2H-tetrazol-2-yl)phenyl]acetamide
(preparation of diaryl substituted tetrazole modulators of metabotropic glutamate receptor-5)
RN 507270-04-4 USPATFULL
CN Acetamide, N-[3-[5-(2-pyridinyl)-2H-tetrazol-2-yl]phenyl]- (9CI) (CA INDEX NAME)



L54 ANSWER 16 OF 23 USPATFULL on STN

ACCESSION NUMBER:	2005:87910 USPATFULL
TITLE:	Heterocyclic compounds for treating hepatitis C virus
INVENTOR(S):	Vourloumis, Dionisios, San Diego, CA, UNITED STATES Takahashi, Masayuki, San Diego, CA, UNITED STATES Winters, Geoffrey C., Coquitlam, CANADA Zhou, Jinglan, San Diego, CA, UNITED STATES Duchene, Russell, San Diego, CA, UNITED STATES
PATENT ASSIGNEE(S):	Anadys Pharmaceuticals, Inc., San Diego, CA (U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2005075375	A1	20050407	
APPLICATION INFO.:	US 2004-845587	A1	20040514	(10)

	NUMBER	DATE	
PRIORITY INFORMATION:	US 2003-470200P	20030514	(60)

DOCUMENT TYPE:	Utility
FILE SEGMENT:	APPLICATION
LEGAL REPRESENTATIVE:	CONNOLLY BOVE LODGE & HUTZ LLP, SUITE 800, 1990 M STREET NW, WASHINGTON, DC, 20036-3425
NUMBER OF CLAIMS:	8
EXEMPLARY CLAIM:	1
LINE COUNT:	8178

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention is directed to heterocyclic compounds and pharmaceutical compositions of the same for treating Hepatitis C virus.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT **814259-16-0P**
(preparation of disubstituted pyrazoles, oxadiazoles and triazoles for treating hepatitis C virus)

RN 814259-16-0 USPATFULL

CN Carbamic acid, [4-hydroxy-3-[3-(3-methyl-2-pyridinyl)-1,2,4-oxadiazol-5-yl]phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



IT **814259-25-1P 814259-41-1P 814259-49-9P**
(preparation of disubstituted pyrazoles, oxadiazoles and triazoles for treating hepatitis C virus)
RN 814259-25-1 USPATFULL
CN Acetamide, N-[4-hydroxy-3-[3-(3-methyl-2-pyridinyl)-1,2,4-oxadiazol-5-yl]phenyl]- (9CI) (CA INDEX NAME)



RN 814259-41-1 USPATFULL
CN Benzamide, N-[4-hydroxy-3-[3-(3-methyl-2-pyridinyl)-1,2,4-oxadiazol-5-yl]phenyl]- (9CI) (CA INDEX NAME)



RN 814259-49-9 USPATFULL
CN Carbamic acid, [2-hydroxy-3-[3-(3-methyl-2-pyridinyl)-1,2,4-oxadiazol-5-yl]phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



L54 ANSWER 17 OF 23 USPATFULL on STN
ACCESSION NUMBER: 2005:31526 USPATFULL
TITLE: Heteroaryl substituted pyrazole modulators of metabotropic glutamate receptor-5
INVENTOR(S): Cosford, Nicholas D.P., San Diego, CA, UNITED STATES
Chen, Chixu, San Diego, CA, UNITED STATES
Eastman, Brian W., San Diego, CA, UNITED STATES
Huang, Dehua, San diego, CA, UNITED STATES
Munoz, Benito, San Diego, CA, UNITED STATES
Prasit, Petpiboon, San Diego, CA, UNITED STATES
Smith, Nicholas D., San Diego, CA, UNITED STATES

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2005026963	A1	20050203	
APPLICATION INFO.:	US 2004-497122	A1	20040526	(10)
	WO 2002-US40147		20021213	

	NUMBER	DATE
PRIORITY INFORMATION:	US 2001-341382P	20011218 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: MERCK AND CO INC, P O BOX 2000, RAHWAY, NJ, 070650907
NUMBER OF CLAIMS: 44
EXEMPLARY CLAIM: 1
LINE COUNT: 4944
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Pyrazole compounds substituted directly, or by a bridge, with a heteroaryl moiety containing N adjacent to the point of connection of the heteroaryl, are mGluR5 modulators useful in the treatment of psychiatric and mood disorders such as, for example, schizophrenia, anxiety, depression, bipolar disorder and panic, as well as in the treatment of pain, circadian rhythm disorders, and other diseases.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT **507270-04-4P**, N-[3-(5-Pyridin-2-yl-2H-tetrazol-2-yl)phenyl]acetamide
(preparation of diaryl substituted tetrazole modulators of metabotropic glutamate receptor-5)
RN 507270-04-4 USPATFULL
CN Acetamide, N-[3-[5-(2-pyridinyl)-2H-tetrazol-2-yl]phenyl]- (9CI) (CA INDEX NAME)



L54 ANSWER 18 OF 23 USPATFULL on STN
ACCESSION NUMBER: 2005:24036 USPATFULL
TITLE: Heteroaryl substituted triazole modulators of metabotropic glutamate receptor-5
INVENTOR(S): Cosford, Nicholas D.P., San Diego, CA, UNITED STATES
Prasit, Petpiboon, San Diego, CA, UNITED STATES
Roppe, Jeffrey R., Temecula, CA, UNITED STATES
Smith, Nicholas D., San Diego, CA, UNITED STATES
Tehrani, Lida R., San Diego, CA, UNITED STATES

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2005020585	A1	20050127	
APPLICATION INFO.:	US 2004-499391	A1	20040617	(10)
	WO 2002-US41720		20021213	

	NUMBER	DATE

PRIORITY INFORMATION: US 2001-341582P 20011218 (60)
DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: MERCK AND CO INC, P O BOX 2000, RAHWAY, NJ, 070650907
NUMBER OF CLAIMS: 26
EXEMPLARY CLAIM: 1
LINE COUNT: 2022
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Triazole compounds substituted directly, or by a bridge, with a heteroaryl moiety containing N adjacent to the point of connection of the heteroaryl which are metabotropic glutamate receptor--subtype 5 ("mGluR5") modulators useful in the treatment of psychiatric and mood disorders such as, for example, schizophrenia, anxiety, depression, bipolar disorder and panic, as well as in the treatment of pain, Parkinson's disease, cognitive dysfunction, epilepsy, circadian rhythm disorders, drug addiction, drug abuse, drug withdrawal and other diseases.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT **507270-04-4P**, N-[3-(5-Pyridin-2-yl-2H-tetrazol-2-yl)phenyl]acetamide
(preparation of diaryl substituted tetrazole modulators of metabotropic glutamate receptor-5)
RN 507270-04-4 USPATFULL
CN Acetamide, N-[3-[5-(2-pyridinyl)-2H-tetrazol-2-yl]phenyl]- (9CI) (CA INDEX NAME)



L54 ANSWER 19 OF 23 USPATFULL on STN
ACCESSION NUMBER: 2005:11742 USPATFULL
TITLE: Methods of identifying HCV NS5B polymerase inhibitors and their uses
INVENTOR(S): Lu, Henry, Foster City, CA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2005009877	A1	20050113
APPLICATION INFO.:	US 2004-847822	A1	20040517 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2003-471444P	20030515 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: DORSEY & WHITNEY LLP, INTELLECTUAL PROPERTY DEPARTMENT, 4 EMBARCADERO CENTER, SUITE 3400, SAN FRANCISCO, CA, 94111
NUMBER OF CLAIMS: 50
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 26 Drawing Page(s)
LINE COUNT: 2407
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to a variety of screening methods, utilizing both biochemical and cellular assays as well as in silicon assays, for use in the discovery of agents active in the treating or preventing Hepatitis C virus (HCV) infections. The invention also relates to methods of inhibiting an HCV NS5B polymerase and to the treatment and/or prevention of HCV infections with compounds having specified binding properties.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT **667931-24-0 667931-30-8 667931-46-6**
(methods of identifying hepatitis C virus gene NS5B polymerase inhibitors and their uses)

RN 667931-24-0 USPATFULL

CN Acetamide, 2,2-dichloro-N-[2-[3-[2-fluoro-6-(trifluoromethyl)phenyl]-5-isoxazolyl]-4-pyridinyl]- (9CI) (CA INDEX NAME)



RN 667931-30-8 USPATFULL

CN Acetamide, 2,2-dichloro-N-[2-[3-(2,6-dichlorophenyl)-5-isoxazolyl]-4-pyridinyl]- (9CI) (CA INDEX NAME)



RN 667931-46-6 USPATFULL

CN Acetamide, 2,2-dichloro-N-[2-[3-[2-(4-morpholinyl)-6-(trifluoromethyl)phenyl]-5-isoxazolyl]-4-pyridinyl]- (9CI) (CA INDEX NAME)



L54 ANSWER 20 OF 23 USPATFULL on STN

ACCESSION NUMBER:	2004:328092 USPATFULL		
TITLE:	Heteroaryl substituted imidazole modulators of metabotropic glutamate receptor-5		
INVENTOR(S):	Cosford, Nicholas D.P., San Diego, CA, UNITED STATES Huang, Dehua, San Diego, CA, UNITED STATES Smith, Nicholas D., San Diego, CA, UNITED STATES		

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2004259917	A1	20041223	
APPLICATION INFO.:	US 2004-499392	A1	20040617	(10)
	WO 2002-US40237		20021216	

	NUMBER	DATE
PRIORITY INFORMATION:	US 2001-341963P	20011219 (60)

DOCUMENT TYPE:	Utility
FILE SEGMENT:	APPLICATION
LEGAL REPRESENTATIVE:	MERCK AND CO INC, P O BOX 2000, RAHWAY, NJ, 070650907
NUMBER OF CLAIMS:	28
EXEMPLARY CLAIM:	1
LINE COUNT:	1795

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Imidazole compounds substituted directly, or by a bridge, with a heteroaryl moiety containing N adjacent to the point of connection of the heteroaryl, are mGluR5 modulators useful in the treatment of psychiatric and mood disorders such as, for example, schizophrenia, anxiety, depression, bipolar disorder and panic, as well as in the treatment of pain, circadian rhythm disorders, and other diseases.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT **507270-04-4P**, N-[3-(5-Pyridin-2-yl-2H-tetrazol-2-yl)phenyl]acetamide
(preparation of diaryl substituted tetrazole modulators of metabotropic glutamate receptor-5)

RN 507270-04-4 USPATFULL

CN Acetamide, N-[3-[5-(2-pyridinyl)-2H-tetrazol-2-yl]phenyl]- (9CI) (CA INDEX NAME)



L54 ANSWER 21 OF 23 USPATFULL on STN

ACCESSION NUMBER:	2004:240480 USPATFULL		
TITLE:	Heteroaryl substituted tetrazole modulators of metabotrophic glutamate receptor-5		
INVENTOR(S):	Cosford, Nicholas D P, San Diego, CA, UNITED STATES Chen, Chixu, San Diego, CA, UNITED STATES Reger, Thomas S, San Diego, CA, UNITED STATES Roppe, Jeffrey R, Temecula, CA, UNITED STATES Smith, Nicholas D, San Diego, CA, UNITED STATES		

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2004186295	A1	20040923	
APPLICATION INFO.:	US 2004-491613	A1	20040402	(10)
	WO 2002-US31294		20021001	

	NUMBER	DATE	
PRIORITY INFORMATION:	US 2001-327132P	20011004	(60)

DOCUMENT TYPE:	Utility
FILE SEGMENT:	APPLICATION
LEGAL REPRESENTATIVE:	MERCK AND CO INC, P O BOX 2000, RAHWAY, NJ, 070650907
NUMBER OF CLAIMS:	45
EXEMPLARY CLAIM:	1
LINE COUNT:	4657

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Tetrazole compounds substituted directly, or by a bridge, with a heteroaryl moiety containing N adjacent to the point of connection of the heteroaryl, are mGluR5 modulators useful in the treatment of psychiatric and mood disorders such as, for example, schizophrenia, anxiety, depression, and panic, as well as in the treatment of pain and other diseases.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT **507270-04-4P**, N-[3-(5-Pyridin-2-yl-2H-tetrazol-2-yl)phenyl]acetamide
(preparation of diaryl substituted tetrazole modulators of metabotropic glutamate receptor-5)

RN 507270-04-4 USPATFULL

CN Acetamide, N-[3-[5-(2-pyridinyl)-2H-tetrazol-2-yl]phenyl]- (9CI) (CA INDEX NAME)



L54 ANSWER 22 OF 23 USPATFULL on STN
ACCESSION NUMBER: 2004:127571 USPATFULL
TITLE: Concomitant drugs
INVENTOR(S): Ohkawa, Shinegori, Takatsuki-shi, JAPAN
Naruo, Kenichi, Sanda-shi, JAPAN
Miwatashi, Seiji, Ikeda-shi, JAPAN

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2004097555	A1	20040520	
APPLICATION INFO.:	US 2003-451839	A1	20030625	(10)
	WO 2001-JP11353		20011225	

	NUMBER	DATE
PRIORITY INFORMATION:	JP 2000-396220	20001226

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: Mark Chao, Takeda Pharmaceuticals North America Inc, Intellectual Property Department, Suite 500 475 Half Day Road, Lincolnshire, IL, 60069
NUMBER OF CLAIMS: 12
EXEMPLARY CLAIM: 1
LINE COUNT: 8688
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention relates to a pharmaceutical agent containing one or more kinds of a p38 MAP kinase inhibitor and/or a TNF-α production inhibitor and one or more kinds of drugs selected from the group consisting of (1) a non-steroidal antiinflammatory drug, (2) a disease-modifying anti-rheumatic drug, (3) an anti-cytokine drug, (4) an immunomodulator, (5) a steroid and (6) a c-Jun N-terminal kinase inhibitor in combination. This combination agent is useful as a prophylactic or therapeutic agent of the diseases such as rheumatism, arthritis and the like, and other diseases.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT **303162-77-8P 303162-91-6P 303162-92-7P**
(combination drugs containing p38MAP kinase inhibitors and/or TNF-α production inhibitors with other specified agents)
RN 303162-77-8 USPATFULL
CN Benzeneacetamide, N-[4-[2-(2-chlorophenyl)-4-(3-methylphenyl)-5-thiazolyl]-2-pyridinyl]- (9CI) (CA INDEX NAME)



RN 303162-91-6 USPATFULL
CN Benzamide, N-[4-[2-(2-chlorophenyl)-4-(3-methylphenyl)-5-thiazolyl]-2-pyridinyl]- (9CI) (CA INDEX NAME)



RN 303162-92-7 USPATFULL
CN Benzenepropanamide, N-[4-[2-(2-chlorophenyl)-4-(3-methylphenyl)-5-thiazolyl]-2-pyridinyl]- (9CI) (CA INDEX NAME)



L54 ANSWER 23 OF 23 USPATFULL on STN
ACCESSION NUMBER: 2004:95421 USPATFULL
TITLE: Substituted thiazole derivatives bearing 3-pyridyl groups, process for preparing the same and use thereof
INVENTOR(S): Kuroda, Noritaka, Toyono-gun, JAPAN
Nara, Yoshi, Suita-shi, JAPAN
Hashiguchi, Shohei, Toyonaka-shi, JAPAN
Tasaka, Akihiro, Suita-shi, JAPAN
Kusaka, Masami, Kobe-shi, JAPAN
Yamaoka, Masuo, Kobe-shi, JAPAN
Kaku, Tomohiro, Nishinomiya-shi, JAPAN

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2004072876	A1	20040415	
APPLICATION INFO.:	US 2003-433910	A1	20030604	(10)
	WO 2001-JP10723		20011207	

	NUMBER	DATE
PRIORITY INFORMATION:	JP 2000-373868	20001208

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: TAKEDA PHARMACEUTICALS NORTH AMERICA, INC, INTELLECTUAL PROPERTY DEPARTMENT, 475 HALF DAY ROAD, SUITE 500, LINCOLNSHIRE, IL, 60069

NUMBER OF CLAIMS: 60
EXEMPLARY CLAIM: 1
LINE COUNT: 5677
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention provides a pharmaceutical composition having a steroid C.sub.17,20-lyase inhibitory activity, which is useful as a prophylactic or therapeutic agent of prostatism, tumor such as breast cancer and the like, more particularly, a steroid C.sub.17,20-lyase inhibitor containing a compound represented by the formula: ##STR1##

wherein A.sup.1 is an aromatic hydrocarbon group optionally having substituents or a heterocyclic group optionally having substituents, one of A.sup.2 and A.sup.3 is a hydrogen atom, a halogen atom, a C.sub.1-4 aliphatic hydrocarbon group optionally having substituents or an optionally esterified carboxyl group, the other of A.sup.2 and A.sup.3 is an aromatic hydrocarbon group optionally having substituents or a heterocyclic group optionally having substituents, and at least one of A.sup.1, A.sup.2 and A.sup.3 is a 3-pyridyl group optionally having substituents, or a salt thereof or a prodrug thereof.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT **435272-05-2P 435272-60-9P**, N-[3-[4-(4-Methylpyridin-3-yl)-1,3-thiazol-2-yl]phenyl]acetamide **435272-63-2P**, N-[4-Methyl-3-[4-(4-methylpyridin-3-yl)-1,3-thiazol-2-yl]phenyl]acetamide (preparation of substituted pyridylthiazole derivs. as steroid C17,20 lyase inhibitors for treatment and prevention of sex hormone-dependent diseases)

RN 435272-05-2 USPATFULL

CN Acetamide, N-[3-[2-[4-(trifluoromethyl)-3-pyridinyl]-4-thiazolyl]phenyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 435272-60-9 USPATFULL

CN Acetamide, N-[3-[4-(4-methyl-3-pyridinyl)-2-thiazolyl]phenyl]- (9CI) (CA INDEX NAME)



RN 435272-63-2 USPATFULL

CN Acetamide, N-[4-methyl-3-[4-(4-methyl-3-pyridinyl)-2-thiazolyl]phenyl]-
(9CI) (CA INDEX NAME)



=>

This Page Blank (uspto)